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Contrary to systemic injection of therapeutics, oral formulations represent clear advantages to 
patients, healthcare systems, and pharmaceutical companies including safety, low cost and patient 
compliance. However, oral delivery remains a major obstacle due to (1) drug instability in the harsh 
environment of the gastrointestinal (GI) tract owing to low gastric pH and enzymatic hydrolysis; 
(2) low permeability through the mucus layer and subsequent adhesion to the GI epithelium; and 
(3) suboptimal transport into or across the GI epithelium- the cell barrier responsible for selective 
absorption of substances into the circulation, for local or systemic delivery. While encapsulation 
methods have been developed to overcome barriers to stability and adhesion to the GI epithelium, 
safe and effective transport into and across this lining has not yet been achieved for several drugs, 
especially biotherapeutics. Hence, our goal is to overcome these challenges for delivery of 
therapeutics (including biotherapeutics) via the oral route. For this purpose, we targeted drugs to 
intercellular adhesion molecule-1 (ICAM-1), a protein expressed on the GI epithelium and other 
 
 
cell types. We previously demonstrated, that polymer nanocarriers (NCs) coated with antibodies to 
bind multiple copies of ICAM-1 (multimeric targeting) triggered uptake and transport across 
cultured GI epithelial cells, enabling intracellular and transcellular drug delivery. To implement 
this strategy in vivo, we successfully encapsulated antibody-coated NCs in chitosan-alginate 
microspheres for gastric protection of labile targeting antibodies, site-specific release in the 
intestinal environment (the site of drug absorption) and retention of targeting ability following 
release in vitro, in cell culture, and in vivo. Furthermore, to expand the utility of the ICAM-1 
targeting approach, we explored a novel drug delivery system that binds only one to two molecules 
of ICAM-1 (monomeric targeting), which provides distinct advantages for oral drug delivery 
compared with multimeric strategies. In order to elucidate the advantages offered by this 
monomeric targeting approach, we compared the uptake and intracellular trafficking of ICAM-1 
targeted monomeric antibodies vs. multimeric antibody-coated NCs in cultured endothelial cells, a 
commonly used cellular model to study ICAM-1 transport. We then revealed that the distinct 
itinerary of transport offered by monomeric ICAM-1 targeted antibodies led to enhanced uptake 
and transport across cultured GI epithelial cells, showing promise for oral delivery. Finally, in order 
to exploit this transport pathway for oral drug delivery, we conjugated a model drug cargo to 
monomeric ICAM-1 targeted antibodies, which was shown to endow drug targeting and delivery 
into and across cultured GI epithelial cells, while preserving the functional activity of the drug 
cargo. These findings demonstrate that monomeric vehicles serve as a viable alternative to 
multimeric strategies, expanding the range of oral delivery applications afforded by ICAM-1 
targeting. Taken together, the work performed in this dissertation advocates the potential of ICAM-
1 targeting strategies for improving oral absorption of therapeutics, and provides a foundation for 
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Chapter 1: Introduction and Overview  
 
 
1.1 Problem Description and Motivation 
Among the various routes of drug administration, oral delivery through the gastrointestinal 
(GI) tract, whereby tablets, capsules, or drops are taken orally, remains the most favorable 
[1]. Relative to parenteral, or injectable therapies, oral formulations present clear 
advantages to patients, healthcare workers, and pharmaceutical industries. Patients prefer 
oral forms for the convenience of self-administration, which allows a flexible dosing 
schedule and fewer healthcare appointments, and comfort of swallowing a drug relative to 
receiving an injection. Oral formulations also minimize costs to patients, healthcare 
workers, and manufacturers, since they can be formulated in bulk, and do not necessitate 
specialized personnel and sterilization procedures [1]. In addition, given that oral therapies 
do not necessitate sterility, they pose lower safety concerns associated with potential 
contamination and systemic infections [1]. As a result of these advantages, there is a 
substantial demand for making pharmaceuticals available in oral form. Indeed, oral 
formulations presently comprise 90% of all medicines and a USD $49 billion market (as 
of 2010), which represents over half of the total pharmaceutical market [1]. The market 
value of oral dosages is expected to grow by 10% each year [1]. Physiologically, the GI 
tract is relatively suitable for systemic absorption of drugs owing to its high surface area 
(500 sq. meters), dense vasculature, and significant blood perfusion supporting sink 




Access to the systemic circulation via the oral route, or oral bioavailability, requires 
transport across the GI epithelial lining, a layer of cells responsible for selective absorption 
of nutrients and drugs from the GI tract into the systemic circulation [2, 3]. Yet, oral 
bioavailability is curtailed by a number of physiological barriers, including (A) premature 
degradation or deactivation by the low pH and proteolytic activity in the stomach, (B) 
suboptimal mucus permeation and subsequent adhesion to the GI epithelium, and (C) poor 
penetration into and/or across these cells for the treatment of disorders that affect the GI 
lining or those that require delivery into the circulation, respectively [2, 3].  
While encapsulation, in hydrogels or drug vehicles for instance, has circumvented 
issues of gastric stability as well as have facilitated release and adhesion at the site of drug 
absorption [4, 5], transport of therapeutics into/across the GI tract that is both efficient and 
safe (i.e., maintains the integrity of the GI permeability barrier) has not yet been achieved 
for numerous drugs and drug vehicles. This is particularly the case for biotherapeutics, a 
rapidly emerging class of drugs composed of biological components, including monoclonal 
antibodies, peptide and protein hormones, enzymes, vaccines, etc. [3], designed to treat a 
number of autoimmune, cardiovascular, gut, metabolic, and neurological disorders and 
cancers [3]. Oral delivery of such therapeutics can be enhanced by active targeting 
strategies, which involves coupling drugs or their vehicles to targeting moieties, such as 
antibodies, peptides, sugars, and vitamins (see Fig. 1.1 below) [2, 6]. These targeting 
moieties recognize and bind to specific markers, such as transporters and receptors, on the 
GI epithelial cell lining, which not only improves adhesion to the GI epithelium, but may 




the goal of this work is to utilize active targeting strategies to improve absorption of 
therapeutics, particularly biotherapeutics, via the oral route.  
 
1.2 Our Approach 
Targeting of therapeutics can be achieved by: (A) direct conjugation of targeting ligands 
to the drug itself (drug conjugates), or by (B) coupling targeting ligands to the surface of 
drug-loaded nanocarriers (NCs) (Fig. 1.1) [7]. NCs are macromolecular vehicles composed 
of a variety of natural or synthetic biomaterials, which may be functionalized to optimize 
drug solubility, protection, biodistribution, release kinetics, metabolism, elimination, etc. 
for GI or systemic delivery [8]. Prominent examples of NCs include dendrimers, 
liposomes, metallic nanoparticles, micelles and polymer particles [8]. Both of these 
targeting strategies are valuable in that they may provide distinct advantages from a 
manufacturing and drug delivery standpoint. For example, ligand-drug conjugates 
constitute a less complex formulation and in most cases, better mimic ligands found in 
nature [7], while targeted NCs allow for high drug loading and control over the parameters 
noted above. Importantly, these strategies differ in targeting valency, or the number of 
binding interactions with cell-surface markers (Fig. 1.1). Drug conjugates often contain a 
single ligand that binds 1-2 markers (monomeric targeting), whereas NCs present multiple 
copies of ligands that bind 2 or more markers (multimeric targeting). The differences in 
such binding interactions typically trigger alternative itineraries of drug transport though 






Figure 1.1. Monomeric vs. multimeric targeting strategies.  
In this dissertation, we have focused on one such cell-surface marker, intercellular 
adhesion molecule-1 (ICAM-1) that triggers differential transport outcomes upon 
monomeric vs. multimeric targeting [9]. ICAM-1 is a transmembrane glycoprotein that is 
typically involved in the attachment and transmigration of leukocytes across cellular 
barriers [10]. ICAM-1 represents an attractive target for drug delivery in both the GI tract 
and other tissues accessed from the systemic circulation, as it is expressed on the GI 
epithelium and other epithelial cell types, vascular endothelial and immune cells, astrocytes 
and neurons, among others [10]. Another valuable feature is upregulation of ICAM-1 in 
pathological conditions, which promotes specific targeting to sites of disease [10, 11].  
In a previous publication, we established the potential of ICAM-1 targeting for oral 
delivery into and across the GI epithelial cell barrier. This work employed a multimeric 




onto polymeric drug nanoparticles (anti-ICAM NCs; Fig. 1.2), which bind multiple ICAM-
1 molecules [12]. Multimeric targeting to ICAM-1 on cultured GI epithelial and vascular 
endothelial cells induces a novel pathway of transport into and across these cells, referred 
to as cell adhesion molecule (CAM)-mediated transcytosis [13, 14]. CAM-mediated 
transcytosis is a non-classical avenue of transport that is independent of clathrin or caveolin 
[13]. Importantly, this pathway does not compromise cell barrier integrity, suggesting a 
safer means of oral delivery [13]. Hence, utilizing this multimeric targeting strategy 
provided significant delivery of a model therapeutic enzyme (α-Galactosidase, used for the 
treatment of Fabry disease) into and across GI epithelial cells [13].  
 
Figure 1.2. Monomeric and multimeric ICAM-1 targeting models. 
A very important point to consider in designing an oral drug delivery system is the 
instability of many drug delivery vehicles in the acidic milieu of the stomach. In fact, 
although oral administration of anti-ICAM NCs in mice demonstrated the ability of these 
strategies to adhere to GI tissue [15], premature degradation of the targeted antibodies 
during transit through the stomach precluded the efficacy of this strategy by limiting 
intestinal biodistribution [15]. Hence it is necessary to effectively encapsulate ICAM-1 




encapsulation should provide: (A) protection of targeting moieties from gastric 
degradation; (B) site-specific release in the intestine, the main site of drug absorption; and 
(C) retention of targeting ability to allow ICAM-1 binding and subsequent transport into 
cells. For this purpose, we employed hydrogels, which are three-dimensional networks of 
natural or synthetic polymers [4, 5]. More specifically, we have chosen natural and 
biocompatible chitosan and alginate hydrogels, since they are well-established for their 
ability to preserve biological cargoes, including targeted antibodies, in the GI environment 
and provide pH-triggered release in the intestine [16, 17]. To meet the size requirements 
for oral gavage in mice, in this dissertation, we formulated chitosan-alginate microspheres 
loaded with antibody-coated NCs, which reflect our multimeric ICAM-1 targeting strategy 
that has previously demonstrated efficacy for oral delivery (Fig. 1.3) [13].  
 
Figure 1.3. Requirements for encapsulation of ICAM-1 targeted nanocarriers. 
 
In the case of monomeric ICAM-1 ligands, however, previous work demonstrating 
low cellular uptake precluded further characterization of transport by this strategy [9]. 




alternative vehicles for drug delivery into and across GI epithelial cells, which would 
expand the range of oral delivery applications afforded by ICAM-1 targeting. As a model, 
we utilized single copies of antibodies against ICAM-1 (anti-ICAM; Fig. 1.2 shown 
above), which bind one to two ICAM-1 molecules, directly conjugated to an enzyme (drug 
cargo). 
In light of previous literature supporting our research approach, we hypothesized 
that encapsulation of targeted NCs (i.e., antibody-coated NCs) in chitosan-alginate 
microspheres will provide protection of targeting antibodies in gastric conditions, release 
in intestinal conditions, and retention of targeting ability following release from 
microspheres. In order to determine the oral delivery potential of monomeric ICAM-1 
targeting moieties as an alternative to multimeric targeting vehicles, we also hypothesized 
that, similar to anti-ICAM NCs, anti-ICAM and anti-ICAM-drug conjugates will provide 
binding, uptake, and transport across GI epithelial cells, and that this pathway provides an 
avenue for the delivery of active therapeutics. This hypothesis was evaluated with the 
following specific aims: 
Specific Aim 1: Encapsulate ICAM-1 targeted NCs in chitosan-alginate microspheres 
for oral delivery. 
 Sub-aim 1: Formulate and characterize chitosan-alginate microspheres loaded with 
targeted NCs (i.e., antibody-coated NCs). 
 Sub-aim 2: Study protection of encapsulated targeted NCs from degradation in 




 Sub-aim 3: Evaluate degradation status and cellular binding of targeted NCs after 
release from microspheres. 
Specific Aim 2: Assess targeting and cellular transport of monomeric ICAM-1 
ligands. 
 Sub-aim 1: Compare binding, uptake, and intracellular trafficking of anti-ICAM 
antibody vs. anti-ICAM NCs in vascular endothelial cells. 
 Sub-aim 2: Quantify binding, uptake, and transepithelial transport of anti-ICAM 
antibody in GI epithelial cells. 
Specific Aim 3: Evaluate monomeric ICAM-1 targeting for delivery of an active drug 
cargo into and across GI epithelial cells. 
 Sub-aim 1: Formulate and characterize anti-ICAM antibody directly conjugated to 
a therapeutic cargo, using the enzyme horseradish peroxidase as a model. 
 Sub-aim 2: Determine whether anti-ICAM-enzyme conjugates delivers and 
preserves the activity of enzymes into and across GI epithelial monolayers. 
 
In achieving the above aims, this dissertation provided insight on ICAM-1-mediated 
transport across the GI tract and set the stage for future exploration of ICAM-1-targeted 







As described in Section 1.1, oral delivery of drugs, particularly biotherapeutics, is restricted 
by (A) instability in the harsh environment of the GI tract due to low gastric pH and 
digestive enzymes in the stomach and small intestine, (B) poor transport through the mucus 
layer and/or adhesion to the GI epithelial barrier, and (C) suboptimal transport into and/or 
across this barrier for local GI interventions or delivery into the circulation [2, 3]. Whereas 
present strategies have effectively overcome the luminal barriers encompassing (A) and 
(B), safe and effective transport into/across the intestinal barrier remains unachieved for 
certain therapies, such as macromolecular biotherapeutics and drug vehicles [3]. Active 
targeting strategies, such as the example explored herein, are significant in that it may 
overcome these challenges to improve absorption of such agents via the oral route.  
First, targeting therapeutics to specific markers on the GI epithelium has been 
shown to improve affinity to the cell surface (i.e. mucoadhesion), minimizing clearance 
from the body and improving biodistribution to the site of drug absorption [2, 3, 6]. This 
would ultimately reduce dosages needed for therapeutic efficacy. An example that shows 
particular promise in this regard is targeting drugs to ICAM-1. ICAM-1 is expressed on 
the apical surface of GI epithelial cells, allowing targeting to this tissue for oral delivery. 
Upon entering the systemic circulation, targeting ICAM-1 may also provide enhanced 
biodistribution to other cells that express this marker, including vascular endothelial cells 
on blood vessels, immune cells, various epithelial cells, neurons, etc. [10]. In addition, 
ICAM-1 is upregulated during inflammation [18], allowing specific targeting to diseased 
sites. This is the case for many gut pathologies, including infections, Crohn’s disease, 




targeting moiety, either free in solution or bound to drug NCs, may improve permeation 
through hydrophobic mucus in light of their high charge density, yet neutral net charge 
[23]. 
Targeting drugs to certain markers also triggers transport into and/or across the GI 
epithelium, which is significant for treating intracellular GI pathologies or providing entry 
into the systemic circulation [2, 3]. We have previously shown that targeting to ICAM-1 
triggers a non-classical pathway of transport into and across GI epithelial cells [13]. ICAM-
1 mediated transport is valuable because unlike classical modes of cellular transport that 
are selective to carrier geometry, the CAM pathway accommodates drugs and drug carriers 
of various sizes (e.g., 100 nm to several µm), shape, chemistry, targeting valency, dose, 
etc. [9, 12, 24-34]. In addition, ICAM-mediated transport does not appear to breach the GI 
permeability barrier [13], whose function is to prevent non-specific transport of pathogens 
and other undesired substances into the body. Therefore, ICAM-1-targeting could provide 
a novel opportunity for safe transport across the GI epithelium. The proposed work is also 
expected to provide mechanistic insight about transport, particularly non-classical 
pathways, in the GI and other cell barriers (e.g., the blood-brain-barrier), an important yet 
unanswered question in cell biology. This information would also allow for the design of 
more effective therapeutics with the ability to access target sites restricted by such barriers.  
By exploiting such transport, ICAM-1-targeted systems have been used for 
effective delivery of various imaging and therapeutic agents in cell culture and animal 
models [9, 25-28, 31-35], particularly biotherapeutics [25, 27, 30, 31, 36-38]. While these 
applications were intended for intravenous administration, the research proposed herein 




the biotherapeutics explored by our group for ICAM-1-mediated delivery, replacement 
enzymes for lysosomal storage disorders (LSDs) including α-Galactosidase (α-Gal) for the 
treatment of Fabry disease has been a large focus [25, 27, 30, 31, 36-38]. Current therapy 
involves frequent injections from an early age and costs ~150K per year [39]. 
Manufacturers, healthcare systems, and patients would greatly benefit from oral forms of 
these enzymes, yet no strategies exist for delivery into and across the GI tract for local and 
systemic treatment. ICAM-1-targeted NCs have shown promise in resolving this issue, as 
demonstrated using α-Gal as a model enzyme [13]. The significance of using enzymes as 
a model biotherapeutic for our targeting strategies is an attractive and novel application to 
treat LSDs via the oral route. 
While ICAM-1 mediated drug delivery into and across cells has been demonstrated 
using multimeric targeting strategies, such as anti-ICAM NCs, this dissertation examines 
drug delivery by monomeric ICAM-1 targeting moieties (i.e., single anti-ICAM 
molecules). The significance of utilizing monomeric drug carriers with a different targeting 
valency is to provide alternative drug delivery outcomes, such as loading, biodistribution, 
intracellular trafficking, transport across cells, etc. A wider range of therapeutic 
applications can thus arise from studying both monomeric and multimeric anti-ICAM as 
oral drug carriers. 
Mice studies by our group revealed that multimeric anti-ICAM NCs administered 
orally without protective coatings were degraded by gastric enzymes and retained in the 
stomach tissue due to premature targeting [15]. Encapsulation, in hydrogels and NCs for 
instance, has circumvented issues of stability, solubility, mucus permeation, and release in 




capsules would serve as the first attempt to preserve their activity in the stomach and 
provide release in the intestine, a suitable target due to high absorptive capacity. 
Characterization of an encapsulation strategy is significant for future translation of these 
targeting strategies for oral delivery in vivo. 
 
1.4 Innovation 
Ligands that have been used to target biotherapeutics to receptors in the GI tract include 
lectins, toxins, viral haemmaglutinins, invasins, transferrin, and vitamins [3, 6, 42-44]. A 
recent publication by our group revealed for the first time the potential of targeting ICAM-
1 on the GI epithelium for oral drug delivery [13].  While this study employed multiple 
copies of ICAM-1-targeted antibodies coated onto drug NCs, the opportunity to target 
therapeutics directly conjugated to single antibody molecules has not been explored for 
oral delivery. Characterization of this strategy, using monomeric anti-ICAM as a model, is 
important because, compared to multivalent counterparts, it provides a simpler formulation 
method and can endow drugs with different delivery features, such as loading, targeting 
and biodistribution, intracellular trafficking, metabolism, clearance, etc., which may be 
better suited for certain therapeutic applications.  
Intravenously injected antibodies and antisense nucleotides were previously used 
to target ICAM-1 on vascular endothelial cells in the gut to neutralize its involvement in 
gut pathologies such as inflammatory bowel disease [45]. However, ICAM-1 has not been 
exploited for the purpose of delivering therapeutics into and across the GI epithelium for 




circulation. While, classical clathrin- and caveolin-dependent endocytosis and transcytosis 
have been described fundamentally and in the context of oral delivery [6, 46], our previous 
study utilizing anti-ICAM NCs was the first observation of a non-classical, CAM-mediated 
pathway providing such transport in cultured GI epithelial cells [13]. It was also the first 
documented instance of CAM-mediated transcytosis in any cell type. Thus, our work 
involving characterization of anti-ICAM uptake and trafficking in vascular endothelial and 
GI epithelial cells (Aim 2) will for the first time, evaluate the potential of this strategy as 
an oral drug vehicle as well as elucidate the role of valency and size of targeting agents on 
CAM-mediated transport and GI transport in general. Moreover, the ability of ICAM-1-
targeted strategies to preserve the activity of drug cargoes during transit through GI 
epithelial cells (Aim 3) has not yet been performed, and will provide insight for both 
fundamental knowledge of CAM-mediated transcytosis and future translation of these 
approaches for oral delivery. 
Encapsulation of ICAM-1 targeted platforms for protection in transit through 
stomach and release in the intestine also has yet to be characterized. While chitosan-
alginate capsules have been previously used for oral delivery applications involving large 
biological entities, such as proteins, antibodies, cells, etc., [47-49], applications involving 
targeted NCs have not been explored. In Aim 1, characterization of loading, protection, 
and release of targeted NCs, and the effect of encapsulation on the integrity of targeted 
NCs, are novel outcomes.  
Therefore, the research performed herein is innovative because targeting ICAM-1 
on the GI epithelium, using single or multiple copies of antibodies, has not been explored 




novel in terms of advancing these strategies for future pre-clinical studies. Overall, the 
findings of this dissertation can elicit positive impact and advancement in the field of 





Chapter 2: Background 
2.1 Targeting Therapeutics to the Gastrointestinal Epithelium 
As described in Section 1.1, oral delivery through the GI tract is the preferred form of drug 
administration by patients, healthcare workers, and pharmaceutical industries [1]. 
However, owing to the physiochemical nature of numerous drugs, there are no present 
solutions for safe and effective transport into and/or across the GI epithelial lining, the cell 
barrier responsible for selective absorption of substances into the circulation, for local or 
systemic delivery [2, 3]. As previously noted, active targeting is a promising strategy for 
overcoming these obstacles. Hence, the physiological and design principles underlying 
targeting strategies will be the focus of the following section.  
 
2.1.1 Binding to the Gastrointestinal Epithelium 
As noted above, one of the major challenges to oral drug delivery is poor attachment to the 
small intestinal mucosa, the innermost lining of the intestine exposed to the GI lumen 
which is responsible for absorbing ~90% of all ingested contents. The mucosa is divided 
into three sections: (1) the epithelium, which has protective and absorptive or secretory 
functions; (2) the lamina propria, a network of loose connective tissue, capillaries, and 
lymphatic vessels that carry substances transported across the epithelium to the systemic 
circulation; and the (3) muscularis mucosae, a double layer of inner circular and outer 
longitudinal smooth muscle. Within the mucosa, the GI epithelium serves as the interface 
between the luminal contents and the underlying circulatory vessels in the lamina propria 




nutrients (e.g., protein, carbohydrates, lipids, water, vitamins, and minerals) and drugs, 
while simultaneously excluding harmful substances, such as toxins and pathogens, from 
entering the circulation. [50] 
 
Figure 2.1. The gastrointestinal epithelium. 
The epithelial lining is folded into large villi projections and invaginations (crypts 
of Lieberkühn), maximizing the absorptive surface area of the intestine. Within the lining 
are mainly columnar epithelial cells referred to as absorptive enterocytes, and less 
populated secretory cells, such as goblet cells, which secrete mucus into the lumen, and 
bicarbonate-secreting cells, which serve to neutralize stomach acid. A minor portion of the 
GI epithelium also consists of M cells or microvilli-lacking immune cells that deliver 




present several distinctive features upon differentiation that are geared for nutrient and drug 
absorption: the apical membrane or brush border contains numerous folds, or microvilli, as 
a means of increasing surface area in contact with the intestinal lumen, as well as hydrolytic 
enzymes and transporters/receptors embedded in the membrane to breakdown essential 
nutrients and transport them into cells [50]. The basolateral membrane facing the abluminal 
space, containing underlying capillary and lymphatic networks, lacks microvilli and 
contains different types and amounts of transporters to maintain ionic concentration 
gradients used to drive transport. Due to the distinction between the apical and basolateral 
cell surfaces, enterocytes are referred to as polarized cells. In addition, the lateral 
membrane connecting adjacent epithelial cells is also responsible for regulating the 
permeability barrier. Within this lateral space, restricted passage of luminal substances is 
regulated by the (A) the tight junctions, a branching network of sealing strands mainly 
composed of the proteins occludins and claudins, and (B) anchoring junctions known as 
adherens junctions, which maintain cell-cell adherence by linking transmembrane proteins 
on adjacent cells to the cytoskeleton. [50, 51]  
Binding to the intestinal epithelium, which increases residence time for absorption, 
is precluded by poor penetration of drugs through the mucus layer overlying epithelial cells 
as well as suboptimal affinity to the epithelial surface. Regular shedding of the mucus layer 
results in clearance and elimination of entrapped drugs, lowering biodistribution to the 
intestine [2, 3]. Another factor limiting binding is clearance by phagocytic immune cells 
present in the small intestine [2, 3]. Endowing therapeutics with specific affinity to the GI 
epithelium (i.e., active targeting) has shown much success for overcoming these obstacles 




vitamins, sugars, amino acids, lectins, etc.), other affinity molecules (e.g., antibodies, 
antibody fragments, peptides, aptamers, etc.), or molecules derived from pathogens (e.g., 
toxins and viral hemagglutinins) that bind specifically to membrane transporters and 
receptors on the apical surface of GI cells [2, 7, 52, 53]. Common markers that have been 
exploited for this purpose include transporters for amino acids, glucose, and vitamins, as 
well as receptors that bind transferrin, vitamin B12, lectins, toxins, and viral 
hemagglutinins [2, 3, 6, 42, 44, 54-56]. Transmembrane receptors of the immunoglobulin 
superfamily, such as integrins, cell adhesion molecules, and cytokine receptors have also 
been explored for targeted therapies aimed at treating GI disorders, as they are 
overexpressed in inflammatory conditions [45, 57, 58]. Molecular recognition and binding 
to these markers enhances biodistribution to the intestinal lining. This increases the 
residence time at the site of absorption and reduces the likelihood of clearance and 
excretion from the GI tract, which ultimately minimizes the effective dosage required for 
therapy and potential drug toxicity [3, 6, 42, 44].  
 
2.1.2 Transport Into and Across Gastrointestinal Epithelial Cells 
In addition, targeting to markers on the GI epithelium not only enhances intestinal 
biodistribution, but may also trigger transport into these cells, a significant requirement for 
treating intracellular pathologies, such as those affecting the GI epithelium itself, and/or 
across cells for delivery into the systemic circulation [2, 3]. As shown in Fig. 2.2, there are 
four main mechanisms of transport of nutrients/drugs from the apical space to the 
basolateral space: the (A) transcellular routes, whereby substances cross the cell body, 




transcytosis, whereas (B) paracellular transport takes place between adjacent cells [2, 3, 
51]. 
 
Figure 2.2. Mechanisms of transport across gastrointestinal epithelial cells. (A) Transcellular 
routes of transport, which involve passage across the cell body, include: (1) passive diffusion, (2) 
carrier-mediated transport (facilitated or active), and (3) transcytosis. Alternatively, (B) the 
paracellular route involves transport through the junctions between adjacent cells.  
 
2.1.2.1 Passive Transcellular Diffusion 
In passive diffusion, small solutes, such as water, gases, ethanol, and lipids, diffuse across 
the apical and basolateral membranes as a result of a concentration gradient. Drugs 
employing this pathway must exhibit a similar small size and certain degree of 
hydrophobicity, allowing permeation through the phospholipid bilayer of cell membranes 
[59]. A predictive measure of hydrophobicity may be represented by a drug’s partition 




solvents (hydrophobic and aqueous) [59]. The optimal range of log P for passive diffusion 
of these drugs lies between -1 and 3.5 [59]. Therefore, large, hydrophilic drugs, such as 
biotherapeutics, cannot innately undergo this pathway. Enhanced transcellular 
permeability of these compounds has been achieved using agents that enhance membrane 
fluidity, such as surfactants, bile salts, and fatty acids and their derivatives [3, 60-63]. 
However, a major drawback of these absorption-enhancement agents is that they are non-
specific, and in turn risk importing toxins, allergens, or pathogens that may reside in the 
GI tract, along with the drug of interest, into the bloodstream [3, 63]. Furthermore, 
modulating membrane fluidity of the GI epithelial barrier often cause cytotoxicity, 
inflammation, and mucosal damage [3, 63]. Moreover, although passive diffusion is an 
efficient mode of transport, the rate of diffusion cannot be well regulated. Targeting of 
therapeutics to markers involved in the transport pathways described below, on the other 
hand, may offer greater regulation of transport into and/or across the GI epithelium.  
 
2.1.2.2 Carrier-Mediated Transcellular Transport 
Facilitated, carrier-mediated transport is another passive mechanism, as it is driven by a 
concentration gradient, which relies on membrane transporters on the apical and basolateral 
membranes to carry small polar compounds that are membrane-impermeable, including 
amino acids, oligopeptides, mono- and disaccharides, micronutrients (e.g., water-soluble 
vitamins), nucleic acids, bile acids, monocarboxylic acids, and phosphates [51]. Active, 
carrier-mediated transport of these compounds also uses membrane transporters, yet is 
driven by ATP or coupled to H+ or Na+ transporters, to mediate transport against a 




apical surface of epithelial cells, by coupling them to the said substrates that undergo 
facilitated and active transport. For example, a strategy that has shown much success 
involves targeting to the PepT1 transporter, which is specific to a wide range of substrates, 
but mainly di- and tripeptides [6, 64]. Derivatization of the parent drugs aclovir and 
enalaprilat, an ACE inhibitor, with substrates for PepT1 significantly increased their oral 
bioavailability [6, 64]. However, as a result of the size constraint required to access 
membrane transporters, this targeting strategy is limited to relatively small drugs. In 
addition, carrier-mediated transport is not limited to influx of drugs to the cell interior but 
is also responsible for efflux to the intestinal lumen, namely by the P-glycoprotein (P-gp) 
efflux transporter [6]. As a result, drugs that enter the cell by carrier-mediated transport 
may also undergo efflux by P-gp transporters, resulting in reduced oral absorption [2, 3, 
6].  
 
2.1.2.3 Transcellular Transcytosis 
As opposed to transcellular diffusion and carrier-mediated pathways, transcellular 
transcytosis provides transport of bulky compounds, such as transferrin, vitamin B12-
intrinsic factor complexes, immunoglobulins, globular proteins, lectins, and viral 
hemagglutinins [6, 46]. Binding to cell-surface receptors involved in this pathway triggers 
internalization of materials on the apical surface via membrane invagination (endocytosis), 
traffic of endocytic vesicles across the enterocyte, and exocytosis at the basolateral 
membrane [46]. The classical endocytic pathways include: (A) macropinocytosis, a 
mechanism allowing uptake of extracellular fluid into large micrometer size vesicles and 




utilized by specialized immune cells, which involves uptake of large particulate ligands via 
formation of large endocytic vesicles called phagosomes; (C) clathrin-mediated 
endocytosis, the major route of endocytosis in most cell types, which is triggered by 
binding of specific ligands to their receptors in the plasma membrane, leading to 
internalization of extracellular macromolecules along with extracellular fluid into vesicles 
coated by the cytosolic protein, clathrin (clathrin-coated pits); and (D) caveolae-mediated 
endocytosis, a mechanism used by many cell types, characterized by uptake of materials 
into flask-shape vesicles enriched with the protein caveolin-1, which occurs in areas of the 
plasma membrane concentrated with cholesterol and glycolipids [6, 51, 52, 65]. 
In many cases, these uptake pathways determine the subsequent intracellular 
trafficking of the internalized materials. Macropinocytosis, phagocytosis, and clathrin-
mediated pathways generally deliver materials via endosomes to lysosomes for 
degradation, whereas caveolae-mediated endocytosis delivers materials to various 
compartments including the cytosol, the Golgi complex, and the endoplasmic reticulum, in 
addition to lysosomes [51, 52, 65, 66]. Importantly, both clathrin- and caveolae-mediated 
endocytosis can transport materials across cells via transcellular transcytosis [6, 46]. 
However, classical endocytic pathways exploited by current targeting strategies may be 
sub-optimal in that they undergo non-specific uptake, as in the case of phagocytosis and 
macropinocytosis, or are restricted to ligands typically <100 nm, as in the case of clathrin- 
and caveolae-mediated endocytosis. Non-classical endocytic pathways that are 
independent of clathrin pits and caveoli may also trigger transcytosis [13, 46], yet these 




Targeting to receptors involved in transcytosis has shown significant promise for 
enhanced oral delivery of high molecular weight drugs and drug carriers that do not meet 
the size restrictions for carrier-mediated transport, such as numerous peptide and protein 
therapeutics and their delivery vehicles [2, 6]. Notable examples include targeting drugs to 
vitamin B12 and transferrin receptors, which results in clathrin-mediated endocytosis and 
transcytosis of the ligand-drug complex [6, 46, 67], and targeting to the folate receptor, 
which triggers caveolae-dependent vesicular transport [46, 68]. Another well characterized 
strategy is coupling of drugs or their vehicles to plant- or pathogen-derived lectins, such as 
wheat germ agglutinin, concavalin A, and tomato lectin, that bind to carbohydrate receptors 
on the apical cell membrane [3, 69]. Such binding has been shown to induce transport into 
and across GI epithelial cells by classical and non-classical vesicular pathways, depending 
on the type of carbohydrate receptor that is engaged [69].   
 
2.1.2.4 Paracellular Transport 
On the other hand, the paracellular pathway involves transepithelial transport of molecules 
across the aforementioned junctions that interlock adjacent epithelial cells. For instance, 
small and hydrophilic compounds <200 Da may diffuse through small pores (~4.5 Å) of 
tight junctions. Passive diffusion via the paracellular route also depends on other 
physicochemical properties, such as molecular dimension and overall ionic charge [70, 71]. 
For example, anionic peptides with α-helix conformation are transported to a significant 
extent, while β-sheet conformers of the same peptide do not [72]. Therefore, the ability of 
drugs to adopt a flexible conformation may bypass size constraints for paracellular 




substances is difficult to regulate. Alternatively, paracellular transport can be induced by 
disturbance of intercellular junctions, leading to the passage of macromolecules from the 
lumen [73]. The latter phenomenon can be induced by targeting to certain cell-surface 
receptors, such as those that bind cytokines, toxins, and pathogenic factors [73, 74], which 
in turn, cause cytoskeletal changes that regulate opening of epithelial junctions [73]. 
Another strategy for this purpose is co-administration of reagents to enhance paracellular 
transport of drugs, including calcium chelators and cationic and anionic polymers used for 
drug delivery [3]. However, similar to the strategies described above for enhancing passive 
transcellular diffusion, prolonged modulation of epithelial junctions may compromise 
barrier integrity in that it leads to non-specific passage of undesired materials across the 
mucosa. Hence, the specificity of carrier- or receptor-mediated transcellular mechanisms 
may offer a safer and more controlled route of oral absorption.  
In summary, targeting therapeutics to membrane transporters and endocytic 
receptors that mediate transcellular and paracellular transport may provide: (A) improved 
biodistribution to the GI epithelium, the site of drug absorption; and (B) delivery into 
and/or across this barrier, valuable for interventions aimed at treating the lining itself or 
entering the systemic circulation for treating tissues beyond the GI tract. While paracellular 
transport is indiscriminate in its passage of substances, risking entry of pathogens, the 
specificity of transcellular pathways to the drug of interest may better maintain the 
permeability barrier and allow greater regulation of transport. Moreover, relative to carrier-
mediated transport, receptor-mediated transcytosis is less restrictive in terms of the size 
and chemistry of drugs that may employ these pathways. In addition, the cellular fate of 




depends on the design of the targeted systems. For example, transport parameters are 
influenced by the type of receptor targeted as well as the number of receptor-ligand 
engagements during binding, which we will describe in more detail in the following 
section. In light of the flexibility of receptor-mediated pathways, and the ability to better 
regulate delivery outcomes, the work herein explores this avenue for improving oral drug 
delivery.   
 
2.2 Targeting of Drug Conjugates vs. Drug-Loaded Nanocarriers 
Targeting of therapeutics can be achieved by (A) direct conjugation of targeting ligands to 
the drug itself (drug conjugates), or by (B) coupling targeting ligands to the surface of drug-
loaded NCs. NCs are macromolecular nano-assemblies fabricated from a variety of 
biocompatible materials, designed to carry therapeutic agents by encapsulation or surface-
loading [8, 41]. Functions of nanocarriers include solubilization of hydrophobic drugs, 
protection of drugs against premature inactivation and en route to the target, optimization 
of a drug’s pharmacokinetics (including circulation and tissue distribution), control of drug 
release kinetics, and control of drug metabolism and elimination [8, 41]. A great diversity 
of NCs has been designed with this purpose, including (but not restricted to) nanotubes and 
other carbon nanostructures, branched dendrimers, phospholipid liposomes, and 
amphiphilic polymers formulated as self-assembled micelles or polymer particles (Fig. 2.3) 





Figure 2.3. Nanocarriers for drug delivery. 
Dendrimers are the smallest of NCs, with a diameter of only a few nanometers, yet 
their extensive branching allows for high drug loading [75-78]. However, their small size 
makes it difficult to control their passive diffusion through tissues within the body, which 
may be an advantage or disadvantage depending on the application [76, 78].  Phospholipid-
based vehicles, called liposomes, arguably represent the most extensively studied drug 
vehicles [8, 79]. Liposomes are highly unstable in the GI tract, as a result of degradation 
by low gastric pH, pancreatic lipases, and bile salts, as well as the circulation, due to uptake 
by macrophages in the reticuloendothelial system [8]. To prolong circulation time and 
lower side effects of immune activation, “stealth” liposomes have been formulated by 
surface-grafting of poly(ethylene glycol) (PEG) [80]. However, the stability of “stealth” 
liposomes is limited, given that they are unable to bear more than 15% PEG on their surface 
without destruction of the phospholipid membrane. Polymersomes, the polymer analog of 
liposomes, have overcome these limitations, as they are capable of handling up to 100% 




prolonged circulation half-life of days as compared to hours for “stealth” liposomes [81, 
82]. In addition, polymer nanoparticles can be designed to present varied shapes, sizes, and 
drug loading capacities, almost entirely modulated by the processing conditions used [83-
85]. Once formed, they are the most stable of the NCs [83, 85]. Hydrophobic drugs can be 
incorporated into the polymer matrix during formulation, and hydrophilic drugs can be 
loaded into interior compartments during formulation or subsequently attached to the 
particle surface [83, 85].  
Solid polymer nanoparticles served as model NCs in this dissertation, provided that 
they are capable of adsorbing hydrophilic targeting agents and therapeutics onto their 
surface, while retaining the stability of these components in physiological conditions [12-
15, 27, 30, 31, 37]. As a result, this model provides ample targeting and subsequent 
endocytosis and intracellular trafficking in cell culture and in vivo, according to numerous 
studies by our lab [27, 30, 31, 37].  
Both receptor-targeting conjugates and carriers are valuable drug vehicles, yet it is 
expected that they would significantly differ in their ligand-receptor interactions and, 
therefore, subsequent drug delivery outcomes, such as biodistribution, cellular uptake, 
intracellular trafficking, transcytosis, metabolism, and elimination [7]. In particular, 
different targeting outcomes are influenced by the valency of such ligand-receptor 
engagement: a small, monomeric drug conjugate typically involves interaction of one 
ligand with one receptor (or two if a divalent antibody is used), while larger, multimeric 
drug conjugates and NCs employ multiple copies of a ligand to engage multiple copies of 
a cell surface receptor [7]. Therefore, understanding the cellular fate of monomeric (one 




systems is important in order to determine the efficacy of these strategies and the selection 
of suitable therapeutic applications, while also providing insight on the biological 
regulation of their cell surface receptors.  
In addition to providing distinct physiological outcomes, monomeric and 
multimeric carriers may endow different formulation advantages and drawbacks. For 
example, monomeric ligand-drug conjugates constitute a simpler formulation that lack 
exogenous materials and processing steps in synthesizing NCs. Due to the reduced 
complexity of these systems, they better reflect natural ligands, and in turn, may minimize 
immunogenicity and toxicity. However, direct conjugation to drugs by physical or 
chemical means may compromise the structure and activity of drug compounds. 
Encapsulation into nanocarriers may help to preserve drug activity, as well as provide 
higher drug payload. In light of these varying benefits from the perspectives of 
manufacturing and therapeutic efficacy, it is worthy to evaluate the potential of direct 
conjugation and carrier methods in parallel, as we aimed to do in this work.  
 
2.3 ICAM-1 Targeting for Oral Delivery 
2.3.1 Targeting to the ICAM-1 Receptor 
Among the various endocytic receptors targeted for drug delivery, extensive work by our 
lab has demonstrated that ICAM-1 is particularly favorable for circumventing various 
challenges encountered in oral and systemic drug delivery. Constitutive expression of 
ICAM-1 on the GI epithelium and various other cell types, including endothelial cells in 




these sites, as demonstrated by efficient binding of ICAM-1-targeted platforms in GI 
epithelial and endothelial cell cultures [12, 13, 31, 86] and biodistribution to various organs 
(e.g., heart, lung, and brain) in mice  [9, 24, 25, 27, 31]. ICAM-1 is a transmembrane 
glycoprotein that contains 5 extracellular domains that extend out into the luminal space 
[10, 11]. For endothelial cells, this has been shown to provide access to drug delivery 
systems from the circulation even in conditions with high shear stress (i.e. rapid blood 
flow) [31, 87]. This may also be the case for the GI tract, which exhibits high shear from 
peristalsis and mucus turnover. Indeed, anti-ICAM and anti-ICAM NCs were able to target 
GI tissue in vivo to a greater extent than non-targeted counterparts [15]. In addition, ICAM-
1 is overexpressed in many pathologies in light of its role in leukocyte binding and 
transmigration during inflammation [10], favorable for targeting sites of disease in the GI 
and other tissues. Indeed, moieties with affinity to ICAM-1, including peptides and 
antibodies and their fragments, are currently being explored as therapeutics and targeting 
agents for intervention against inflammation, immune disorders, cardiovascular disease, 
genetic and metabolic syndromes, and cancers, among other conditions, as evaluated in 
cell cultures, animal models, and clinical trials, and do not seem to induce adverse side 
effects [9, 25-27, 33, 36, 88-92].  
 
2.3.2 CAM-Mediated Endocytosis and Transcytosis 
As depicted in Fig. 2.4, binding of polymer carriers bearing multiple copies of ICAM-1-
targeting moieties (multimeric binding) induces ICAM-1 clustering followed by uptake 
into cells by a pathway known as CAM-mediated endocytosis, which is distinct from the 




not previously observed for anti-ICAM antibodies in solution, which were shown to remain 
on the cell surface [9]. Carrier binding causes ICAM-1 to cluster in membrane domains 
that are enriched in sphingomyelin and Na+/H+ exchanger 1 (NHE1) [12, 93]. These 
domains promote recruitment of acid sphingomyelinase (ASM) from intracellular 
compartments to sites of NC binding. ASM hydrolyzes sphingomyelin into ceramide, a 
lipid involved in plasmalemma deformability and cytoskeletal reorganization [93]. 
Multimeric binding to ICAM-1 also initiates a signal transduction pathway that activates 
protein kinase C, Src kinase, and Rho-dependent kinase (ROCK). Along with ceramide 
production, these signals regulate the interaction of ICAM-1 with the cytoskeleton (e.g., 
through alpha-actinin and ezrin-radixin-moesin -ERM- proteins) and also help regulate the 
recruitment of other effectors to the plasma membrane, such as dynamin-2, which 
associates with the actin cytoskeleton to induce vesiculization and subsequent vesicle 
traffic [12]. Following internalization, ICAM-1-targeted NCs traffic to early and late 
endosomes, a process that takes 1-2 hours, during which the NCs dissociate from ICAM-1 
and ICAM-1 recycles to the plasma membrane [92]. The NCs then arrive at lysosomes 
about 3 hours after internalization [92]. CAM-mediated endocytosis has been shown to 
pervade various cell types that express ICAM-1, including cultured vascular endothelial 
cells, GI epithelial cells, neurons, astrocytes, and fibroblasts, as well as vascular endothelial 






Figure 2.4. CAM-mediated endocytosis and transcytosis. Reprinted with permission [95]. 
 
 
Relative to classical endocytic routes, this pathway provides much flexibility in 
terms of internalizing carriers of different size (100 nm – 10 µm), shape, chemistry, 
targeting valency, and bulk concentration [24, 25, 27]. The kinetics of trafficking and 
subcellular destination can further be controlled by certain pharmacological agents and the 
size, shape, and targeting valency of carriers [24, 25, 91]. Fundamental characterization of 
CAM-mediated endocytosis and strategies for optimizing uptake and intracellular 
trafficking has allowed us to exploit this pathway for effective and precise intracellular 
delivery of various therapeutic and imaging agents, while preserving their functional 




mediated delivery of biotherapeutics for improving systemic delivery upon intravenous 
injections. Among the biotherapeutics studied for this purpose, delivery of replacement 
enzymes for the treatment of lysosomal storage disorders (LSDs) has shown much success 
over non-targeted counterparts, in terms of biodistribution to target organs in mice, as well 
as binding, trafficking to the target intracellular destination (lysosomes), and attenuation 
of disease symptoms in cell culture [30, 31, 36]. As a result of these promising results, our 
subsequent studies, including the work shown herein, evaluated the potential of this 
strategy for oral delivery of enzymes as a model therapeutic. 
In addition to providing intracellular uptake, ICAM-1 has been shown to mediate 
transcellular transport of anti-ICAM NCs across an in vitro models of the GI epithelial and 
brain vascular endothelial barriers [13, 14]. Our results suggest this occurs by CAM-
mediated transcytosis (Fig. 2.4) that does not lead to passive leakage of substances 
associated with the paracellular route. We also observed efficient transport of a model 
biotherapeutic enzyme, alpha-galactosidase (α-Gal), into and across GI epithelial cells 
[13]. These results show the promise of using ICAM-1-targeted platforms for oral delivery. 
In addition, the plasticity demonstrated in terms of the targeting valency in addition to the 
chemistry and size of carriers and cargo molecules that can efficiently use the CAM 
pathway over more restrictive vesicular mechanisms (e.g., clathrin, caveolar) [9, 12, 24-
34], as described above, make this strategy particularly attractive to explore GI delivery 






2.3.3 Potential for Oral Delivery using Monomeric Ligands against ICAM-1 
Whereas previous literature alluded to minimal uptake of monomeric anti-ICAM by 
radioisotope tracing, precluding further characterization [9], recent findings utilizing 
fluorescence microscopy revealed that uptake of monomeric anti-ICAM is indeed 
significant (Chapter 5). Unlike multimeric ICAM-1-targeting strategies used in the past, 
this revealed a novel opportunity for oral delivery of agents directly coupled to single 
copies of ICAM-1-targeting moieties. Monomeric ligand-drug conjugates offer greater 
simplicity relative to anti-ICAM NCs, which could ultimately reduce manufacturing costs. 
As mentioned above, moieties that do not bear drugs bind to and neutralize ICAM-1, which 
demonstrated therapeutic efficacy and safety in clinical trials [45, 89]. Therefore, targeting 
by monomeric anti-ICAM may serve a double function by anchoring drugs to the GI 
mucosa to improve oral bioavailability and diminishing ICAM-1-involvement in 
pathology. In addition, as seen in previous literature and unpublished findings by our 
group, ICAM-1-targeting valency affects the mode of intracellular and transcellular 
trafficking [37]. Hence, anti-ICAM may provide alternative avenues of delivery that are 
more amenable to certain therapeutic applications than those provided by multimeric 
carriers. However, these avenues have yet to be fully characterized to understand the oral 
delivery potential of this strategy. 
 
2.3.4 Need for Encapsulation of ICAM-1 Targeted Systems 
To evaluate the potential of ICAM-1 targeting strategies for oral delivery in vivo, 




revealed targeting of these systems to GI tissue, the efficacy of these strategies was limited 
by gastric degradation, which in turn, curtailed intestinal biodistribution [15]. This 
prompted the need to encapsulate ICAM-1 targeted platforms to more accurately evaluate 
oral delivery in vivo. Encapsulation of anti-ICAM NCs was performed in this dissertation, 
since the efficacy of this system for delivery into and across GI epithelial cells has been 
previously demonstrated in cell culture [13]. As shown in Fig. 1.3 (Section 1.2), the main 
requirements of encapsulation would therefore be to provide protection of the targeting 
antibody from harsh gastric conditions, site-specific release of targeted NCs in intestinal 
conditions, and preservation of targeting ability following release.  
 
2.4 Encapsulation for Oral Delivery 
Whereas targeting of therapeutics may address various cellular barriers to oral delivery, 
such as mucosal adhesion and transport, the efficacy of these strategies in vivo is 
nevertheless limited by premature degradation or deactivation of labile drugs and targeting 
components, as in the case of ICAM-1 targeted systems. For instance, the low gastric pH 
and proteolytic enzymes of the stomach may prematurely deactivate, denature, or degrade 
drugs, particularly those that are protein-based or acid-sensitive [3]. In addition, 
therapeutics may experience changes in hydrophobicity, ionization, and aqueous solubility 
upon transitioning from low gastric pH to neutral intestinal pH, leading to potential 
destabilizing effects and/or suboptimal absorption [1]. The lumen of the small intestine, 
mainly the duodenum, as well as the brush border of enterocytes, also contains a variety of 





2.4.1 Hydrogels as Controlled Release Vehicles for Drug Delivery 
The obstacles described above can be overcome by encapsulation in controlled release 
vehicles. Ideally, controlled release vehicles meet the following requirements: (A) 
protection of encapsulated contents from premature degradation/deactivation in the 
stomach, and (B) release at the site of drug absorption, with the most common site being 
the small intestine owing to its large absorptive capacity [4]. Encapsulation strategies may 
also provide controlled release, which entails maintaining the drug concentration within a 
therapeutic window over an extended period of time. This, in turn, minimizes the amount 
and frequency of dosages, and reduces potential toxicity and ineffectiveness associated 
with a rapid burst and fall of drug concentration, respectively [4]. 
Among the encapsulation materials used for this purpose, hydrogels offer 
significant potential for oral delivery in that they fulfill the essential requirements of 
controlled release vehicles [4]. Hydrogels are composed of hydrophilic polymers that are 
crosslinked by physical or chemical means to form three-dimensional networks entrapping 
a drug of interest [4].  They may employ one or more natural polymers which are 
biodegradable and biocompatible, such as alginate, chitosan, agarose, gellan, carrageenan, 
pectin, gelatin, etc., and/or synthetic polymers that can be tailored with desired 
biodegradability and functionality, including polyacrylic and polymethacrylic acids, PEG, 
and poly(vinyl alcohol) [4, 5, 16, 96]. These materials are also approved for commercial 
use [5]. A variety of processing methods allows flexibility in creating hydrogels of different 
size, shape, morphology, and other physical characteristics suiting the desired application. 




mucoadhesive, whereby they adhere to the mucus layer on the GI epithelium, thereby 
reducing the rate of clearance from the absorption site [4, 5, 16, 97]. 
 
2.4.2 Characteristics of Hydrogels for Oral Drug Delivery  
2.4.2.1. Stability in Storage Conditions 
When hydrogel networks are intact, they retain aqueous media from its surrounding 
environment. Hence, hydrophilic drugs, such as biotherapeutics, are likely to remain stable 
when loaded into hydrogels. The degree of drug loading and diffusion in or out of the 
hydrogel network is dependent on the chemical structure of polymers and mesh size, as 
determined by the density of a crosslinking agent [98, 99]. For instance, a higher 
crosslinking density limits the expansion of the polymer strands that contribute to swelling 
and drug leaching [98]. Mesh size also affects the physical properties of the gel, including 
mechanical strength and degradation, both of which affect stability in storage conditions 
[98].  
 
2.4.2.2. Stimuli-Responsive Release 
Hydrogels are also highly favorable for oral drug delivery because of their ability to 
respond to environmental changes in the GI tract that alter their structure, swelling, 
permeability, or mechanical strength, all of which contribute to controlling drug release 
[100]. In the context of oral delivery, responsiveness to stimuli allows hydrogels to protect 




of the GI tract, e.g. the small intestine. Hydrogels have been designed to respond to various 
physical and chemical stimuli, yet those relevant for oral delivery mainly exploit the pH 
transition between the acidic environment of the stomach and neutral environment of the 
intestine [4, 101]. 
The pH-dependent properties of hydrogels often relies on the presence of ionizable 
pendant groups on the polymer chain [4, 16, 101]. Charged pendant groups impart 
electrostatic repulsion between the polymer chains, influx of water, and swelling and/or 
dissolution the network, leading to drug release [4]. Anionic pendant groups, such as those 
containing carboxylic acids (pKa ~3), remain neutral when the pH is below its pKa, and 
negatively charged when the pH is above its pKa [17, 102, 103]. The opposite is true for 
cationic pendant groups (e.g., amines), which are positively charged when the pH is below 
their pKa and neutral when the pH is above their pKa, amenable for release in the stomach 
rather than the intestine [101]. Since cationic polymers remain intact in neutral conditions, 
they are often incorporated with anionic polymers to prevent drug leakage in storage or 
provide a more controlled release pattern at intestinal pH [16, 47-49, 104-107]. The release 
kinetics of pH-responsive polymers can be further optimized by modulating the type and 
number of ionizable pendant groups as well as cross-linking density [101]. Moreover, since 
the strategies utilized to provide stability in storage also affect release patterns in the GI 







2.4.3 Types of Hydrogels 
2.4.3.1 Synthetic vs. Natural Hydrogels 
Both synthetic and natural polymers offer pH-responsive properties, among other 
important functionalities for drug delivery. Engineering of synthetic polymers and their 
derivatives permits greater control and fine-tuning of these functionalities, yet their harsh 
processing conditions may compromise the integrity of loaded drugs, particularly 
biotherapeutics [4, 16]. Many synthetic hydrogels also lack biocompatibility and trigger 
adverse immune reactions in the body [16]. Although formulations consisting of natural 
polymers display lower mechanical stability and control of drug delivery parameters, 
advantages are that they are well characterized, biocompatible, and involve gentle and 
simple encapsulation methods for loading biological materials of diverse size, shape, and 
function [4, 17, 47-49, 105-109]. Their physiochemical properties are also more suitable 
for biological agents, as these polymers are derived from nature [4, 96]. For these reasons, 
natural polymers, namely alginate and chitosan, were utilized for the encapsulation of the 
therapeutic delivery platforms employed in this work. Nevertheless, no hydrogel system is 
ideal, and the benefits and drawbacks of each polymer type must be accounted for when 
selecting a drug delivery application. 
 
2.4.3.2 Alginate Hydrogels  
Alginate is a natural polysaccharide derived from brown algae. It is a linear, anionic 
copolymer comprised of 14 linked -D-mannuronic acid and α-L-guluronic acid 




inexpensive, biocompatible, and biodegradable, justifying its widespread use in the food 
and pharmaceutical industries [17]. Dropwise addition of alginate containing a drug of 
interest into a crosslinking solution of divalent cations, such as Ca2+, is a simple method 
that forms solid beads with a mesh size between 3 and 200 nm, amenable for entrapment 
of macromolecules [17]. Unlike covalent crosslinking methods, such as free radical 
polymerization, physical crosslinking by ionic interactions minimizes side reactions that 
may alter or deactivate the drug and avoids the need for loading after gel formation. Also, 
alginate microspheres can be formed at room temperature [17, 48, 49]. The gentle 
processing conditions associated with this encapsulation strategy has been widely used for 
efficient loading of labile biological entities, such as microbial and eukaryotic cells, 
globular proteins, antibodies, vaccines, etc., without compromising their structure or 
functional activity [16, 17, 47-49, 105-111]. This also demonstrates the flexibility of 
loading a wide range of size and structures. The presence of negatively charged carboxyl 
end groups confers other favorable qualities that improve biodistribution to the intestine 
and ultimately enhanced bioavailability of drugs. These include high mucoadhesion and 
pH sensitivity, whereby alginate beads shrink at low pH and dissolve at neutral or basic pH 
[16, 17, 48, 49, 105, 106, 109]. One caveat of unmodified alginate beads includes poor 
loading if the network mesh size is larger than the encapsulated content. Increasing the 
cation concentration may circumvent this issue and confer greater stability in terms of 
mechanical strength, yet only to certain extent [49]. Another problem is rapid dissolution 
of the alginate matrix at higher pH, leading to burst release in the intestine [16, 48, 49]. 
Hence, techniques for sustained release patterns are being studied for the purpose of 





Figure 2.5. Alginate and chitosan hydrogels. (A) Chemical structure of alginate, a linear anionic 
polymer (pKa ~ 3.5) composed of guluronic (G) and mannuronic acid (M) residues arranged in 
consecutive or alternating order. (B) Consecutive G-blocks of alginate are crosslinked with Ca2+ in 
the form of egg box structures. (C) Chemical structure of chitosan, a linear cationic polymer (pKa 
~ 6.5) containing D-glucosamine and N-acetyl-D-glucosamine residues.  
 
2.4.3.3 Chitosan Hydrogels 
To improve drug entrapment and control over release, alginate beads can be reinforced 
with a chitosan shell by addition of chitosan during or after bead formation [16, 47-49]. 
Chitosan is a natural polysaccharide produced by N-deacetylation of chitin, found in 
crustacean shells (Fig. 2.5C). Like alginate, chitosan is also widely used in the food and 
pharmaceutical industries owing to its affordability and biocompatibility among other 
features. The presence of positively charged amine groups within this copolymer, 
comprised of -(1,4)-linked D-glucosamine and N-acetyl-D-glucosamine, form 
spontaneous electrostatic complexes with alginate and other anionic polymers [16]. In 
addition to providing greater mechanical stability and drug loading in alginate beads, 
chitosan swells and forms a hydrogel in acidic conditions. This helps to slow release of 
drugs from alginate matrices in intestinal conditions [49]. Chitosan is also a mucoadhesive 
agent, which prolongs residence time at the site of absorption [16]. This strategy also 
provides versatility for optimizing loading, stability, and release, for example by varying 
the capsule size, crosslinking density of the polymer core, thickness and crosslinking 




gum, carrageenan, etc.) [16, 48, 49, 96, 105, 106, 109]. As a result, chitosan alone or in 
combination with other polymers has been utilized for many applications, including oral 
delivery of various biological agents with high instability [16, 96].  
Encapsulation in alginate and chitosan hydrogels has not previously been utilized 
for oral delivery of targeting systems, including ICAM-1 targeted systems. These systems 
may particularly benefit from this strategy due to the aforementioned advantages of these 
polymers, including gentle and simple encapsulation, protection in gastric conditions, 
release in intestinal conditions, and functional preservation of various labile materials, such 
as the targeting antibodies used herein [4, 17, 47-49, 105-109]. With these benefits in mind, 
the goal of this work was to encapsulate anti-ICAM NCs, which previously shown to target 







Chapter 3: Materials and Methods 
3.1 Reagents 
Mouse monoclonal immunoglobulin G (IgG) against human ICAM-1 (clone R6.5) and rat 
monoclonal IgG against mouse ICAM-1 (clone YN1), herein collectively called anti-
ICAM, were isolated from the respective hybridomas from ATCC (Manassas, VA, USA). 
Non-labeled mouse IgG, rat IgG, goat anti-mouse IgG, rabbit anti-human lysosomal-
associated membrane protein 1 (LAMP-1), rabbit anti-HRP, as well as FITC- and Texas 
Red (TxR)-labeled secondary antibodies were from Jackson Immunoresearch (West 
Grove, PA, USA). HRP-conjugated secondary antibodies were from General Electric 
Healthcare Bio-Sciences (Pittsburg, PA, USA). Goat anti-human Rab11a was from Abcam 
(Cambridge, MA, USA). Green Alexa Fluor 488-labeled streptavidin, TxR dextran, blue 
Alexa Fluor 350-labeled secondary antibodies, and FluoReporter FITC Protein Labeling 
Kit® were from Invitrogen (Grand Island, NY, USA). Horseradish peroxidase (HRP) 
conjugation kit was from Innova Biosciences (Cambridge, UK). Green Fluoresbrite® 100 
nm diameter polystyrene particles were from Polysciences (Warrington, PA, USA). 
Medium molecular weight chitosan (200-800 cps; 75-85% deacetylated), alginic acid 
sodium salt from brown algae (low viscosity), pepsin, and pancreatin were purchased from 
Sigma Aldrich (St. Louis, MO, USA). Protease inhibitor cocktail was from Thermo 
Scientific (Rockford, IL, USA). Simulated gastric fluid without enzymes (SGF) and 
simulated intestinal fluid without enzymes (SIF) were from Cole-Parmer (Vernon-Hills, 
IL). Reagents for gel electrophoresis were from Bio-Rad (Hercules, CA, USA). 
Chemiluminescent detection reagents for Western blot assays were from General Electric 




Plainfield, NJ, USA). Na125I was from Perkin Elmer-Analytical Sciences (Wellesley, MA). 
Iodination tubes and tetramethylbenzidine (TMB) substrate for HRP was from Thermo 
Fisher Scientific (Rockford, IL, USA). Unless otherwise stated, all other reagents were 
from Sigma Aldrich (St. Louis, MO, USA). 
 
3.2 Cell Culture 
As a model of GI epithelial cells, we used human colorectal adenocarcinoma (Caco-2) 
cells, which were kindly provided by Dr. Jerrold Turner (Department of Biological 
Sciences, University of Chicago, IL). Cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (GibcoBRL, Grand Island, NY, USA) supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin, and maintained at 37 °C, 
5% CO2 and 95% relative humidity. Cells between passages 4-5 were either seeded onto 
12-mm2 gelatin-coated coverslips in 24-well plates, or as shown in Fig. 3.1, onto transwell 
filter inserts (polyethylene terephthalate, 0.4-µm-pore size; BD Falcon, Franklin Lakes, 
NJ) at ~100,000 cells/cm2. When indicated, cells were treated with 10 ng/ml tumor necrosis 
factor-alpha (TNFα; BD Biosciences, Franklin Lakes, NJ, USA) 16 h prior to assays to 
mimic an inflammation-like status, as it pertains to many diseases [13].  
In the transwell system, the status of the cell monolayer was assessed by measuring 
the transepithelial electrical resistance (TEER) using an EVOM™ volt-ohm meter and 
STX100 electrodes (World Precision Instruments, Sarasota, FL). Confluent monolayers 




status was previously verified by the presence of tight junctions and microvilli [13], were 
selected for experiments. 
Figure 3.1. Cell culture models. (A) Cells cultured onto coverslips in 24-well plates. (B) Cells 
cultured onto transwell inserts for evaluating transepithelial transport from the apical chamber to 
the basolateral chamber.  
 
Some mechanistic studies were also assessed in a model of vascular endothelial 
cells, i.e. human umbilical vein endothelial cells (HUVECs) from Clonetics (San Diego, 
CA, USA). This model was used due to its known ICAM-1 expression, which is relatively 
high, and previous experience in our laboratory testing targeting of anti-ICAM NCs on 
these cells [12, 31, 93, 112]. HUVECs were grown in M199 medium (GibcoBRL, Grand 
Island, NY, USA) supplemented with 15% fetal bovine serum, 2 mM glutamine, 15 mg/mL 
endothelial cell growth supplement, 100 mg/mL heparin, 100 U/mL penicillin, and 100 
mg/mL streptomycin. Cell cultures were maintained at 37 °C, 5% CO2, and 95% relative 
humidity. Cells between passages 4 and 5 were seeded onto 12 mm diameter gelatin-coated 
coverslips in 24-well plates and treated with 10 ng/mL TNF-α for 16 h to induce ICAM-1 





3.3 Iodination of Antibodies 
Radioisotope labeling of antibodies with 125Iodine (125I) was done by incubating ~20 µCi 
of Na125I and iodination tubes with 100 µL of 1 µg/µL protein for 5 minutes over ice. Free 
125I not bound to the protein was removed from the iodinated protein mixture through 
centrifugation (1000 × g for 4 min) in a 6 kDa cutoff gel size exclusion column (Biorad, 
Hercules, CA), which eluted only the iodinated protein. Prior to filtering the iodinated 
protein, the column was inverted several times to thoroughly homogenize the gel, then 
washed with 2 mL of phosphate-buffered saline (PBS), and packed by centrifugation 
(1000g for 1 minute). The concentration of the eluted iodinated protein was determined 
with a Bradford assay compared to known bovine serum albumin (BSA) concentrations. 
The amount of free 125I remaining in the eluted iodinated sample was estimated by 
performing a trichloroacetic acid (TCA) precipitation assay by mixing 2 µL of iodinated 
protein with 1 mL of 3% BSA-PBS and 0.2 mL of 100% TCA to precipitate the iodinated 
protein. After a 15 minute incubation period at room temperature, TCA samples were 
centrifuged (2755 × g for 5 min) and the supernatant was measured for 125I content using a 
gamma counter (2470 Wizard2; PerkinElmer; Waltham, MA). From this, the percent of 
free 125I was determined and subtracted to estimate the specific activity, denoted as 125I 
counts-per-minute (CPM) per µg protein. 
 
3.4 Preparation of Model Antibody-Coated Nanocarriers 
For the following monomeric and multimeric ICAM-1 targeting models, a well 




non-specific IgG or anti-ICAM were coated onto 100 nm diameter, green fluorescent 
(Fluoresbrite®) polystyrene particles to render IgG NCs or anti-ICAM NCs. Where 
indicated, antibodies were labeled with 125I for quantification using a gamma-radiation 
counter. As previously described [30, 114], 5 μM antibody was incubated with ∼1013 
particles/mL for 1 h at room temperature to allow adsorption of the antibody on the particle 
surface. Non-coated antibody was removed by centrifugation at 13,800 × g for 3 min, and 
coated particles were resuspended at ∼7 × 1011 NCs/mL in 1% BSA-PBS, and sonicated 
to remove aggregates [30, 114]. The hydrodynamic diameter of the resulting antibody-
coated NCs was determined by nanoparticle tracking analysis (NanoSight LM10, Malvern 
Instruments, Westborough, MA), and the polydispersity index and ζ-potential were 
measured by dynamic light scattering (DLS; Zetasizer NanoZS90, Malvern Instruments, 
Westborough, MA, USA). In addition, the number of antibodies coated per particle was 
calculated using the equation below [30, 114]. The characterization of NCs is described in 
Section 4.2.1. 
Antibody Molecules per NC = [(CPMNC / Specific Activity) / MWAb] * Navo 
where CPMNC are the 
125I counts-per-minute per NC, Specific Activity is the CPM/µg 
protein obtained using the protocol described in Section 3.3, MWAb is the antibody 
molecular weight, and Navo is Avogadro’s number.  
Polystyrene particles were selected as a NC model because this material is not 
biodegradable and, hence, it allows us to evaluate degradation or protection of the antibody 
counterpart in extracellular conditions or during transport, without confounding effects of 
polymer degradation. Our previous works have shown that this model displays similar 




and biodistribution as NCs composed of biocompatible poly(lactic-co-glycolic acid) [39, 
40]. With regard to the antibody coat, surface adsorption of antibodies on polystyrene 
particles is believed to preferentially render an outward display of antibody variable 
regions, owing to hydrophobicity of the Fc region and the antibody concentration used 
[115], although a random orientation is conceivable. This is not conceptually different from 
covalent conjugation of antibodies, which also yields a random antibody orientation 
because the conjugation occurs at any of the available antibody residues. Extensive 
characterization of this formulation has shown negligible coating with serum proteins 
(albumin), presumably due to saturation of the NC surface with antibodies, with no 
apparent changes in aggregation or antibody detachment (whether in storage, physiological 
media, serum, or under varying temperature and pH), or fluorescence intensity at 
physiological pH [12-15, 27, 30, 31, 37, 86, 87, 93, 112, 116, 117]. In these reports, the 
antibody coating, hydrodynamic size, polydispersity index, and ζ-potential were also 
highly reproducible across independent formulations and batches, which is further 
supported by similar observations in binding, uptake, intracellular trafficking, and in vivo 
biodistribution [12-15, 27, 30, 31, 37, 86, 87, 93, 112, 116, 117]. 
 
3.5 Preparation of Multimeric Antibody Conjugates  
An alternative multimeric model lacking a polymer particle consisted of anti-ICAM protein 
conjugates. For this purpose, anti-ICAM was biotinylated at a 1:5 antibody-to-biotin molar 
ratio using 6-biotinylaminocaproic acid N-hydroxysuccinimide ester, as previously 




(green) Alexa Fluor 488-labeled streptavidin at 1:1 molar ratio for 1 h at 4°C. The 
hydrodynamic diameter, polydispersity index, and ζ-potential were determined using DLS.  
 
3.6 Preparation of Monomeric Antibody-Enzyme (HRP) Conjugates 
Following the manufacturer’s instructions (Lightning Link® HRP Conjugation Kit by 
Innova Biosciences; Cambridge, UK), anti-ICAM or non-specific IgG (13 μmol/L) were 
incubated with LL-Modifier reagent® (1 μl/μl of antibody) and lyophilized HRP (21 
μmol/L) for ~ 3 h at room temperature before quenching with LL-Quencher reagent® (1 
μl/μl of antibody). This reaction covalently links primary amine groups of the antibody to 
lysine residues of HRP, and theoretically yields conjugates with a 1:2 antibody-to enzyme 
molar ratio. Verification of the molecular weight and presence of antibody-enzyme 
conjugates were performed using separation by SDS-PAGE followed by Coomassie blue 
staining of the resulting protein bands and, in parallel, Western blot analysis to 
immunodetect either the antibody or enzyme counterparts, as described in the Results 
section. Unconjugated HRP and antibodies served as controls.  
In addition, antibody-enzyme conjugates or control unconjugated counterparts 
were fractionated using Asymmetrical Flow Field-Flow Fractionation (AF4) with Multi-
Angle Light Scattering (MALS) and Quasi-Elastic Light Scattering (QELS) detection 
(Wyatt Technology, Santa Barbara, CA). An Agilent UV detector (wavelength set at 280 
nm) and a Wyatt Optilab T-rEX differential refractive index (RI) (Wyatt Technology, Santa 
Barbara, CA, USA) detectors were connected sequentially to the channel outlet to monitor 




molar mass cut-off regenerated cellulose membrane (Microdyn, Raleigh, NC) for the 
separation inside a short channel. Flow was controlled using Eclipse software (Wyatt 
Technology). The AF4 carrier liquid was 10 mmol/L phosphate buffered saline at pH 7.4. 
Samples were injected while focusing at 2.2 mL/min for 2 min. The injection step was 
followed by a second focusing step of 2.2 mL/min for 2 min. The crossflow was kept 
constant at 1.4 mL/min for 24 min while eluting the injected samples at 0.6 mL/min. UV, 
RI, and MALS data were obtained followed by conversion into molar mass, particle size, 
and size distributions using vendor-supplied software (ASTRA® 6.1.2.84). MALS 
intensity (wavelength of 690 nm) was measured at 15 angles simultaneously. MALS data 
were collected at 1 s intervals and QELS data at 5 s intervals. The QELS data were fitted 
to a single-mode exponential decay model to measure the translational diffusion coefficient 
with the hydrodynamic radii of the particles calculated via Stokes-Einstein equations. The 
apparent molar mass was calculated from the collected UV, RI, and MALS data using 
Zimm formalism with molar extinction coefficient of 1.4 mL/gcm, which is that of 
antibodies in aqueous solutions, and a specific refractive index value (dn/dc) of 0.18 mL/g. 
In addition to this characterization of the conjugate mixture by AF4, the eluted conjugate 
species were separated into two major fractions (233 kDa and 686 kDa), as described in 
Section 6.2.1.  
 
3.7 Preparation of Alginate and Chitosan-Alginate Microspheres and Beads 
The following protocols for alginate microsphere and bead formation were adapted from 
[48, 105, 107, 119, 120], which were optimized to produce the desired physical and loading 




vortexed with antibody-coated NCs (16% and 32% v/v NCs to alginate for microspheres 
and beads, respectively; 2.7 × 1011 NCs/g alginate) to yield a homogenous suspension. As 
shown in Fig. 3.2, alginate solution was pumped at 5 µl/min by a peristaltic syringe pump 
through 100 µm inner diameter polyether ether ketone (PEEK) capillary tubing (SGE 
Analytical Science; Austin, TX, USA) for microspheres or a 20 G, 0.6 mm inner diameter 
needle for larger beads, from a height of 4 cm into a crosslinking medium of 2% CaCl2. In 
the case of microspheres, polymer droplets were extruded by co-axial air flow (5 psi). To 
additionally coat alginate microspheres/beads with chitosan, chitosan was first dissolved 
in 1% v/v aqueous acetic acid at a concentration of 0.25 or 1% w/v , and adjusted to pH 5 
using NaOH. Alginate microspheres/beads, with or without antibody-coated NCs, were 
incubated with the chitosan solution for 1 h at room temperature under gentle agitation, 
and then washed with 2% CaCl2 [119, 121]. When indicated, rhodamine-labeled chitosan 
was used to confirm the presence and location of this coating using fluorescence 
microscopy. To crosslink the chitosan coat, an aqueous solution of genipin (1 mg/ml) was 
incubated with 1% chitosan-alginate microspheres for 24 h at room temperature, and 





Figure 3.2. Encapsulation methods. (A) Method for formulating alginate microspheres ~180 µm 
in diameter, or (B) larger alginate beads ~2.8 mm in diameter. 
 
3.8 Characterization of the Antibody-Coated Nanocarrier Loading in Microspheres 
Radioisotope quantification of 125I-antibody-coated NCs was also used to calculate the 
number of NCs per alginate or chitosan-alginate microsphere, the percent (%) loading, and 
the encapsulation efficiency (EE%), using the following equations: 
NCs per microsphere = CPMmicrosphere / CPMNC 
% Loading = (NCs per microsphere / NC Concentration) / Vmicrosphere × 100% 




where CPM are the 125I counts-per-minute per microsphere (CPMmicrosphere) or per NC 
(CPMNC), and V is the theoretical volume of each microsphere (Vmicrosphere), as derived 
from their mean diameter. In parallel with radioisotope tracing, fluorescence microscopy 
was used to verify the presence of NCs within microspheres (settings described in Section 
3.26).  
 
3.9 Microsphere Stability and Release in Storage Conditions 
To evaluate stability in storage conditions, alginate or chitosan-alginate microspheres 
loaded with antibody-coated, fluorescent NCs were incubated in 2% CaCl2 at 4 C over the 
period of 4 weeks. At the indicated time intervals, small aliquots were removed and 
analyzed by several means. First, fluorescence microscopy (10x objective) was used to 
image sample aliquots, from which the size and number of microspheres that were 
visualized as apparently intact were quantified, as well as their sum and mean fluorescence 
intensity. These parameters indicate potential changes in the microsphere size, their 
degradation, and relative changes in loading over time, as compared to the initial time of 
encapsulation (Day 1).  
In addition, release of 125I-antibody-coated, fluorescent NCs from microspheres 
was quantified by removing aliquots at the indicated time intervals, followed by 
centrifugation at 1000 × g for 1 min to separate the released (supernatant) and encapsulated 
(pellet) fractions. The radioisotope content and fluorescence intensity of each fraction, 
corresponding to the 125I-antibody coat and fluorescent NC counterparts, were quantified 




release was expressed as radioisotope or fluorescence content in the released fraction with 
respect to the total content (the sum of the released fraction and the encapsulated fraction).  
 
3.10 Status of Microsphere-Encapsulated Antibody-Coated Nanocarriers in Storage 
Conditions  
Since no significant release of antibody-coated NCs 4.2.4 was observed under storage 
conditions (2% CaCl2, 4 °C), after 24 h in storage, we incubated microspheres for 4 h at 37 
C in 50 mM EDTA in dH2O with shaking (150 rpm). Given that EDTA serves to extract 
Ca2+ (the reversible crosslinking agent) from the alginate matrix, this provides a means to 
induce the release of encapsulated NCs, enabling us to study their status while in storage.  
To examine the status of the antibody moiety of encapsulated NCs, which is 
responsible for their targeting ability, 125I-antibody counterparts were used in the NC 
formulation. Antibody degradation was assessed by quantifying the free 125Iodine present 
in the released NC fraction, as determined by a trichloroacetic acid (TCA) precipitation 
assay [30, 114]. This was expressed as a percentage of the total radioisotope content in said 
released fraction.  
In parallel, the ability of released NCs to bind to a surface-immobilized model 
target (a secondary antibody that recognizes the primary antibody on the NC coat) was 
evaluated using an in vitro binding assay in 24-well plates. For this purpose, wells were 
coated with 1 μg/ml goat anti-mouse IgG for 1 h at room temperature, then washed to 
remove unbound secondary antibody, and blocked with 1% BSA-PBS for 2 h at room 




NCs that had been released from microspheres. NCs that bound to immobilized antibodies 
as well as non-bound NCs were collected and measured using a gamma counter. The 
percentage of NCs bound with respect to the total NCs added to wells, as well as the 
absolute number of NCs bound per well were obtained.  
As controls, we incubated antibody-coated NCs that were not encapsulated within 
microspheres in the same conditions as encapsulated counterparts.  
 
3.11 Microsphere Stability and Release in Simulated Gastrointestinal Fluids  
The stability of microspheres loaded with antibody-coated NCs and the release of this 
content from microspheres were also evaluated in conditions mimicking the physiological 
pH of the GI, using methods and reagents adopted from U.S. Pharmacopeia (USP). NC-
loaded microspheres were incubated under agitation (150 rpm) for 2 h at 37 C in simulated 
gastric fluid (SGF; pH 1.2). Then, the microspheres were transferred to simulated intestinal 
fluid (SIF; pH 6.8), where they were incubated under agitation (150 rpm) for 4 h at 37 C. 
Aliquots from the SGF and SIF solutions were removed at the indicated time points, from 
which we evaluated microsphere size, number of microspheres that appeared visibly intact 
(per field), and their fluorescence loading by fluorescence microscopy, as described for 
assays in storage conditions.  
In parallel, release of 125I-antibody NCs from the microspheres was addressed using 






3.12 Status of Encapsulated and Released Antibody-Coated Nanocarriers in Simulated 
Gastrointestinal Conditions 
Microspheres were first incubated up to 2 h at 37 ºC in SGF with or without pepsin, then 
analyzed or transferred to SIF with or without pancreatin for additional 4 h at 37 °C. As in 
the case of microspheres in storage conditions, those incubated for 2 h in SGF showed no 
significant release and, hence, release of antibody-coated NCs was induced by EDTA 
treatment as described above, to assess their status. For other cases, NC release resulted 
from pH-triggered microsphere dissolution, and this step was not necessary. In cases where 
incubations had been conducted in the presence of enzymes, a protease inhibitor cocktail 
was added to the samples at the time of evaluation, to preclude further proteolysis. 
Degradation of antibodies comprising the NC coat was assessed by quantifying the 
free 125Iodine content vs. the total 125Iodine content in the released NC fraction (to obtain 
the percent degradation), as described above for storage conditions. Also, the ability of the 
released NCs to bind a surface-immobilized target (secondary antibody) was pursued, 
following the procedures described above for microspheres in storage conditions. The 
percentage of NCs bound with respect to the total NCs added to wells, as well as the 
absolute number of NCs bound per well, were calculated.  
Non-encapsulated antibody-coated NCs incubated in the same conditions as those 
encapsulated within microspheres, served as controls.  
 





Fluorescent non-specific IgG NCs or anti-ICAM NCs were encapsulated within alginate 
microspheres or 0.25% chitosan-alginate microspheres, and then incubated in SGF and, 
subsequently, SIF (in the presence of pepsin and pancreatin, respectively), as described 
above. At the indicated time points, NCs released from microspheres were incubated for 2 
h at room temperature with ICAM-1-expressing Caco-2 cells and HUVEC (see Section 
3.2). Cells were imaged by fluorescence microscopy (60x objective), and the number of 
NCs bound per cell was quantified using algorithms generated for this purpose, as 
described in previous works [15, 36, 37] and in Section 3.26. Binding was compared to 
that of anti-ICAM NCs that were not encapsulated but subjected to the same GI-mimicking 
conditions.  
 
3.14 Oral Gavage in Mice 
C57BL/6 wild type mice (Jackson Laboratory, Bar Harbor, ME) were first fasted for 2-4 
hours [20]. Then, mice underwent oral gavage with 0.25% chitosan-alginate microspheres 
(~1.5 × 104 microspheres/animal) loaded with 125I-anti-ICAM NCs or non-specific 125I-IgG 
NCs vs. non-encapsulated 125I-anti-ICAM NCs. In all cases, the administered doses were 
similar: ~1.1 mg antibody/kg, equivalent to 1.5 × 1013 NCs/kg. After 1 h from oral gavage, 
mice were sacrificed and the stomach, small intestine (duodenum, jejunum, ileum) and 
large intestine (cecum and colon) were isolated, from which the 125I content, percent free 
125I of the sample, and the weight were measured [15, 30]. These data were used to calculate 
percentage of the total gavaged dose per gram (% dose/g) accumulated in said GI 
compartments, as well as the degradation of the antibody (labile) counterpart of NCs using 




protocol R-13-15, which is in accordance with IACUC and University of Maryland 
regulations.  
 
3.15 ICAM-1 Distribution and Recycling in the Absence of Ligands 
To examine potential transit of ICAM-1 between the cell-surface and intracellular vesicles, 
TNF-α-activated HUVECs were incubated with 10 µg/ml cyclohexamide to inhibit de novo 
protein synthesis which may confound results. After 1 h, cells were fixed and ICAM-1 
expressed on the cell-surface was immunostained in red using anti-ICAM followed by 
TxR-labeled goat anti-mouse IgG. Cells were then permeabilized and total cell-associated 
ICAM-1 (surface + intracellular) was labeled using anti-ICAM followed by green FITC 
goat anti-mouse IgG. Using this method, the percentage of green, single-labeled ICAM-1 
that does not colocalize with double-labeled (FITC+TxR) ICAM-1 represents the 
intracellular fraction, which was quantified by fluorescence microscopy, as described in 
Section 3.26.  
 
 
3.16 Intracellular Trafficking of ICAM-1 in the Absence of Ligands 
To assess endocytosis of ICAM-1 in the absence of ligands, TNF-α-activated HUVECs 
were incubated continuously for 30 min, 1 h, 3 h, or 5 h at 37°C with 20 µg/ml TxR-labeled 
tomato lectin to stain the cell surface. After different periods of time, cells were washed 




followed by blue Alexa Flour 350-goat anti-mouse IgG. Cells were then permeabilized and 
total cell-associated anti-ICAM was labeled in green with anti-ICAM and FITC goat anti-
mouse IgG. Using this method, surface-located ICAM-1 should colocalize with lectin and 
appear white (green FITC + red TxR + blue Alexa Fluor 350), while intracellular ICAM-1 
that was endocytosed from the cell surface should colocalize with lectin and appear yellow 
(green FITC + red TxR). Cell-surface ICAM-1 which did not colocalize with lectin should 
appear turquoise (blue Alexa Fluor 350 + green FITC) and intracellular ICAM-1 which 
does not colocalize with lectin should be green (FITC). Tracking these different fractions 
and their ratios over time, it is possible to discern potential trafficking of ICAM-1 between 
the cell surface and internal compartments by fluorescence microscopy. The mechanism of 
such a transport was also tested in the presence of 3 mM amiloride (inhibited in CAM-
mediated endocytosis and macropinocytosis) or 0.5 μM wortmannin (inhibited in 




3.17 Binding of Monomeric Anti-ICAM Assessed by Fluorescence Immunostaining 
Control or TNFα-activated Caco-2 cells cultured on coverslips or transwell inserts were 
incubated continuously at 37 °C from 30 min to 5 h with complete cell medium containing 
75 pM anti-ICAM or non-specific IgG. Cells were washed to remove non-bound 
antibodies, then fixed for 15 min at room temperature with 2% paraformaldehyde and 




with cells were immunostained using green FITC-labeled goat anti-mouse IgG for 1 h at 
room temperature, followed by visualization by fluorescence microscopy, as described in 
Section 3.26 [114].  
 
3.18 Verification of Targeting and Enzyme Activity upon Targeting of Anti-ICAM-HRP 
Conjugates 
Control Caco-2 cells were fixed to preclude uptake and permit only binding, and then 
incubated for 1 h at room temperature with either anti-ICAM-HRP conjugates or control 
IgG-HRP conjugates (75 pM antibody and 150 pM HRP, as per the 233 kDa conjugate 
observed in the Results section), vs. non-conjugated HRP (150 pM; 43 kDa) or anti-ICAM 
(75 pM; 155 kDa). Other controls consisted of incubation with anti-ICAM-HRP conjugates 
in the presence of 75 pM anti-ICAM, a specific competitor for ICAM-1 binding, or non-
specific IgG. Total cell-bound antibody counterparts were immunostained using green 
FITC-labeled goat anti-mouse IgG, while total cell-bound HRP (naked or conjugated to 
antibodies) was immunostained with rabbit anti-HRP followed by TxR-goat anti-rabbit 
IgG. Binding was assessed by quantifying in micrographs the mean green or red 
fluorescence intensity (in arbitrary units, A.U.) for anti-ICAM or HRP, respectively, which 
also allowed us to determine the percentage of antibody colocalization with HRP, or vice 
versa, as dual-labeled (yellow) fluorescence [36, 114].  
In addition to fluorescence quantification by microscopy, we also measured HRP 
activity that remained bound on cells after washing. This was conducted by incubating the 




vendor instructions, followed by quenching with 2 M sulfuric acid. Absorbance at 450 nm 
was then quantified by spectrophotometry and the amount of HRP was derived from 
standard curves correlating absorbance and HRP activity (for unconjugated and conjugated 
forms) under the same reaction conditions. 
 
3.19 Degree and Mechanism of Uptake of Monomeric vs. Multimeric Anti-ICAM  
HUVEC (TNF-α-activated) or Caco-2 cells (control or TNF-α-activated) were incubated 
with monomeric anti-ICAM (140 pM), multimeric anti-ICAM NCs (36 pM antibody, since 
this formulation has greater avidity vs. anti-ICAM [86]), or multimeric anti-ICAM 
conjugates (214 pM antibody) for 30 min in 1% BSA-supplemented cell medium to allow 
their binding to the cell surface (pulse period). Control experiments were performed using 
either non-specific IgG or IgG NCs, or by incubating anti-ICAM conjugates in the presence 
of competing anti-ICAM vs. non-specific IgG. After this time, cell medium containing 
non-bound counterparts was removed, and cells were washed and incubated at 37ºC with 
fresh medium for 30 min to 4.5 h to allow internalization of surface-bound materials (chase 
period). In parallel, incubation at 4ºC served as a negative control for energy-dependent 
uptake. Alternatively, to evaluate the mechanism of uptake, incubations were performed in 
the presence of either 3 mM amiloride (an inhibitor of macropinocytosis and CAM-
mediated endocytosis), 50 μM monodansylcadaverine (MDC; inhibitor of clathrin-
mediated endocytosis), 1 μg/ml filipin (inhibitor of caveolar endocytosis), or 0.5 μM 
wortmannin (inhibitor of phosphatidylinositol 3 kinase (PI3K), involved in 
macropinocytosis) [12]. The specificity of these inhibitors was previously confirmed using 




All cell samples were then fixed with 2% paraformaldehyde for 15 min at room 
temperature. Surface-bound anti-ICAM, anti-ICAM NCs, or anti-ICAM conjugates were 
immunostained with TxR-labeled goat anti-mouse IgG for 1 h. Since polymer particles and 
streptavidin contain a green fluorescent label, all cell-associated anti-ICAM NCs and anti-
ICAM conjugates are visible in the green channel while only surface-located counterparts 
fluoresce in the red channel, thus enabling differential visualization and quantification, as 
described [12, 114]. In the case of monomeric anti-ICAM, after similarly immunostaining 
cell-surface counterparts in red, cells were permeabilized with 0.2% Triton X-100, 
followed by incubation with green FITC-labeled goat anti-mouse IgG, which would label 
all cell-associated anti-ICAM in green, thereby enabling similar distinction and 
quantification of cell-surface bound vs. internalized counterparts by fluorescence 
microscopy. In both cases, in addition to endocytosis, the localization of anti-ICAM, anti-
ICAM NCs, and anti-ICAM conjugates within 5 μm of the cell nucleus (perinuclear) or 
within 5 μm from the cell border (herein called periphery) was also quantified. 
 
3.20 Cellular Uptake of Anti-ICAM-HRP Conjugates 
Anti-ICAM-HRP conjugates were either non-separated (control mixture) or separated by 
AF4 into the 233 kDa and 686 kDa fractions described above (to distinguish uptake upon 
monomeric vs. multimeric binding) and their uptake was assessed by fluorescence 
immunostaining. For this purpose, control Caco-2 cells were incubated with non-separated 
and separated anti-ICAM conjugates or IgG-HRP conjugates (75 pM antibody and 150 pM 
HRP) for a pulse period of 30 min at 37 °C, followed washing and incubation at 37 °C with 




vs. presence of 3 mM amiloride, to verify CAM-mediated uptake. Cells were fixed and the 
antibody counterpart of surface-bound conjugates was immunostained in red using TxR-
goat anti-mouse IgG. Cells were then permeabilized and incubated with green FITC-goat 
anti-mouse IgG, to label all bound and internalized antibody molecules. In parallel 
experiments, a similar procedure was used to immunodetect surface-bound vs. internalized 
HRP counterpart. Hence, in both cases, the cell-surface bound fraction was double-labeled 
in green and red (yellow) while internalized counterparts were single-labeled in green. 
Using the methods noted above, cell samples were analyzed by fluorescence microscopy 
to quantify the absolute internalized fluorescence and the percentage of internalized 
fluorescence corresponding either to the antibody or the enzyme [36, 114].   
In addition to microscopy analysis, internalized enzyme activity was evaluated by 
incubating Caco-2 cells for 30 min at 37 °C with non-conjugated anti-ICAM or HRP vs. 
anti-ICAM-HRP conjugates or IgG-HRP conjugates (same concentrations as noted above), 
in the absence vs. presence of 3 mM amiloride, which inhibits CAM-mediated endocytosis. 
Cells were washed and tested for HRP activity without permeabilization, which would 
primarily render activity bound on the cell surface. In parallel, cells treated similarly were 
washed and permeabilized to gain access to the cell interior and obtain the total surface-
bound and internalized enzyme activity. In both cases, HRP activity was assessed by 
incubation with TMB for 20 minutes at room temperature and spectrophotometric 
measurement, from which the HRP amount was derived using activity standard curves, as 
described above.  
 




TNF-α-activated HUVECs or control Caco-2 cells cultured on coverslips were incubated 
with either green FITC-labeled anti-ICAM, non-specific IgG, anti-ICAM coated onto 
green Fluoresbrite® NCs, or green Alexa Fluor 488-labeled anti-ICAM conjugates for a 
pulse of 30 min, as described above. Cells were then washed and incubated for up to 1 h, 
3 h, or 5 h (37°C) in the absence of a ligand, as described above. Cells were subsequently 
fixed and permeabilized, and lysosomes or recycling compartments were immunostained 
with anti-LAMP-1 or anti-Rab11a, respectively, followed by TxR-labeled secondary 
antibodies. In the case of anti-ICAM conjugates, an additional lysosomal labeling method 
was used to avoid cell permeabilization and subsequent leakage of the fluorescent dye from 
degraded conjugates. Here, cells were pre-treated with 10 kDa TxR dextran for 45 min at 
37°C, washed, and incubated with fresh medium for another 45 min at 37ºC prior to 
addition of anti-ICAM conjugates [122]. This protocol enables lysosomal trafficking of 
dextran, which allows visualization of this compartment due to lack of dextran degradation 
by mammalian cells, as previously verified [122]. Colocalization of green-labeled anti-
ICAM, anti-ICAM NCs, or anti-ICAM conjugates with each one of these red-labeled 
compartments (lysosomes or recycling endosomes) was calculated from fluorescence 
micrographs, as described in Section 3.26 [122]. The number of endocytic vesicles 
containing monomeric or multimeric anti-ICAM and the number of LAMP-1 and dextran-
labeled compartments was additionally quantified (Section 3.26).  
 
3.22 Intracellular Degradation of Monomeric vs. Multimeric Anti-ICAM 
Using the protocol described above, degradation of naked green FITC-labeled anti-ICAM 




total fluorescence remaining over time (chase incubation) to the cell-associated 
fluorescence achieved after the first 30 min pulse incubation. Agents that have been 
previously shown to inhibit lysosomal trafficking, nocodazole (20 μM) [122], or to inhibit 
activation of lysosomal hydrolases, chloroquine (300 μM) [122], were used as controls for 
degradation. These agents were incubated with cells during the chase period only to 
preclude potential effects on uptake. In the case of green anti-ICAM NCs, cells were 
incubated with TxR goat anti-mouse IgG after permeabilization, to immunodetect anti-
ICAM on the surface of internalized particles. Hence, lack of antibody degradation was 
visualized as colocalization of TxR-labeled anti-ICAM with green fluorescent particles, 
while degradation was observed as single-labeled green-particles. Time-dependent 
degradation of anti-ICAM on NCs was calculated by comparing the number of antibody-
free particles to the total number of cell-associated particles, as described [122].  
3.23 Transepithelial Transport of Anti-ICAM in Epithelial Cell Monolayers  
To track total binding and transport of anti-ICAM vs. control IgG in live Caco-2 
monolayers, antibodies were labeled with 125-Iodine [13]. The radioisotope content of 125I-
antibodies was measured using a gamma counter and protein concentration was determined 
by a Bradford assay. Control 125I-IgG or 125I-anti-ICAM (70 pM; 56 nCi/ml) was added to 
the chamber above Caco-2 cells and incubated at 37C for the indicated time intervals. The 
radioisotope content in the chamber above the cells (non-bound antibodies), the chamber 
below the cells (transported antibodies), and the cell fraction (bound and internalized 
antibodies) was measured using a gamma counter. Free 125Iodine released from antibodies 
(i.e., from degradation) was determined by TCA precipitation of each fraction, and this 




antibodies present in the samples. After subtraction, the number of molecules bound to the 
epithelial monolayer, the number of molecules transported across the monolayer, the 
percentage of molecules transported with respect to the total number associated to cells, 
and the apparent permeability coefficient (Papp) were determined using the following 
equations, 
 
Molecules bound/cell = [(CPMcell fraction / Specific Activity) / MW × Navo] / 150,000 cells 
Molecules transported/mm2 = [(CPMbasolateral / Specific Activity) / MW × Navo] / 0.32 
mm2 
% Transported = 100 x [CPMbasolateral / (CPMbasolateral + CPMcell fraction)] 
Papp (cm/s) = (CPMbasolateral  Vol.) / (A × t × CPMadded) 
 
where CPM are the 125Iodine counts-per-minute added to the upper chamber (CPMadded), 
the cell fraction (CPMcell fraction), or the lower chamber (CPMbasolateral), and Specific Activity 
is the CPM/g of protein, MW is molecular weight (g/mol), Navo is Avogadro’s number, A 
is the surface area of the filter membrane (cm2), Vol. is volume of medium in the upper 
chamber (ml), and t is time of incubation (s). 
 
3.24 Mechanism of Transepithelial Transport of Anti-ICAM 
Transcellular transport of 125I-anti-ICAM by a vesicular mechanism was assessed in 20 
µmol/L 5-(N-ethyl-N-isopropyl) amiloride (EIPA), which inhibits the exchanger protein, 
NHE-1, involved in macropinocytosis and CAM-mediated transport [91]. Paracellular 




albumin) added above Caco-2 cells, in the presence of anti-ICAM. This was compared to 
125I-albumin transport in the absence of anti-ICAM or in 5 mM H2O2 known to disrupt cell 
junctions. In all experiments, TEER was monitored before and after all incubations to 
evaluate the status of the permeability barrier. 
 
3.25 Transport of Anti-ICAM-HRP Conjugates in Epithelial Monolayers 
Anti-ICAM-HRP conjugates were either non-separated (control mixture) or separated by 
AF4 into the 233 kDa and 686 kDa fractions described above (to distinguish uptake upon 
monomeric vs. multimeric binding), and 70 pM of control vs. separated conjugates were 
incubated with Caco-2 monolayers cultured on transwell inserts for 24 h at 37 °C. To assess 
the specificity of transport, Caco-2 monolayers were incubated for the indicated time 
intervals at 37°C with 70 pM HRP, anti-ICAM, non-specific IgG-HRP conjugates, or anti-
ICAM-HRP conjugates in the presence or absence of anti-ICAM or IgG competitors. The 
apical, cell, and basolateral fractions were collected and measured for HRP activity by a 
spectrophotometric enzyme assay in phenol red-free cell culture media. Absorbance at 450 
nm was then converted to the amount of active HRP (pM) using standard curves conducted 
in experimental reaction conditions, as described above.  
To assess the mechanism of transepithelial transport of anti-ICAM-HRP 
conjugates, the above experiment was conducted in the presence of 20 µM EIPA, as 
described above. Paracellular transport was evaluated by monitoring TEER during 
transport of conjugates. 
 




Samples were analyzed using a 10x or 60× PlanApo objective, as indicated, and the 
Olympus IX81 inverted 3-axe automatic fluorescence microscope (Olympus Inc., Center 
Valley, PA). Samples were observed by phase contrast and fluorescence using filters from 
Semrock (Rochester, NY) in the red channel (excitation BP360–370 nm, dichroic DM570 
nm, emission BA590–800+ nm), green channel (excitation BP460–490 nm, dichroic 
DM505 nm, emission BA515–550 nm), or blue channel (excitation BP380–400 nm, 
dichroic DM410 nm, emission BA415–480 nm). Micrographs were taken using Orca-ER 
camera from Hamamatsu (Bridgewater, NJ) and SlideBook 4.2 software from Intelligent 
Imaging Innovations (Denver, CO). Images were analyzed using Image-Pro 6.3 from 
Media Cybernetics Inc. (Bethesda, MD). Algorithms programmed for automatic image 
analysis were used to quantify diameter of objects, sum and mean fluorescence, number of 
NCs or objects ∼100-300 nm, and colocalization of objects labeled with different 
fluorophores [12, 36, 92, 122]. 
 
3.27 Statistical Analysis 
Data were calculated as mean ± standard error of the mean (S.E.M). For in vitro and animal 
studies the number of independent samples was ≥ 6. For cell culture assays conducted on 
coverslips (for fluorescence microscopy), the number of independent samples was ≥ 2. For 
cell culture assays conducted in transwell inserts, the number of independent wells was ≥ 
4. Statistical significance was determined by Student’s unpaired t-tests for comparisons 
between two groups, and one-way ANOVA followed by Tukey test for comparisons among 





Chapter 4: Encapsulation of ICAM-1 Targeted Nanocarriers 
into Chitosan-Alginate Hydrogels for Gastric Protection and 
Intestinal Release  
 
4.1 Introduction 
As described in Chapter 2, active targeting of therapeutics to specific markers within the 
body may enhance biodistribution to sites of disease, minimizing the effective dose 
required for therapy and hence, the associated toxicity [7, 52, 123]. Targeting ligands may 
be directly conjugated to a therapeutic of interest or coupled to the surface of drug-bearing 
NCs to further improve drug solubility, stability, biodistribution, metabolism, and 
clearance [7, 8].  
As said, active targeting is not only employed to improve drug biodistribution 
toward selected cells, but may also trigger receptor-mediated endocytosis, which in some 
cases leads to transcytosis [7, 52, 123]. This allows for transport of targeted drugs and their 
carriers across cells that control the passage of substances between body compartments, 
e.g. the endothelial lining that separates the bloodstream from underlying tissue or 
epithelial barriers at other interfaces [7, 52, 123]. 
To this end, active targeting and transport is valuable in the context of oral drug 
delivery, since targeted attachment to GI epithelial cells or uptake within these cells may 
improve treatment of GI disorders, while induced transport across this lining may enhance 
absorption into the circulation [2, 6, 54-58]. However, this strategy is limited by 
degradation or deactivation of labile targeting molecules (particularly protein-based ones) 




delivery systems to the intestine, the main site of drug absorption [53]. Hence, there is a 
need for protection of targeted drug carriers from degradation in gastric conditions as well 
as site-specific release in intestinal conditions, while preserving the activity of their 
targeting moieties.   
As an example, the work in this chapter looked into improving GI targeting upon 
oral delivery of NCs addressed to ICAM-1. As described in Chapter 2, targeting to ICAM-
1, e.g. using NCs coated with anti-ICAM antibodies or peptides, induces transport into and 
across cells via a CAM-mediated pathway that is clathin- and caveolae-independent [12-
14, 93, 112]. This strategy has demonstrated enhanced delivery of therapeutic enzymes into 
and across GI epithelial monolayers in culture [13]. In vivo implementation of this strategy 
via oral gavage in mice has also shown promise, as specific targeting was observed vs. 
non-specific IgG-coated NCs [15]. Yet, intestinal biodistribution was largely restricted by 
retention of anti-ICAM NCs in the stomach, as well as substantial degradation [15]. 
Therefore, anti-ICAM NCs, and other targeted formulations, could benefit from protection 
and site-specific release in the GI tract.  
Among the various polymers employed to satisfy these requirements [4], we 
selected alginate in light of numerous advantages, including low cost, low toxicity, 
biocompatibility, and biodegradability, as well as its effective encapsulation of active 
biological agents for protection and pH-sensitive release in GI conditions [16, 17, 48, 49, 
105-107, 109, 119, 121, 124]. Dropwise addition of alginate to an aqueous crosslinking 
solution of polyvalent or divalent cations, such as Ca2+, forms solid gel beads [16, 17]. The 
size of beads can range from a sub-millimeter (microspheres) to sub-centimeter scale 




In addition, alginate beads are often optimized by reinforcement with a chitosan coat during 
or after bead formation, providing greater mechanical stability as well as reduced drug 
leaching and burst release from alginate beads [16]. Chitosan is also a mucoadhesive agent, 
which prolongs residence time in the intestine [16, 124-126]. Despite the popularity of this 
strategy for encapsulation of therapeutics, encapsulation of targeted (ligand-coated) NCs 
in alginate and chitosan-alginate matrices for oral delivery has yet to be examined. Using 
the example of ICAM-1-targeted NCs, the work herein aimed at exploring this strategy. 
Our results demonstrate potential to improve ligand-mediated targeting for drug delivery 
systems to be administered via the oral route. 
 
4.2 Results 
4.2.1 Characterization of Antibody-Coated Nanocarriers  
Our overall goal is to enable the study of ICAM-1-targeted NCs administered via the oral 
route, which requires encapsulation of said NCs within controlled release vehicles, to 
protect their labile targeting moiety from premature gastric degradation and provide 
intestinal release. As a NC model, we used polystyrene nanoparticles labeled with a pH-
independent fluorophore, which were coated by surface adsorption with non-specific IgG 
or anti-ICAM (see Section 3.4). As shown in Table 4.1, this protocol rendered similar 
hydrodynamic diameter, polydispersity index, ζ-potential, and number of antibody 
molecules per NC for IgG NCs and anti-ICAM NCs. Antibody coating was also verified 
by an increase in NC diameter and more positive ζ-potential with respect to non-coated 




ICAM NCs compared to non-specific IgG NCs. For microsphere encapsulation and 
characterization of their stability, release, and protection against degradation we used IgG 
NCs, since this antibody is less costly and the properties of microspheres encapsulating 
IgG NCs should reflect those encapsulating anti-ICAM NCs, given that anti-ICAM is an 
IgG with similar molecular characteristics.  
 
Table 4.1. Nanocarrier characterization. 
 





Non-coated NCs 109 ± 2 0.06 ± 0.01 -39 ± 2 - 
IgG NCs 158 ± 5 0.19 ± 0.03 -31 ± 2 176 ± 8 
Anti-ICAM NCs 156 ± 2 0.22 ± 0.05 -27 ± 5 208 ± 43 
NCs = nanocarriers. Data are shown as means ± S.E.M. (n ≥ 3). 
 
4.2.2 Preparation of Nanocarrier-Loaded Alginate and Chitosan-Alginate Microspheres  
Alginate was selected based on its biocompatibility and gentle formulation [16, 17]. We 
employed a previously established co-axial air flow technique (see Materials and 
Methods), which renders homogeneous alginate microspheres with diameter <400 µm 
[107], a suitable size for oral gavage in mice. These microbeads are crosslinked by Ca2+ to 
efficiently entrap loaded contents [107]. Whereas this and other alginate 
microencapsulation methods have been extensively used for various biological agents [47-
49, 105-107, 109, 121], microencapsulation of antibody-coated NCs had not yet been 
assessed. To examine this aspect, we used the 125I-IgG-coated fluorescent NCs described 
above for both radioisotope and fluorescence quantification. Initial studies involved 




coat to increase their stability (Table 4.2). Contrary to internal gelation techniques, surface 
modification with chitosan was performed after formation of alginate microspheres to 
minimize changes in size and loading. 
 
Table 4.2. Size and loading of alginate and chitosan-alginate microsphere formulations. 




181 ± 0.4 
 
1.95 ± 0.01 × 106 
 
96.7 ± 1.7 
 
15.5 ± 0.3 
0.25% Chitosan-
Alginate 
185 ± 0.4 1.96 ± 0.01 × 106 99.1 ± 0.9 15.9 ± 0.2 
1% Chitosan-
Alginate 




178 ± 0.5 1.77 ± 0.05 × 106 95.1 ± 1.7 15.2 ± 0.3 
Theoretical Loading: 2.7 × 1011 NCs/g alginate; 16% v/v; 10% w/w. 
 
As shown in Table 4.2, both preparations rendered a uniform microsphere size 
distribution of ~180 μm in diameter, and spherical shape, as observed by phase contrast 
microscopy as well as by fluorescence microscopy of fluorescence-labeled NCs (Fig. 
4.1A). Fluorescence visualization also confirmed the presence of a chitosan coat (shown 
in red) for the corresponding microspheres, and NCs (shown in green) distributed within 
the alginate mesh (Fig. 4.1B). Quantification of entrapped NCs by fluorescence 
microscopy, which tracked the particle counterpart, revealed similar loading in both 
microspheres formulations (~1.2 x 108 A.U.; Fig. 4.1C). This corresponded to ~1.9 x 106 
NCs per microsphere, as per quantification of the antibody counterpart by radioisotope 
tracing (Fig. 4.1C and Table 4.2). As such, % loading and EE% were similar for both 




Table 4.2). Therefore, these formulations contained equivalent physical and loading 
characteristics with or without a chitosan coat, and both radioisotope and fluorescence 
tracing are viable methods to examine these parameters. 
 
 
Figure 4.1. Encapsulation of antibody-coated nanocarriers into alginate or chitosan-alginate 
microspheres. 125I-IgG-coated fluorescent NCs were encapsulated into alginate microspheres by 
co-axial air flow-driven extrusion through a 100 μm-diameter capillary needle into a crosslinking 
CaCl2 solution. Chitosan-alginate microspheres were prepared by further incubation of alginate 
microspheres with 0.25% chitosan. (A) Phase contrast and fluorescence microscopy images of 
alginate microspheres and 0.25% chitosan-alginate microspheres. Scale bar = 100 µm. (B) Dual-
fluorescence visualization of microspheres, with green NCs within the alginate core, in the presence 
(right) or absence (left) of a red rhodamine-labeled chitosan coat. Scale bar = 100 µm. (C) Loading 
assessed by radioisotope quantification of the antibody coat or fluorescence quantification (in 
arbitrary units, A.U.) of the NC counterpart. Data are Mean ± S.E.M. No statistically significant 
differences between alginate and chitosan-alginate formulations were observed.  
 
In addition, alginate and chitosan-alginate beads ~2.8 mm in diameter were 
prepared for future in vivo studies in larger animals, including rats, by similar methods 
employed to formulate microspheres except polymer was extruded through a 0.6 mm-
diameter needle. Coating with 0.25% chitosan was similarly performed following alginate 




of loaded fluorescent NCs (shown in green) within the alginate core was confirmed using 
confocal microscopy (Fig. 4.2A). Similar to microspheres, alginate beads were relatively 
homogenous in size and morphology, which was not altered with the addition of a chitosan 
shell following alginate bead formation (Table 4.3). Furthermore, we were capable of 
loading varying amounts of NCs into beads, as shown by UV illumination and fluorescence 
microscopy images (Fig. 4.2B). Radioisotope tracing of the 125I-antibody counterpart of 
NCs also revealed efficient loading of alginate beads (23% loading and 70 EE%; Table 
4.3), albeit lower than that of microspheres in terms of EE% (Table 4.2). This was 
equivalent to ~3.9 × 109 NCs/bead. The loading efficiency was not significantly altered 
with chitosan modification, as observed with microsphere formulations.  
Table 4.3. Size and loading of alginate and chitosan-alginate beads. 




2.8 ± 0.03 
 
3.9 ± 0.1 × 109 
 
70.8 ± 1.3 
 
22.7 ± 0.4 
0.25% Chitosan-
Alginate 
2.9 ± 0.04 4.0 ± 0.2 × 109 76.4 ± 3.9 24.4 ± 1.2 
Theoretical Loading: 2.7 × 1011 NCs/g alginate; 32% v/v; 20% w/w. 
 
 
Figure 4.2. Formulation and loading of alginate and chitosan-alginate beads. Alginate was 
extruded through a 0.6 mm needle and crosslinked with Ca2+ to produce beads ~2.8 mm. Chitosan-
alginate beads were formulated by incubating alginate beads in a 0.25% chitosan solution. (A) 
Confocal visualization of microspheres, with green NCs within the alginate core and a red 
rhodamine-labeled chitosan coat (left) and fluorescence intensity plots (middle and right). Bar = 
100 µm. (B) Fluorescence imaging of alginate or chitosan-alginate capsules with various loads of 
FITC-labeled IgG NCs (0-30% w/w) using UV illumination (top panel) and fluorescence 





Nevertheless, the following studies were conducted using 180 µm-diameter 
microspheres, given that they suit the size requirements for oral gavage in mice. Mice were 
selected for in vivo studies to provide a comparison with previous literature on GI 
biodistribution of non-encapsulated ICAM-1 targeted NCs [15].   
 
4.2.3 Stability of Nanocarriers-Loaded Microspheres in Storage Conditions 
To assess the stability of these formulations in storage conditions (CaCl2 at 4 °C), we first 
examined the release of 125I-IgG-coated fluorescent NCs from alginate microspheres or 
0.25% chitosan-alginate microspheres over time. Radioisotope tracing revealed minimal 
(<10%) release of encapsulated contents for both microsphere formulations over 28 days 
(Fig. 4.3A). This was in agreement with the low level (also <10%) of release observed by 
spectrofluorometry (Fig. 4.4A), indicating sufficient stability of these two formulations in 
storage. The similar release pattern determined by tracing the antibody vs. NC counterparts 
suggest that they exist as antibody-coated NCs within either microsphere type, given that 
their size difference would otherwise account for a different release rate from the alginate 
network. In fact, when release of antibody-coated NCs from microspheres was induced by 
incubation with EDTA (after 24 h in storage), and the released NCs were tested for their 
ability to bind surface-immobilized secondary antibodies, we observed similar binding 
(~90%) to that of antibody-coated NCs which were not encapsulated in microspheres (Fig. 
4.3B). Also, minimal amounts (<5%) of free 125Iodine, which is released upon antibody 
degradation, were found upon EDTA-induced release of NCs from the either microsphere 





Figure 4.3. Stability of nanocarrier-loaded microspheres in storage conditions. Alginate vs. 
0.25% chitosan-alginate microspheres loaded with 125I-IgG-coated fluorescent NCs were incubated 
in storage conditions (CaCl2, 4 °C). (A) At the indicated times, the radioisotope content of the 
released and encapsulated fractions were measured to calculate the percent release. (B) The 
encapsulated 125I-IgG-coated NCs were extracted from microspheres using EDTA and their ability 
to bind to surface-immobilized secondary antibody was assessed using radioisotope tracing. (C) 
The percentage of free 125Iodine, reflective of antibody degradation, was evaluated using 125I-
antibody-coated NCs extracted from microspheres as in (B). Non-encapsulated (non-encaps.) NCs 
were used as controls in (B) and (C). (D) After 28 days in storage, the diameter and number of 
microspheres per microscopy field were analyzed from fluorescence images, and expressed as the 
percentage of respective values at day 1. Data are Mean ± S.E.M. * Compares alginate vs. chitosan-
alginate formulations; & compares values between microsphere-encapsulated and non-
encapsulated NCs; # compares values at day 28 vs. day 1 (p<0.05, Student’s t test).  
 
Furthermore, the size, number, and loaded fluorescence content of alginate 
microspheres or chitosan-alginate counterparts, as measured by fluorescence microscopy, 
did not differ between the two formulations nor decreased over 28 days in storage (Fig. 
4.3D and 4.4B). Hence, encapsulated antibody-coated NCs are not degraded and retain 
their binding capacity during encapsulation and incubation in storage, concurrent with 






Figure 4.4. Release of fluorescent nanocarriers from microspheres in storage conditions. 
Alginate vs. 0.25% chitosan-alginate microspheres containing IgG-coated fluorescent NCs were 
incubated in storage conditions. (A) At the indicated times, aliquots were removed to assess the 
fluorescent NC content in the released vs. encapsulated fraction by spectrofluorometry, to 
determine percent release. (B) At day 28 in storage conditions, the sum fluorescence (in A.U.) per 
microsphere was quantified by fluorescence microscopy and expressed as a percentage of the 
fluorescence measured at day 1. Data are Mean ± S.E.M. No statistically significant differences 
were observed between alginate and chitosan-alginate formulations. # Compares values at day 28 
vs. day 1 (p<0.05, Student’s t test).  
 
4.2.4 pH-Dependent Release of Antibody-Coated Nanocarriers from Microspheres  
Next, we examined whether encapsulation within microspheres provided the intended 
release pattern at intestinal pH conditions, while precluding premature release at gastric 
pH. For this purpose, alginate microspheres and 0.25% chitosan-alginate microspheres 
(both containing similar loads of 125I-IgG fluorescent NCs) were first incubated in SGF 
(pH 1.2) for 2 h followed by SIF (pH 7.8) for 4 h. These experiments were first conducted 
without GI enzymes to assess the effect of pH transitions on release, while subsequent 
experiments examined microsphere behavior in the presence of GI enzymes.  
As seen in Fig. 4.5A, radioisotope tracing indicated that microspheres exhibited 
negligible release of antibody-coated NCs in SGF, with a slightly lower (but not 
significant) release in the absence of the chitosan coat (1% vs. 5% for alginate alone). 




fluorescence content did not markedly vary upon incubation at gastric pH: ~85-95% of 
microspheres appeared to be intact (Fig. 4.5B), their size was slightly reduced by ~20-30% 
(Fig. 4.5C), and they retained ~95% of the initial sum fluorescence content while the mean 
fluorescence per area increased ~40% (Fig. 4.6). This suggests that in gastric pH, 
microspheres shrank to a modest degree, yet did not release NCs and may, hence, protect 




Figure 4.5. pH-dependent release of nanocarriers from microspheres. Alginate and 0.25% 
chitosan-alginate microspheres loaded with 125I-IgG fluorescent NCs were incubated for 2 h at 37 
˚C in SGF at pH 1.2, and then transferred for 4 h at 37 ˚C to SIF at pH 7.8. (A) At the indicated 
times, aliquots were removed to assess the release of encapsulated NCs using radioisotope tracing. 
Aliquots were also removed after 1 h in SGF and 4 h in SIF (total incubation = 6 h) to quantify: (B) 
the number and (C) diameter of visibly intact microspheres from fluorescence microscopy images, 
expressed as the percentage of control values measured prior to GI incubations (t = 0). Data are 
Mean ± S.E.M. * Compares alginate vs. chitosan-alginate formulations; # compares values at each 






Figure 4.6. pH-dependent release of fluorescent nanocarriers from microspheres. Alginate 
and 0.25% chitosan-alginate microspheres loaded with IgG-coated fluorescent NCs were incubated 
for 2 h in SGF (pH 1.2) followed by a 4 h incubation in SIF (pH 7.8), as described in Fig. 4.5. At 
the indicated times, the: (A) sum fluorescence and (B) mean fluorescence intensity (sum / area) of 
visibly intact microspheres were quantified from fluorescence microscopy images. Values were 
expressed as a percentage of those measured prior to incubations (t = 0). Data are Mean ± S.E.M. 
* Compares alginate vs. chitosan-alginate formulations; # compares values at each time point 
against those at t = 0 (p<0.05, Student’s t test). 
 
Upon transferring microspheres to SIF, both formulations displayed burst release 
of antibody-coated NCs within the first hour (60-75% release), albeit to a lower extent for 
chitosan-coated microspheres (20% lower release; Fig. 4.5A). Whereas alginate 
microspheres reached the maximum level of release by this time, release from chitosan-
alginate microspheres did not appear to plateau until 4 h in SIF (Fig. 4.5A). Therefore, the 
chitosan coat may help modulate burst release from microspheres, as expected. In 
agreement with these results, alginate microspheres fully dissolved by 4 h in SIF, as 
revealed by microscopy (Fig. 4.5B and 4.5C). Hence, no fluorescent content could be 
measured (Fig. 4.6). Meanwhile, 25% of the initial amount of chitosan-alginate 
microspheres remained (Fig. 4.5B), which swelled to ~160% of their initial size in this 
milieu (Fig. 4.5C) and retained only 50% of their initial fluorescence content (Fig. 4.6A). 
As a result, the mean fluorescence per area of chitosan-alginate microspheres considerably 
decreased (by 86%; Fig. 4.6B). Hence, both types of microspheres showed release at 
intestinal, but not gastric pH, and chitosan-coated formulations may be more amenable to 
control burst release in this environment.  
 
 
4.2.5 Effect of Chitosan Concentration and Crosslinking on Microsphere Release 
 
Given the results obtained by coating alginate microspheres with chitosan, we then 




1%, and also that of crosslinking this coat with 1 mg/ml genipin. Genipin is a natural 
compound that provides a gentle, non-toxic method for crosslinking polymers, in contrast 
to synthetic crosslinking reagents, such as glutaraldehyde [119, 127]. As shown in Table 
4.2, these modifications produced nearly equivalent characteristics as the former 
microsphere formulations, with a similar size distribution of ~180 µm, high encapsulation 
efficiency of ~95% and loading capacity of ~15% (w/w; NCs/alginate), corresponding to 
~1.8 x 106 NCs/bead.  
Similarly negligible (<4%) release of antibody-coated NCs was observed for all 
formulations in SGF at pH 1.2 (Fig. 4.7A), in agreement with minimal changes in this 
condition regarding the number of microspheres per field (Fig. 4.7B) and the total 
fluorescence content per microsphere (Fig. 4.8A). As seen above, all formulations showed 
a comparable (~20%) decrease in diameter in SGF (Fig. 4.7C), with a concomitant increase 
(~30-50%) in the mean fluorescence per area (Fig. 4.8A).  
 
Figure 4.7. Effect of chitosan concentration and crosslinking on pH-dependent release from 
microspheres. Alginate microspheres containing 125I-IgG fluorescent NCs were coated with either 
0.25%, 1%, or genipin-crosslinked 1% chitosan, and incubated for 2 h in SGF at pH 1.2 followed 
by 4 h incubation in SIF at pH 7.8 (total incubation = 6 h). (A) NCs released from microspheres 
was assessed by radioisotope tracing of the released and encapsulated fractions, expressed a 
percentage of the total radioisotope content. In parallel, the (B) number and (C) diameter of visibly 
intact microspheres were quantified from fluorescence microscopy images, and expressed as the 
percentage of values measured prior to incubations (t = 0). Data are Mean ± S.E.M. * Compares 
0.25% vs. 1% chitosan formulations; # compares 0.25% vs. 1% chitosan-genipin formulations; † 






Figure 4.8. Effect of chitosan concentration and crosslinking on the pH-dependent release of 
fluorescent nanocarriers. Alginate microspheres loaded with 125I-IgG fluorescent NCs were 
coated with 0.25% chitosan, 1% chitosan, or genipin-crosslinked 1% chitosan, and incubated in for 
2 h in SGF (pH 1.2) followed by 4 h in SIF (pH 7.8) (6 h total incubation). At the indicated times, 
the (A) sum fluorescence and (B) mean fluorescence intensity (sum / area) of visibly intact 
microspheres were quantified from fluorescence microscopy images. Values were expressed as the 
percentage of those measured prior to incubations (t = 0). Data are Mean ± S.E.M. * Compares 
0.25% vs. 1% chitosan formulations; # compares 0.25% vs. 1% chitosan-genipin formulations; †, 
compares 1% vs. 1% chitosan-genipin formulations (p<0.05, Student’s t test). 
 
 
Upon incubation in SIF at pH 7.8, microspheres with 1% chitosan coat displayed a 
similar release profile as 0.25% chitosan-alginate microspheres, with 61% release by 1 h 
after their transfer into SIF and 69% release by 4 h (Fig. 4.7A). Crosslinking of the 1% 
chitosan coat with genipin curtailed release by 25% after 1 h and 11% by 2 h in SIF (Fig. 
4.7A), indicating that this formulation may better help control burst release. In parallel, 
when examining microspheres by microscopy, all formulations showed dissolution in SIF 
(Fig. 4.7B), swelling (Fig. 4.7C), and reduction of fluorescent content (Fig. 4.8). However, 
interesting differences were observed among these formulations. For instance, the diameter 
of 1% chitosan-coated microspheres was lower in intestinal conditions than that of 0.25% 
chitosan-coated microspheres (113 vs. 164% of t = 0 by 4 h in SIF; Fig. 4.7C). Hence, 




Although we had observed similar release of the 125I-antibody counterpart (Fig. 4.7A), the 
lower sum fluorescence per microsphere of the 1% vs. 0.25% chitosan coat (e.g., 21 vs. 
53% of t = 0 by 4 h in SIF; Fig. 4.8A), may indicate that NCs (not antibodies that may have 
detached from the NC coat) are better retained in the latter preparation. Crosslinking the 
1% chitosan coat with genipin resulted in similar behavior as 0.25% chitosan microspheres, 
e.g., it increased the diameter by 39% at 4 h in SIF with respect to 1% chitosan 





4.2.6 Microsphere Protection and Release of Nanocarriers in Gastrointestinal Conditions 
 
In addition to examining the pH-dependent release of 125I-IgG NCs from microspheres in 
fluids mimicking GI pH, we evaluated this aspect as well as the status of encapsulated NCs 
in the presence of GI enzymes, to infer the protection provided by microspheres. First, we 
examined whether all four formulations of alginate and chitosan-alginate microspheres 
would protect encapsulated antibody-coated NCs (only the antibody counterpart is labile) 
from premature gastric degradation. For this purpose, microspheres were incubated for 2 h 
in SGF in the presence vs. absence of pepsin (Fig. 4.9A). Since microspheres remained 
intact in gastric pH, we used EDTA to induce their release after incubation in these milieus. 
The level of free 125Iodine (indicative of antibody degradation) in the released NC fraction 
was then quantified. In the absence of pepsin, the contents in all formulations, as well as 
non-encapsulated IgG NCs, displayed <10% degradation (Fig. 4.9A), which is expected 
since low pH should not result in antibody proteolysis. Most importantly, in the presence 




largely attenuated by encapsulation within all microsphere formulations (<15% 
degradation) (Fig. 4.9A). Although all microspheres performed similarly in this regard, 








Figure 4.9. Microsphere protection and release of nanocarriers in gastrointestinal conditions. 
(A) Non-encapsulated 125I-IgG NCs vs. 125I-IgG NCs encapsulated in alginate microspheres with 
or without a 0.25%, 1%, or genipin-crosslinked 1% chitosan coat, were incubated for 2 h at 37 ˚C 
in SGF (pH 1.2) in the presence or absence of pepsin. Due to lack of NC release at this pH, 
microspheres were dissolved in EDTA to release the NC content. Content degradation was assessed 
by radioisotope quantification of free 125Iodine (indicative of antibody degradation), expressed as 
a percentage of the total radioisotope content. (B) Microspheres were incubated in SGF containing 
pepsin as in (A) followed by a 4 h incubation at 37 ˚C in SIF containing pancreatin (pH 7.8). The 
percentage of 125I-IgG NCs released from microspheres was determined by radioisotope tracing. 
Data are Mean ± S.E.M. * Compares non-encapsulated NCs vs. other formulations; no statistically 
significant difference was observed between other groups (p<0.05, one-way ANOVA followed by 
Tukey test). † Compares the presence vs. absence of pepsin; # compares 3 h vs 6 h (p<0.05, 
Student’s t test). 
 
Then, we examined NC release after a 2 h incubation in pepsin-containing SGF, 
followed by a 4 h incubation in pancreatin-containing SIF. Significant release (75-80%) of 




level of release that had been observed in the absence of enzymes. Hence, this more 
physiologically relevant condition indicated that encapsulation within alginate and, 
primarily, chitosan-alginate microspheres, prevents premature gastric degradation of the 




4.2.7 Receptor Targeting by Nanocarriers Released from Microspheres under 
Gastrointestinal Conditions 
Given the above results, we next examined if antibody-coated NCs can bind an 
immobilized target (secondary antibody, as described above), when released from 
microspheres after incubation in enzyme-containing SGF and SIF. First, to provide a 
baseline for the subsequent comparison to GI conditions, we measured the extent of 
binding after EDTA-induced release from microspheres in storage. As shown in Fig. 4.10, 
NCs that had been encapsulated displayed substantial binding, with 106 – 107 NCs bound 
per well, with greater binding observed for 1% chitosan microspheres and the non-
encapsulated control. Incubation of non-encapsulated antibody-coated NCs with enzyme-
containing SGF, or SGF followed by SIF, resulted in a significant reduction in their binding 
ability: 102 NCs/well in SGF alone (95% reduced binding compared with storage 
conditions) and no detectable binding in SGF 
followed by SIF incubation (Fig. 4.11A). This 
parallels the high degradation observed for 




In contrast, NCs encapsulated within microspheres retained their targeting ability after 
incubation in SGF, or SGF followed by SIF: 105 – 107 NCs bound/well (Fig. 4.11A). This 
suggests that the protection and controlled release afforded by encapsulation may render 
sufficient receptor-targeting of antibody-coated NCs when administered via the oral route.  
 
Figure 4.10. Binding of fluorescent nanocarriers released from microspheres in storage 
conditions. The binding ability of non-encapsulated 125I-IgG NCs vs. 125I-IgG NCs encapsulated in 
alginate, 0.25% chitosan-, 1% chitosan-, or genipin-1% chitosan-alginate microspheres was 
assessed after 1 day in control storage conditions, serving as a comparison to binding of respective 
formulations in GI conditions. This required release of NCs by EDTA-induced dissolution of 
microspheres, since no natural release occurs in storage. IgG NCs were incubated with secondary 
antibody-coated wells to allow binding, as described in Fig. 2. Wells were washed to remove non-
bound counterparts, and radioisotope tracing was used to quantify the number of NCs bound per 
well. Data are Mean ± S.E.M. * Compares non-encapsulated NCs vs. other formulations; ǂ, 
compares 1% chitosan microspheres vs. other formulations (p<0.05, one-way ANOVA followed 




Figure 4.11. Receptor targeting by nanocarriers released from microspheres in 
gastrointestinal conditions. Non-encapsulated 125I-IgG NCs vs. 125I-IgG NCs encapsulated in 
alginate microspheres with or without a 0.25%, 1%, or genipin-crosslinked 1% chitosan coat, were 
incubated in enzyme-containing SGF, or SGF followed by SIF as in Fig. 5. NCs that were released 
by EDTA in the case of SGF incubation, or those naturally released after SGF + SIF incubation, 
were tested. (A) Binding of non-encapsulated vs. microsphere-released 125I-IgG NCs onto 
secondary antibody-coated wells, measured by radioisotope tracing. (B) Anti-ICAM NCs (non-
encapsulated vs. loaded into alginate or 0.25% chitosan-alginate microspheres) vs. non-specific 
IgG NCs loaded into 0.25% chitosan-alginate microspheres, were incubated in pepsin-containing 
SGF as in (A). Due to lack of release in this condition, NCs were released by EDTA and their 
ability to bind to cells (reflective of microsphere protection under gastric conditions) was tested. 
Binding was assessed by incubation for 2 h at room temperature with ICAM-1-expressing, fixed 
HUVECs. The number of NCs bound per cell was quantified by fluorescence microscopy after 
washing non-bound NCs. (C) Cell binding of non-encapsulated vs. anti-ICAM NCs naturally 
released from microspheres after incubation with enzyme-containing SGF followed by SIF was 
examined by fluorescence microscopy, and normalized to their binding prior to reaching intestinal 




encapsulated vs. microsphere-encapsulated NCs; # compares binding to that of anti-ICAM NCs 
within chitosan-alginate microspheres; † compares binding in SGF vs. SGF followed by SIF; 
(p<0.05, Student’s t test). & compares 0.25% chitosan microspheres vs. other formulations (p<0.05, 
one-way ANOVA followed by Tukey test). 
 
 
To further verify this hypothesis, we examined the targeting potential of antibody 
(anti-ICAM)-coated NCs to its receptor (ICAM-1) expressed on cells, after release from 
microspheres. First, we tested binding on HUVEC (vascular endothelial cells), which serve 
as a comparison to extensive literature on targeting to these cells [9, 37, 86, 117, 128, 129]. 
Since no major differences had been observed among the three chitosan-alginate 
formulations tested, we selected the simplest formulation composed of 0.25% chitosan-
alginate to compare with alginate alone. As shown in Fig. 4.12B, after 2 h in pepsin-
containing SGF, minimal binding (8 NCs bound/cell) was observed for control anti-ICAM 
NCs that had not been encapsulated in microspheres, as expected due to considerable 
degradation (Fig. 4.9A). In contrast, anti-ICAM NCs retained within microspheres and then 
released by EDTA (since there is no release in SGF) revealed significant binding: 48 
NCs/cell and 159 NCs/cell for alginate and chitosan-alginate formulations, respectively. 
This reflected specific targeting by anti-ICAM NCs, since non-specific IgG NCs loaded 
into chitosan-alginate microspheres only resulted in 4 NCs bound/cell, signifying 49-fold 
enhanced targeting for anti-ICAM NCs vs. IgG NCs. Further transfer of anti-ICAM NC-
loaded microspheres from pepsin-containing SGF to pancreatin-containing SIF caused a 
reduction in NC binding on cells (~60% reduction), yet considerable binding was still 
detected: 60-70 NCs/cell. Hence, it seems possible to achieve receptor-mediated targeting 




We then similarly evaluated ICAM-1 targeting of encapsulated vs. non-
encapsulated antibody-coated NCs in Caco-2 cells, a prevalent GI epithelial cell model 
[130]. This will allow us to evaluate potential binding to the GI epithelium, which may 
differ from binding to endothelial cells as a result of varying morphology (e.g., endothelial 
cells are large and flat, while GI epithelial cells are narrow, columnar, and villous), ICAM-
1 expression, and the presence of brush border enzymes [13]. As shown in Fig. 4.12, after 
2 h in pepsin-containing SGF, minimal binding (3 NCs bound/cell) was observed for non-
encapsulated anti-ICAM NCs, similar to our findings in endothelial cells (Fig. 4.11B). 
Anti-ICAM NCs protected by chitosan-alginate microspheres, on the other hand, revealed 
significantly greater binding: 20 NCs/cell, yet lower than levels observed in endothelial 
cells. This discrepancy was previously observed for anti-ICAM NCs in storage conditions, 
suggesting that lower binding can be attributed to differences between these cell types, as 
described above. The specificity of targeting was demonstrated by the comparatively low 
binding of non-specific IgG NCs loaded into chitosan-alginate microspheres (6 NCs 
bound/cell). 
Figure 4.12. Nanocarrier targeting to GI 
epithelial cells after release from 
microspheres in gastrointestinal conditions. 
Anti-ICAM NCs (non-encapsulated vs. loaded 
into 0.25% chitosan-alginate microspheres) vs. 
non-specific IgG NCs loaded into 0.25% 
chitosan-alginate microspheres, were 
incubated in pepsin-containing SGF. NCs 
were released by EDTA, and their binding was 
assessed by incubation for 2 h at room 
temperature with ICAM-1-expressing, fixed 
Caco-2 cells. The number of NCs bound per 
cell was quantified by fluorescence 
microscopy after washing non-bound NCs. 
Data are Mean ± S.E.M. * Compares binding 




encapsulated NCs; # compares binding to that of anti-ICAM NCs within chitosan-alginate 
microspheres; (p<0.05, Student’s t test).  
 
 
4.2.8 Oral Gavage of Encapsulated ICAM-1-Targeted Nanocarriers in Mice 
Following verification of protection and release afforded by microspheres, and the 
resulting targeting to ICAM-1-expressing cells, we examined the degradation and 
biodistribution of encapsulated anti-ICAM NCs following in vivo administration in mice. 
For these studies, 125I-anti-ICAM NCs were encapsulated in 0.25% chitosan-alginate 
microspheres. This formulation was administered to mice via oral gavage and compared to 
oral gavage of non-encapsulated 125I-anti-ICAM NCs.  
We first evaluated whether microspheres conferred protection against anti-ICAM 
degradation by quantifying the level of free 125Iodine with respect to the total 125Iodine 
content in each section of the GI tract (Fig. 4.13A). In agreement with observations in vitro, 
encapsulation in chitosan-alginate microspheres resulted in significant protection, with 60-
70% of the total antibody content being preserved, while only 20-40% of the non-
encapsulated control was preserved. This represented a 2-3-fold enhancement in protection 
for encapsulated anti-ICAM NCs as compared to non-encapsulated formulations. 
Importantly, anti-ICAM NC encapsulation within microspheres rendered lower retention 
in the stomach vs. non-encapsulated counterparts (36% vs. 59% ID/g), which is important 
for minimizing degradation (Fig. 4.13B). Instead, encapsulation enhanced NC 
biodistribution in the small intestine (22% vs. 6% ID/g) and the large intestine (8 vs. 0.9 
%ID/g; Fig. 4.13B), desirable for treatment of pathologies in these regions or absorption 




small intestine showed that enhanced intestinal biodistribution conferred by encapsulation 
was attributed to 9-fold greater localization in the duodenum.   
 
 
Figure 4.13. Protection and biodistribution of microsphere-encapsulated ICAM-1-targeted 
nanocarriers in the GI tract of mice. Mice were orally gavaged with 125I-anti-ICAM NCs (non-
encapsulated vs. encapsulated in 0.25% chitosan-alginate microspheres) or non-specific 125I-IgG 
NCs encapsulated in 0.25% chitosan-alginate microspheres. One hour after administration, the 
indicated sections of the GI tract were harvested and subjected to TCA precipitation to determine: 
(A) the percentage of free 125Iodine (reflective of degradation) with respect to the total 125Iodine 
content, (B-C) the 125I-content and tissue weight, to calculate the percent gavaged dose per gram. 
Data are Mean ± S.E.M. * Compares non-encapsulated and encapsulated groups. # compares 




Finally, to assess targeting specificity, we compared anti-ICAM NCs to IgG NCs, 
both of which were encapsulated within 0.25% chitosan-alginate microspheres. Similar to 
targeted counterparts, IgG NCs showed a similar decrease in retention in the stomach (64 
%ID/g) and enhanced accumulation in the small and large intestine (16 and 4 %ID/g) with 
respect to the non-encapsulated control (Fig. 4.13B). However, intestinal accumulation was 
reduced compared to that of anti-ICAM NCs, suggesting specific targeting. In fact, 
duodenal biodistribution of IgG NCs was significantly lower (3-fold) than that of anti-
ICAM NCs (Fig. 4.13C). Taken together, ICAM-1-targeted NCs encapsulated in chitosan-
alginate microspheres provide enhanced protection in the stomach, and site-specific 






Receptor-mediated targeting of drug carriers offers an opportunity to enhance their 
biodistribution as well as transport within or across cells [7, 52, 123]. These advantages 
also apply to oral delivery of drugs [2, 6, 53-58]. However, most targeting moieties are 
labile molecules (antibodies, peptides, aptamers, etc.) susceptible to premature inactivation 
and degradation en route to the intestine, an important target for therapeutic intervention 
and primary site of drug absorption [53]. Although encapsulation of drugs, biologicals, and 
carriers within controlled release hydrogels has been extensively studied [4, 16, 17, 48, 49, 
105, 107, 109, 119, 121, 124], this approach remains largely unexplored in the case of 
receptor-targeted NCs. Using the example of ICAM-1 targeting by model antibody-coated 
polystyrene NCs, we have examined whether encapsulation within controlled released 
hydrogels provides protection against degradation in gastric conditions and intestinal 
release for specific targeting, and demonstrated this in in vitro, cell culture, and mice 
studies.  
As described, we selected alginate microspheres as a model based on its 
biocompatibility and gentle formulation [17, 48, 49, 105, 107, 109, 121, 124]. The method 
employed produced uniform microspheres, in terms of size and shape, with a suitable size 
for oral gavage in mice (~180 µm in diameter). The encapsulation efficiency was very high 
(97%), with minimal release (<10%) over 28 days in storage conditions. These parameters 
did not vary when alginate microspheres were modified with different chitosan coatings, 
as expected since these modifications were conducted after, not during, encapsulation into 




from other works that observed drug leaching from alginate beads [16, 17]. Similar, yet 
still lower, encapsulation efficiency has been seen for antibodies (~80%) [48]. This 
suggests that the porosity and mesh-pore size of the alginate matrix does not prevent 
leaching of small contents and water-soluble drugs [16, 17, 48], but it can prevent diffusion 
of encapsulated antibody-coated NCs, likely because of their greater size. Hence, this may 
be a viable application for alginate hydrogels. In fact, the stability of microspheres and 
minimal release of encapsulated NCs over 28 days in storage contrasts that of other alginate 
microspheres with similar size: this is the case for <300 µm diameter formulations which 
showed compromised microsphere stability, particularly when bulky loads (e.g., 
mammalian cells) occupied a large volume within the polymer [107]. 
Whereas microspheres suit the size requirements for oral gavage in mice, we have 
also formulated ~2.8 mm-diameter alginate and chitosan-alginate beads for future in vivo 
studies in larger animals, such as rats. The encapsulation strategy is similar to that used to 
create microspheres, except that alginate was extruded through a larger diameter needle, as 
in [48]. Similar to the microsphere formulations, larger beads exhibited a uniform size and 
spherical shape, even distribution of encapsulated NCs throughout the alginate core, and 
relatively efficient loading (70-80 EE%), which did not significantly differ in the presence 
of a chitosan shell. However, the encapsulation efficiency was considerably lower than that 
observed for microspheres, and paralleled that shown for previously reported beads of this 
size [48]. We speculate that higher percent loading of NCs in these beads (32 vs. 16%, v/v) 
may have compromised the strength of the alginate network, given the large volume 
occupied by NCs. Moreover, the distinct processing conditions used to create larger beads, 




encapsulation efficiency for larger beads [48, 49]. Hence, future optimization of these 
conditions may be required for higher loading. Nevertheless, these beads serve as a viable 
alternative to microspheres for in vivo experiments.  
With regard to encapsulation of biological agents in alginate beads, we observed 
minimal degradation (<5%) of the antibody coat within microspheres, which did not seem 
to result from the encapsulation procedure itself, since the level of degradation was similar 
to that of non-encapsulated counterparts in storage conditions. In addition, encapsulated 
NCs retained ~90% of their targeting ability with respect to non-encapsulated counterparts, 
indicating that encapsulation is not detrimental to this function and, once released, the 
polymer does not interfere with binding. These results are key in pursuing these 
formulations for receptor-targeted applications, and agree with previous reports 
documenting the binding ability of IgY antibodies following encapsulation in chitosan-
alginate beads [48].  
Yet, a prevailing requirement of encapsulation strategies for oral therapies 
containing labile targeting agents, particularly proteins, is to provide protection from low 
gastric pH as well as proteases present in the stomach [4]. In agreement with previous 
literature, alginate microspheres remained insoluble at a low pH characteristic of the 
stomach and retained encapsulated NCs, as observed by tracking both the antibody and NC 
counterparts. Microspheres also appeared to shrink in gastric buffer, which may be a result 
of displacement of Ca2+ by monovalent H+ ions prevalent in a low pH environment, causing 
the gel network to collapse [17]. It appears that the chitosan shell is permeable to this ion 
exchange, as all chitosan-alginate formulations decreased in diameter to a similar degree 




As expected, alginate microspheres solubilized within 1 h of incubation at intestinal 
pH, likely due to Ca2+ displacement and the negative charge of carboxylic groups acquired 
at neutral pH. Coating with 0.25% chitosan reduced the level of burst release to some 
extent, confirming previous reports [48, 49]. Observations by fluorescence microscopy 
indicated that while the alginate core may have dissolved, the chitosan shell allowed some, 
but not all, microspheres to remain visible. Consequently, these “visible” chitosan-alginate 
microspheres could be traced, allowing us to observe a significant degree of swelling. 
Importantly, these microspheres retained the majority of the encapsulated fluorescent 
content (the NC counterpart) by 1 h in intestinal pH, which was then slowly released to 
~50% of the initial content by 4 h at this pH. Radioisotope tracing of the antibody 
counterpart revealed faster release, suggesting that some antibodies may detach from the 
NC coat during this process and diffuse through the chitosan coat. Nevertheless, binding 
of released NCs onto cells indicated that a sufficient degree of antibodies remained on NCs 
to provide specific targeting.  
The results described above suggest that the combination of burst release and 
swelling contribute to the mechanism of release from chitosan-alginate microspheres. 
Increasing the concentration of chitosan from 0.25% to 1% did not significantly alter the 
degree or mechanism of release. However, crosslinking the chitosan shell with genipin 
further curtailed the initial burst release, in agreement with previous work [119, 127]. Yet, 
while this was observed when tracking antibody release by radioisotope tracing, such 
crosslinking did not increase the number of intact microspheres or fluorescence content per 
microsphere compared to non-crosslinked formulations. As such, it can be speculated that 




has a larger contribution to overall release than release from intact microspheres. 
Alternatively, it is possible that genipin crosslinking helps to retain the fraction of 
antibodies which may detach from the NC surface, suggesting that genipin crosslinking 
may not exert an advantage for NC formulations where targeting antibodies are covalently 
attached on their surface. Nevertheless, the microspheres studied herein exhibited pH-
sensitive release, which holds significance for oral formulations requiring protection from 
gastric conditions and release in intestinal conditions.  
Moreover, in agreement with minimal release from microspheres at gastric pH, 
encapsulated NCs showed minimal degradation and considerable targeting after exposure 
to SGF, which was also the case in the presence of gastric enzymes. Non-encapsulated 
NCs, on the other hand, were degraded to a great extent and showed little binding after 
incubation in these conditions. Hence, the mesh pore size of microspheres is seemingly 
small enough to prevent penetration of enzymes into the alginate core. Counterintuitively, 
increasing the chitosan concentration and crosslinking chitosan resulted in a modest, yet 
increase in degradation, which was unexpected. However, it is plausible that these changes 
are merely due to restricted release through the chitosan coat of NCs bearing degraded 
antibody. In support of this, degradation and loss of targeting ability of NCs encapsulated 
in 1% chitosan and crosslinked 1% chitosan microspheres did not increase in the presence 
of gastric enzymes, indicating that the increase in degradation was not due to greater 
penetration of enzymes but rather, greater retention of degraded products within the 
microsphere, which could then be measured. In addition to encapsulated NCs retaining 
binding ability after incubation in gastric conditions, significant targeting was also verified 




counterparts was abolished. Therefore, encapsulation affords protection of targeted NCs in 
gastric and intestinal conditions in the presence of digestive enzymes, preserving functional 
activity of targeting moieties to a considerable extent.  
An application that could benefit from this encapsulation strategy is targeting to 
ICAM-1, a molecule expressed on the GI and other tissues, involved in GI (among other) 
pathologies associated with inflammation, including infections, immune alterations, 
cancers, genetic conditions, etc. [10, 113]. NCs and conjugates directed by ICAM-1-
targeted ligands have shown promising results regarding delivery of therapeutic and 
imaging agents in numerous disease applications [9, 27, 30-32, 37, 131-138]. Moreover, in 
GI epithelial monolayers, anti-ICAM NCs facilitated intra- and transepithelial delivery of 
a model therapeutic enzyme (α-Galactosidase, deficient in Fabry disease [139]), revealing 
particular promise for oral delivery [13]. However, oral delivery in vivo was limited by 
premature degradation of ICAM-1 targeted antibodies in the stomach [15]. Our results 
hereby indicate that encapsulation in chitosan-alginate microspheres could overcome these 
obstacles for oral delivery of ICAM-1 targeted systems. In fact, after incubation in GI-
mimicking buffers containing digestive enzymes, encapsulated NCs demonstrated a 
significant degree of specific binding to ICAM-1 expressing cells, including both vascular 
endothelial and GI epithelial cells, relative to both control IgG NCs loaded into chitosan-
alginate microspheres and non-encapsulated anti-ICAM NCs. Importantly, relative to non-
encapsulated counterparts, microspheres revealed substantial protection of anti-ICAM NCs 
against degradation in all sections of the GI tract upon oral gavage in mice. Encapsulation 
also lowered retention in the stomach and enhanced biodistribution in the small and large 




targeting was apparent compared to that of encapsulated IgG NCs. Therefore, enhanced 
intestinal biodistribution of anti-ICAM NCs loaded within chitosan-alginate microspheres, 
particularly in the duodenum, is a result of both pH-dependent release from microspheres 
and ICAM-1 targeting.  
 
4.4 Conclusion 
Alginate and chitosan-alginate microspheres formulated in the present study provided 
protection of antibody-targeted NCs in storage and gastric conditions (including pH and 
digestive proteases), with pH-sensitive release in intestinal conditions. Following transit in 
gastric and intestinal conditions, NCs released from microspheres retained a significant 
degree of targeting ability, as measured in vitro, cell culture, and animal models. Therefore, 
this encapsulation strategy may be valuable for implementing oral delivery of targeted drug 
carriers, where protection from harsh gastric conditions and intestinal bioavailability is 
required. Whereas this encapsulation strategy was hereby illustrated for ICAM-1 targeting 
and antibody-coated polymer NCs, similar approaches may benefit other targeted systems 







Chapter 5: Distinct Endocytic Routing of Monomeric ICAM-1 
Targeted Ligands Enables Transport Into and Across 





In Chapter 4, we demonstrated that encapsulation of anti-ICAM NCs in chitosan-
alginate microspheres affords them with protection in gastric conditions, pH-triggered 
release in intestinal conditions, and targeting to ICAM-1-expressing cells following 
release. It is therefore conceivable that following release from microspheres and 
subsequent binding to cells, anti-ICAM NCs will induce CAM-mediated uptake and 
transport across cultured GI epithelial cells, as previously demonstrated [13]. Moving 
forward, the goal of Chapter 5 was to evaluate whether these phenomena also hold for 
targeted carriers that bind to ICAM-1 in a monomeric fashion (e.g., anti-ICAM antibodies). 
Cellular transport of monomeric ICAM-1 ligands may provide an opportunity for direct 
conjugation of these ligands to therapeutic or imaging agents for oral delivery. This holds 
significance because, in contrast to multimeric targeting strategies, direct conjugation may 
offer a simpler formulation from a manufacturing perspective and may lead to distinct 
characteristics regarding biodistribution, cellular trafficking, metabolism, clearance, etc., 
expanding the range of future oral applications of ICAM-1 targeting beyond existing 
multimeric strategies. 
Following release from encapsulation vehicles, targeted delivery systems must be 
capable of binding to absorptive cells in the GI epithelium, which triggers transport into 
and/or across these cells, e.g., by endocytic mechanisms. As described in Chapter 2, 




interactions and subsequent endocytic fates [7]. For example, a small drug conjugate 
typically involves interaction of one ligand with one receptor (or two if a divalent antibody 
is used), while larger drug conjugates and NCs employ multiple copies of a ligand to 
engage multiple copies of a cell surface receptor [7]. In nature, receptors typically bind to 
either monomeric or multimeric ligands, but rarely both [140]. As a consequence, drug 
targeting to endocytic receptors does not guarantee a similar uptake efficacy or mechanism 
to that of natural, unmodified ligands of said receptors, as observed in several studies [37, 
141-143]. This is also the case with regard to intracellular routing after endocytosis: some 
receptors may follow more than one itinerary (e.g., to lysosomes, recycling compartments, 
transcytosis, etc.), which further depends on whether they are bound by natural or artificial 
ligands, or by monomeric vs. multimeric counterparts, as observed for receptors of 
immunoglobulins, transferrin, and folate, for instance [141, 142, 144-146]. Therefore, 
understanding the endocytic fate of ligands employed for targeted drug delivery is 
important in order to determine the efficacy of these strategies and the selection of suitable 
therapeutic applications. Our knowledge of endocytic events not only benefits the 
translation of targeted systems exploiting these pathways [52], but also provides insight on 
the biological regulation of cell surface receptors: endocytosis of cell surface receptors 
mediates a wide range of physiological functions, including cellular uptake of nutrients, 
signal transduction, recycling of membrane components, and clearance of foreign or 
pathogenic elements [140, 147].  
Most previous studies comparing the endocytic fates of drug targeting platforms 
against natural ligands have examined receptors whose said natural ligands are monomeric 




regarding receptors whose natural ligands are multimeric. Perhaps one of the examples 
where more mechanistic information is available is that of drug targeting to ICAM-1 [12, 
87, 92, 93, 117]. Previous studies on ICAM-1 targeting in vascular endothelial and GI 
epithelial cells revealed that this molecule undergoes efficient uptake by CAM-mediated 
endocytosis when bound in a multimeric manner [9, 12, 37]. This pairs well with the fact 
that natural ligands of ICAM-1 bind this molecule in a multimeric fashion, including 
leukocytes, apoptotic bodies, plasmodium-infected erythrocytes, and pathogens such as 
major class rhinoviruses, etc. [148-152]. As a result of such prominent uptake, CAM-
mediated endocytosis and the subsequent intracellular itinerary of multimeric ICAM-1 
conjugates and carriers has been well documented, using vascular endothelial cells as a 
model, allowing us to exploit this pathway for intracellular drug delivery [9, 25-28, 31-35]. 
In addition to providing intracellular delivery, CAM-mediated uptake of multimeric 
carriers leads to transcytosis across GI epithelial cells, enabling delivery of therapeutics 
across this barrier [13]. Therefore, ICAM-1 mediated transport provides a valuable 
gateway for oral therapies aimed at entering GI epithelial cells, for local interventions, or 
traversing these cells for entry into the systemic circulation.  
While endocytosis of monomeric ligands targeting ICAM-1 did not seem 
prominent a priori [9], their pathway of uptake has not been examined. In addition, certain 
plasmalemma receptors can be internalized in the absence of ligand binding and their 
intracellular itinerary can differ from that of the ligand-receptor complex [146, 153, 154], 
yet potential endocytosis of unbound ICAM-1 also remains largely unexplored. Indeed, 
ICAM-1 has been observed to recycle back to the cell surface after separating from ligands 




redistribution of ICAM-1 between the cell surface and an intracellular pool in certain 
immune cells [155]. Hence, the first portion of this chapter seeks to evaluate the endocytic 
regulation of ICAM-1 itself and its monomeric vs. multimeric ligands, to shed light on the 
biological regulation of ICAM-1 and its utility for diverse therapeutic applications. This 
was performed in vascular endothelial cells, where fundamental knowledge on multimeric 
ICAM-1 ligands was previously characterized [12, 87, 92, 93, 117].  
As described in Section 2.3.2, CAM-mediated endocytosis induced by targeting 
ICAM-1 leads to transcytosis across cellular barriers, as previously shown for ICAM-1-
targeted NCs in cultured GI epithelial and brain microvascular endothelial cell monolayers 
[13, 14]. Such transport enabled intracellular and transcellular delivery of a model 
therapeutic enzyme in cultured GI epithelial monolayers, valuable in the context of 
therapies aimed at either treating gastrointestinal disorders or reaching the systemic 
circulation via the oral route [13]. Moreover, no apparent paracellular leakage of a luminal 
marker was observed during transport, suggesting that CAM-mediated transcytosis may 
preserve the integrity of cellular barriers [13]. These findings also agree with delivery of 
ICAM-1 targeted NCs into systemic organs upon intravenous injection in mice, without 
any apparent side effects compromising safety [27]. Therefore, ICAM-1 targeting holds 
promise for drug delivery into cells for the treatment of intracellular pathologies, as well 
as across cellular barriers for access to the circulation (e.g., relevant for oral delivery) or 
tissues beyond the systemic circulation.  
Nevertheless, the potential of monomeric ICAM-1 targeting strategies for oral 
delivery has yet to be elucidated. Therefore, the second portion of this chapter explores 




endothelial cells can be exploited for oral delivery in GI epithelial cells. In doing so, we 
first evaluated whether (A) the pathway of uptake and intracellular trafficking observed for 
monomeric anti-ICAM in endothelial cells also occurs in GI epithelial cells. We then 
determined whether (B) such uptake leads to transcytosis across GI epithelial cells, as it 
does for multimeric anti-ICAM NCs [13]. Hence, this knowledge would provide a novel 
opportunity to utilize monomeric ICAM-1 ligands as an alternative vehicle for intracellular 
and transcellular delivery in the GI epithelium.  
 
5.2 Results 
5.2.1 Degree of Uptake of Monomeric vs. Multimeric ICAM-1 Ligands in Endothelial 
Cells 
A well characterized monoclonal antibody to human ICAM-1 (R6.5) [156, 157] was used 
as a model ligand capable of specific binding to ICAM-1 on human endothelial cells. To 
provide monomeric vs. multimeric binding, the antibody was used either as a naked 
molecule in solution or as multiple copies coated on the surface of polymer nanoparticles 
(see the Sections 3.3 and 4.2.1 for details), both of which have been extensively 
characterized [12, 92, 93, 122]. As previously demonstrated, these two ICAM-1 binding 
entities showed specificity against ICAM-1 expressed on activated endothelial cells: 174 
NCs/cell after a 60 min incubation (90-fold over non-specific IgG NCs) and 3.8 × 108 
fluorescence units (38-fold over IgG) [9, 86].  
Incubation of human endothelial cells with anti-ICAM vs. anti-ICAM NCs was 
conducted in a pulse-chase manner to track endocytosis without concomitant binding 




surface-bound (yellow color in Fig. 5.1A) vs. internalized (green color) ligands by 
fluorescence microscopy [12, 25, 87, 92, 93, 117]. This allowed us to observe a 
significantly high uptake of multimeric anti-ICAM NCs, as expected: ∼90% of total cell-
associated carriers by 1 h (Fig. 5.1B). Negligible binding of control non-specific IgG or 
IgG NCs (described above) rendered uptake undetectable [9, 86]. Internalization of 
monomeric anti-ICAM was markedly lower at this time: ∼10% of total cell-associated 
antibodies (9-fold below the level of uptake of anti-ICAM NCs), as observed previously 
[9]. Yet, uptake of anti-ICAM increased ∼2.5-fold by 3 h, decreasing the difference against 
anti-ICAM NCs to 3.5-fold. Anti-ICAM reached a maximal uptake level of 25% vs. 100% 
for anti-ICAM NCs. Hence, although to a much lower extent than anti-ICAM NCs, 
internalized anti-ICAM still represented a considerable fraction with regard to the total 
amount of antibodies that initially bound to cells.  
Interestingly, examination of the distribution of internalized anti-ICAM vs. anti-
ICAM NCs (Fig. 5.1A) revealed that internalized anti-ICAM localized to the cell 
periphery, whereas anti-ICAM NCs resided in the perinuclear region of the cell, which has 
been previously shown to correspond to lysosomal compartments [122] and will be 
subsequently verified here. This may be due to a differential mechanism of uptake between 







Figure 5.1. Comparative uptake of monomeric vs. multimeric ICAM-1 ligands in endothelial 
cells. (A) TNF-α-activated HUVECs were incubated with monomeric vs. multimeric ligands (anti-
ICAM vs. anti-ICAM NCs) for 30 min to enable binding to cell-surface ICAM-1 (pulse period). 
After washing unbound materials, cells were incubated at 37 ºC for various time intervals to allow 
subsequent uptake (chase period). Samples were then fixed and cell-surface vs. internalized ligands 
were differentially stained (see Methods for details) so that the former appear yellow (green+red; 
arrowheads) while internalized materials appear green (arrows). Dashed lines mark the cell borders. 
Scale bar, 10 μm. (B) Internalization was calculated automatically by fluorescence image analysis 
as the percentage of internalized ligands relative to the total amount of cell-associated ligands. 
Percent internalization values are means ± S.E.M. Where not visible, S.E.M. bars are masked by 
the value symbol.  
 
5.2.2 Mechanism of Uptake of Monomeric vs. Multimeric ICAM-1 Ligands in Endothelial 
Cells 
Hence, we next examined the mechanism responsible for uptake of monomeric anti-ICAM 
by endothelial cells against that of multimeric anti-ICAM NCs, previously identified as 
clathrin- and caveolae-independent CAM-mediated endocytosis [12, 93]. 
As shown in Fig. 5.2A, internalization of both anti-ICAM and anti-ICAM NCs was 
driven by active means, since incubation at 4°C abolished this phenomenon: at this 
temperature uptake was lowered to 7% for anti-ICAM and 1% for anti-ICAM NCs (30 
min), which is consistent with an endocytic event. However, given the different kinetics, 
maximal uptake levels, and subcellular distribution observed above for internalization of 
monomeric vs. multimeric ICAM-1 ligands, it would seem plausible that uptake of these 




Surprisingly, this was not the case (Fig. 5.2B). Just as anti-ICAM NCs, uptake of 
anti-ICAM was not affected by MDC (83% of control) or filipin (88% of control), which 
are inhibitors of clathrin- and caveolin-mediated pathways, respectively. In addition, 
amiloride, an inhibitor of CAM-mediated endocytosis and macropinocytosis, markedly 
reduced uptake of anti-ICAM anti-to a similar extent to that inhibition of ICAM NCs 
(∼50% by 1 h). Wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K) associated 
with macropinocytosis but not CAM-mediated endocytosis, did not significantly alter the 
degree of uptake of anti-ICAM (83% of control). This was also the case for anti-ICAM 
NCs (99% of control). Therefore, uptake of both monomeric and multimeric ICAM-1 
ligands appears to be regulated by CAM-mediated endocytosis, despite the differences 




Figure 5.2. Mechanism of uptake of monomeric vs. multimeric ICAM-1 ligands. (A) TNF-α-
activated HUVECs were incubated with monomeric anti-ICAM or multimeric anti-ICAM NCs for 
30 min at 4ºC or at 37ºC. Cell-surface vs. internalized ligands were imaged and quantified as 
described in Fig. 5.1. Percent internalization values are means ± S.E.M. *: p < 0.05 comparing 4ºC 
vs. 37ºC. #: p < 0.05 comparing anti-ICAM vs. anti-ICAM NCs. (B) TNF-α-activated HUVECs 
were incubated with anti-ICAM or anti-ICAM NCs for 1 h at 37ºC in the absence (Control) or 
presence of inhibitors of CAM endocytosis and macropinocytosis (amiloride), macropinocytosis 
alone (wortmannin (wtm.)), clathrin-coated pits (monodansylcadaverine (MDC)), or caveoli 
(filipin). Cell-surface vs. internalized ligands were stained as indicated in Fig. 1. Dashed lines mark 
the cell borders. Scale bar, 10 μm. (C) The percent internalization was calculated as in Fig. 1 and 





5.2.3 Lysosomal Trafficking and Degradation of Monomeric vs. Multimeric ICAM-1 
Ligands in Endothelial Cells 
Since monomeric anti-ICAM and multimeric anti-ICAM NCs seem to undergo the same 
mechanism of endocytosis, it is possible that their different levels of uptake may reflect 
different intracellular trafficking. Differential distribution of these ligands at the cell 
periphery vs. the perinuclear region after endocytosis, as observed above, seems to support 
this hypothesis. Hence, to examine this aspect in more detail, we tracked the potential 
colocalization of intracellular anti-ICAM to lysosomal compartments characterized by the 
presence of LAMP-1 (Fig. 5.3A), since this represents a predominant destination for anti-
ICAM NCs [30, 122]. Indeed, 78% of all cell-associated anti-ICAM NCs colocalized with 
LAMP-1-positive compartments by 3 h (Fig. 5.3B). In contrast, minimal lysosomal 
colocalization was observed for anti-ICAM: <7.5% within this time frame.  
 
 
Figure 5.3. Lysosomal trafficking of monomeric vs. multimeric ICAM-1 ligands. (A) TNF-α-
activated HUVECs were incubated with green-fluorescent anti-ICAM or anti-ICAM NCs for a 30 
min pulse, washed, incubated for up to 1 h or 3 h at 37ºC, then fixed and permeabilized. Lysosomes 
were labeled with TxR anti-LAMP-1 (red). Yellow color represents green anti-ICAM or anti-ICAM 
NCs localized to the red-labeled lysosomes, marked by arrowheads. Arrows represent anti-ICAM 
or anti-ICAM NCs which do not colocalize with anti-LAMP-1. Dashed lines mark the cell borders. 
Scale bar, 10 μm. (B) The percent colocalization with LAMP-1 with respect to the total cell-
associated anti-ICAM or anti-ICAM NCs was quantified by fluorescence image analysis. Data are 
means ± S.E.M. *: p < 0.05 comparing anti-ICAM vs. anti-ICAM NCs. #: p < 0.05 comparing 1 h 





We must note that, in this experiment, fluorescent tracking of anti-ICAM NCs 
focuses on the polymeric component (fluorescent polystyrene), which is non-degradable. 
Instead, lysosomal colocalization of anti-ICAM may go unnoticed if the antibody was 
subjected to proteolytic degradation in lysosomes. Therefore, we examined potential 
changes over time in the level of immunodetectable anti-ICAM associated with cells, 
which would be indicative of its degradation (Fig. 5.4). In agreement with the lack of 
lysosomal colocalization observed above, only 15% of cell-associated anti-ICAM seemed 
to disappear over a period of 5 h. This was in contrast to anti-ICAM NCs. Immunodetection 
of anti-ICAM on the surface of green-fluorescent carriers using a red-labeled secondary 
antibody (which renders yellow color only when the antibody coat is present on green 
particles; Fig. 5.4A), showed considerable degradation of anti-ICAM on carriers over time: 
from 8% at 1 h, to 67% at 3 h, and 85% by 5 h (Fig. 5.4B), in agreement with their 
lysosomal trafficking (Fig. 5.3B).  
To further ensure that degradation of monomeric anti-ICAM did not go unnoticed, 
similar experiments were performed in the presence of chloroquine, and agent that inhibits 
acidification and, hence, lysosomal degradation [122], or in the presence of nocodazole, an 
agent that disrupts lysosomal trafficking by altering the microtubular network [122]. 
Uptake was not affected in the presence of chloroquine or nocodazole (85 ± 15% and 120 
± 15% of control uptake at 3 h; not shown). Moreover, neither agent decreased degradation 
of anti-ICAM any further (10% and 15% degradation observed for chloroquine and 
nocodazole vs. 11% for the control at 1 h; not shown). In addition, if there was any 
trafficking of anti-ICAM to lysosomes, it would be expected that inhibition of lysosomal 




time. However, as shown in Fig. 5.4C, this parameter remained nearly constant (~25-35 
vesicles/cell) over 5 h and similar to the control.  
 
 
Figure 5.4. Degradation of monomeric vs. multimeric ICAM-1 ligands. (A) TNF-α-activated 
HUVECs were treated with green-fluorescent anti-ICAM or anti-ICAM NCs for a 30 min pulse to 
allow only binding, then washed and incubated for up to 1 h, 3 h, or 5 h at 37ºC  to allow uptake. 
Cells were then fixed and permeabilized. For NCs, permeabilized cells were immunolabeled with 
TxR-goat anti-mouse IgG, which binds non-degraded anti-ICAM on the carrier surface to produce 
yellow, double-labeled particles (arrowheads). The green, single-labeled fraction represents NCs 
with a non-immunodetectable (herein called degraded) antibody coat (arrows). In the case of anti-
ICAM, non-degraded antibody associated to cells is shown in green, which should diminish over 
time if there was degradation. Dashed lines mark the cell borders. Scale bar, 10 μm. (B) Percentage 
of NCs which lack immunodetectable anti-ICAM and percent of anti-ICAM compared to the initial 
anti-ICAM fluorescence at 4ºC. (C) Number of intracellular vesicles containing anti-ICAM after 
incubation in control cell medium vs. medium containing chloroquine or nocodazole during the 
chase period. Data are means ± S.E.M. *: p < 0.05 comparing anti-ICAM vs. anti-ICAM NCs. #: p 
< 0.05 with respect to degradation after 30 min. 
 
5.2.4 Uptake and Intracellular Trafficking of Multimeric Anti-ICAM Conjugates in 
Endothelial Cells 
To ascertain whether the differential trafficking of anti-ICAM NCs vs. monomeric anti-
ICAM was due to chemical/physical factors associated with the polymer particle, we 
examined another multimeric ligand: biotinylated anti-ICAM conjugated with streptavidin. 
With respect to anti-ICAM NCs, which was characterized in Section 4.2.1, this model 
differed in size (320 nm vs. 150 nm in diameter) and charge (-4 vs. -30 mV), yet it similarly 
represents a multimeric entity. Cells incubated with anti-ICAM conjugates from 30 min to 




verifying that conjugate components remain linked throughout this time (not shown). 
Binding of anti-ICAM conjugates to cells was specific: 261 objects/cell at 30 min, which 
was reduced by 65% in the presence of anti-ICAM competitor (data not shown). 
Importantly, over time, anti-ICAM conjugates displayed a significant and increasing 
perinuclear localization (up to 77% at 5 h) and uptake (up to 72% at 5 h) as in the case of 
anti-ICAM NCs (compare Fig. 5.5A vs. Fig. 5.1A-B and Fig. 5.6C), suggesting that this is 
a general property of multimeric ICAM-1 ligands. 
However, when we examined colocalization of anti-ICAM conjugates with LAMP-
1-labeled lysosomes (Fig. 5.5B), we found poor colocalization (e.g., 15% at 5 h). Since 
LAMP-1 labeling requires permeabilization, this result may be due to lysosomal 
degradation of anti-ICAM conjugates and leaching of the fluorophore after 
permeabilization. Indeed, upon quantification of the total cell-associated fluorescence of 
anti-ICAM and streptavidin components of the conjugate over time (Fig. 5.5C), we found 
significant decay for both (53% and 58% degradation at 5 h, respectively), suggesting 
degradation. In addition, the number of perinuclear vesicles containing conjugates 
significantly decreased with permeabilization (13 vs. 33 vesicles at 1 h for permeabilized 
vs. non-permeabilized cells; Fig. 5.5B). This result implied escape of the fluorophore from 
these compartments, also indicative of conjugate degradation. Hence, to avoid 
permeabilization that precludes visualizing conjugates within degradative compartments, 
we pre-labeled lysosomes using TxR dextran as described [122]. To ensure consistency 
between the two methods, we revealed a similar quantity of intracellular vesicles labeled 
by anti-LAMP-1 antibodies and dextran (∼65-70 vesicles/cell). Importantly, significant 




was observed (e.g., 65% at 5 h), which was similar to anti-ICAM NCs and different from 
monomeric anti-ICAM (Fig. 5.3).  
 
 
Figure 5.5. Uptake and intracellular trafficking of multimeric anti-ICAM conjugates. (A) 
TNF-α-activated HUVECs were treated with green-fluorescent anti-ICAM conjugates for a 30 min 
pulse to permit only binding, then washed and incubated for up to 1 h, 3 h, or 5 h at 37ºC  to allow 
uptake. Cells were then fixed and surface-bound conjugates were immunolabeled with TxR-goat 
anti-mouse IgG (yellow; arrowheads). The green, single-labeled fraction represents internalized 
counterparts (arrows). Dashed lines mark the cell borders. Scale bar, 10 μm. The percentage of 
internalized conjugates relative to the total cell-associated fraction and the percentage of 
internalized, perinuclear conjugates relative to the total internalized fraction were quantified by 
fluorescence microscopy. (B) Percentage of green-labeled anti-ICAM conjugates colocalized with 
red lysosomes labeled by two methods: (1) permeabilization and staining with TxR anti-LAMP-1 
vs. pre-labeling with TxR dextran prior to incubation with conjugates (non-permeabilized cells). 
The number of perinuclear vesicles containing conjugates was also quantified by fluorescence 
microscopy. (C) Percentage of anti-ICAM or streptavidin compared to the initial anti-ICAM 
fluorescence at 30 min. Data are means ± S.E.M. #: p < 0.05 with respect to data at the initial 
timepoint. *: p < 0.05 comparing permeabilized to non-permeabilized cells in (B) or anti-ICAM vs. 








The aforementioned results revealed that monomeric anti-ICAM, not multimeric 
counterparts, avoided lysosomal compartments and the associated degradation (Fig. 5.3 
and Fig. 5.4). Also, internalized monomeric anti-ICAM, not multimeric forms, had been 
observed to localize to the cell periphery (Fig. 5.1A). This clearly indicates that, although 
exploiting the same endocytic pathway into cells, monomeric anti-ICAM follows a 
different intracellular routing from multimeric anti-ICAM NCs.  
To complement these studies, we analyzed this differential subcellular distribution 
(Fig. 5.6A). In accord with lysosomal trafficking and degradation, the fraction of 
internalized anti-ICAM NCs detected at the cell periphery decreased with time (from ~40% 
at 30 min to ~15% at 5 h; Fig. 5.6B), while the fraction located at the perinuclear region 
increased (from ~25% at 30 min to ~85% at 5 h; Fig 5.6C), similar to anti-ICAM conjugates 
(Fig. 5.6A). In contrast, in agreement with its lack of lysosomal routing and degradation, 
the trafficking of anti-ICAM to the perinuclear region of cells remained very low over time 
(~8% at 30 min and ~12% at 5 h; Fig. 5.6C), while it remained stably located at the cell 




Figure 5.6. Peripheral and perinculear localization of monomeric vs. multimeric ICAM-1 
ligands. (A) TNF-α-activated HUVECs were incubated with anti-ICAM or anti-ICAM NCs for a 
30 min pulse to allow only binding, then washed and incubated for up to 30 min, 1 h, 3 h, or 5 h at 
37 ºC to allow uptake. Cells were fixed and immunostained to differentially label surface-bound 
(yellow) vs. internalized (green) fractions. Dashed lines mark the cell borders. Scale bar, 10 μm. 
(B) Fluorescence image analysis was used to quantify the percentage of internalized anti-ICAM or 
anti-ICAM NCs localized to the cell periphery (within ~5 µm from the cell border) or (C) 




are means ± S.E.M. *, p < 0.05 comparing anti-ICAM vs. anti-ICAM NCs. #: p < 0.05 with respect 
to percent localization after the pulse (30 min). 
 
5.2.6 Recycling of Monomeric vs. Multimeric ICAM-1 Ligands in Endothelial Cells  
We next tested whether the peripheral localization observed for monomeric anti-ICAM 
may be associated with recycling from endocytic compartments to the plasma membrane. 
For this purpose, we comparatively examined the colocalization of anti-ICAM vs. anti-
ICAM NCs (green in Fig. 5.7A) with Rab11a (red). This marker belongs to the small 
GTPase superfamily of proteins and has been well established for its role in the recycling 
of various ligands and/or their receptors, including transferrin, transferrin receptor, E-
cadherin, LFA-1, GLUT4, etc. [153, 158-162]. Surprisingly, fluorescence microscopy 
revealed that both anti-ICAM and anti-ICAM NCs colocalized significantly with Rab11a-
positive compartments after internalization (yellow color): ~75%-85% in the case of anti-
ICAM and ~55%-60% for anti-ICAM NCs within the first hour (Fig. 5.7B). However, 
localization of anti-ICAM NCs with Rab11a decayed to 23% by 3 h and 13% by 5 h. 
Instead, this was not the case for anti-ICAM, a substantial fraction of which remained 







Figure 5.7. Colocalization of monomeric vs. multimeric ICAM-1 ligands with recycling 
compartments. (A) TNF-α-activated HUVECs were incubated with green fluorescent anti-ICAM 
for a 30 min pulse to allow only binding, then washed and incubated for up to 30 min, 1 h, 3 h, or 
5 h at 37 ºC to allow uptake. Cells were then washed, fixed, and permeabilized. Recycling 
compartments were labeled with antibodies to Rab11a and a TxR secondary antibody. Arrowheads 
denote green anti-ICAM or anti-ICAM NCs localized to red-labeled compartments (yellow color) 
and arrows represent non-colocalized counterparts (green color). Dashed lines mark the cell 
borders. Scale bar, 10 μm. (B) The percent Rab11a colocalization with respect to total cell-
associated anti-ICAM or anti-ICAM NCs was quantified by fluorescence image analysis. Data are 
means ± S.E.M. *: p < 0.05 comparing anti-ICAM vs. anti-ICAM NCs. #: p < 0.05 comparing 
Rab11a colocalization after the pulse (30 min).  
 
Therefore, it appears that both anti-ICAM and anti-ICAM NCs enter cells via the 
same pathway and initially traffic to a similar membrane-proximal intracellular 
compartment, yet anti-ICAM recycles back to the plasmalemma while anti-ICAM NCs 
deviate to lysosomes. Supporting this, tracking the cell-surface vs. intracellular distribution 
of monomeric anti-ICAM over time revealed that, while the total cell-associated fraction 
remained constant (~90% of the original value at 30 min), the intracellular fraction cycled: 
this fraction decreased by 65% at 1 h, then increased to 83% of the original value by 3 h 
(Fig. 5.8). This result could be visualized by fluorescence microscopy in that the 
internalized “green” fraction of anti-ICAM at the cell periphery nearly disappeared 







Figure 5.8. Recycling of monomeric anti-ICAM. (A) TNF-α-activated HUVECs were incubated 
with monomeric anti-ICAM for 30 min to enable binding to cell-surface ICAM-1 (pulse period), 
washed to remove unbound materials, and incubated for various time intervals at 37 ºC  to allow 
subsequent uptake and/or recycling to the cell surface (chase period). Samples were then fixed and 
cell-surface vs. internalized ligands were differentially stained yellow (green+red; arrowheads) and 
green (arrows), respectively. Dashed lines mark the cell borders. Scale bar, 10 μm. (B) 
Fluorescence intensity of total cell-associated and intracellular anti-ICAM was quantified by 
fluorescence image analysis and expressed as a fraction of the respective amount after the pulse 
(30 min; solid line). Values are means ± S.E.M. #: p<0.05 with respect to the fluorescence intensity 
at 30 min.  
 
5.2.7 Endocytic Recycling of Endothelial ICAM-1 in the Absence of Ligands 
In a previous study it was observed that internalized multimeric anti-ICAM NCs trafficked 
to early endosomal compartments, from which the receptor, ICAM-1, recycled back to the 
cell surface while carriers trafficked to lysosomes [92]. Since it is known that Rab11a 
recycling compartments can arise from early endosomes, it seems that recycling of 
monomeric anti-ICAM observed in this study may simply be following the itinerary of its 
receptor after uptake. If this is the case, the question remains whether anti-ICAM induces 
endocytosis and recycling upon binding to ICAM-1, or whether ICAM-1 is constitutively 
endocytosed and recycled in activated endothelial cells whereby anti-ICAM simply 
remains bound to (and follows) its receptor.  
To assess the latter possibility, we tracked the cellular location of ICAM-1 in the 
absence of ligands (Fig. 5.9A). We first labeled the cell surface using red-fluorescent lectin, 
which binds to glycoproteins on the plasma membrane, hence, allowing us to track 
intracellular compartments that may originate from the cell surface as red punctate 
structures (asterisks). At various times after labeling the plasmalemma, surface-located 
ICAM-1 was immunostained in blue and total (surface + intracellular) ICAM-1 was 
additionally immunostained in green (see Section 3.16 for details). As expected, this 




which appeared as triple labeled regions (white; denoted by arrowheads). The presence of 
white regions decreased with time (compare 30 min or 1 h with 5 h), as expected if ICAM-
1 was endocytosed. Verifying this, intracellular ICAM-1 (green with no blue label) could 
be found to colocalize with punctate lectin-containing compartments (red), indicating that 
this pool had been endocytosed from the plasmalemma (yellow; denoted by arrows). This 
fraction represented ∼16% of total ICAM-1 (Fig. 5.9B). Also, we found a fraction of 
intracellular ICAM-1 (green) that did not colocalize with lectin (red), which may originate 
from the biosynthetic route. Therefore, it appears that indeed surface-expressed ICAM-1 
is endocytosed in the absence of ligands.  
Interestingly, with time, there was an increase in the fraction of lectin that 
distributed to the perinuclear region of the cell (from 36% at 30 min to 75% at 5 h; Fig. 
5.9C), and this coincided with a decrease in the colocalization of ICAM-1 and lectin (from 
16% at 30 min to 6% by 5 h). This would be in agreement with endocytic transport of 
ICAM-1 away from perinuclear compartments, just as observed when studying 
endocytosis of anti-ICAM (Fig. 5.6). 
 
Figure 5.9. ICAM-1 internalization in the absence of ligand binding. (A) TNF-α-activated 
HUVECs were incubated at 37ºC continuously for different time intervals with TxR tomato lectin 
(red) to label the cell surface and allow potential endocytosis. Cells were then fixed and 
immunostained to visualize surface-bound ICAM-1 in blue, followed by permeabilization and 
immunostaining of total ICAM-1 (surface and internal) in green. Colocalization of surface ICAM-
1 with lectin appears in white (arrowheads). Colocalization of intracellular ICAM-1 with lectin 
(therefore, originating from the plasmalemma) appears in yellow (arrows). Asterisks indicate 
punctate lectin-containing compartments (red; generated from endocytosis), which do not 
colocalize with ICAM-1. Dashed lines mark the cell borders. Scale bar, 10 μm. (B) The extent of 
colocalization of ICAM-1 and lectin was quantified by fluorescence image analysis. (C) The 
percentage of lectin localized to the perinuclear region (within ~5 µm from the nucleus) relative to 
the total amount of cell-associated lectin is also shown. Data are means ± S.E.M. #: p < 0.05 against 






To verify this, we examined the fraction and location of intracellular ICAM-1 in 
the absence of ligands (sham), using cells that were previously treated with cyclohexamide 
to minimize the presence of intracellular ICAM-1 originating from the biosynthetic route 
(Fig. 5.10). These cells were fixed and cell surface vs. intracellular ICAM-1 were 
differentially immunostained (yellow and green, respectively; see Section 3.15 for details). 
This revealed the presence of intracellular ICAM-1 at the cell periphery (Fig. 5.10A), 
representing ∼26% of total ICAM-1 (Fig. 5.10B). This is comparable to the location and 
fraction of anti-ICAM (29%) that is endocytosed by cells upon incubation with this ligand 
(Fig. 5.10B). Amiloride reduced the fraction of intracellular ICAM-1 by 68% (Fig. 5.10C), 
similar to the inhibition observed with regard to uptake of anti-ICAM shown in Fig. 5.2B. 
Also, in parallel to results obtained in the presence of these ligands, wortmannin did not 
reduce the level of intracellular ICAM-1 in the absence of ligands. This set of results 
indicates that ICAM-1 is endocytosed from the endothelial plasmalemma in the absence of 







Figure 5.10. Presence of intracellular ICAM-1 in the absence of ligand binding. (A) TNF-α-
activated HUVECs were incubated for 1 h at 37°C with anti-ICAM, for ligand-induced uptake. 
Alternatively (sham), cells were treated with cyclohexamide (to minimize intracellular ICAM-1 
arising from de novo synthesis) and fixed before being incubated with anti-ICAM, so that there is 
no ligand-induced uptake. In both cases, samples were then incubated with a TxR-secondary 
antibody to label ICAM-1 at the cell surface, followed by permeabilization and staining of total 
ICAM-1 (surface + intracellular) with anti-ICAM and FITC-secondary antibody. This labels cell-
surface ICAM-1 in yellow (red + green; arrowheads) vs. intracellular ICAM-1, which appears green 
only (arrows). Dashed lines mark the cell borders. Scale bar, 10 μm. (B) Images were scored by 
fluorescence analysis to quantify the percentage of intracellular ICAM-1 with respect to the total 
pool of cell-associated ICAM-1. (C) A similar analysis was performed comparing sham cells from 
(A-B) (Control) to sham cells treated with an inhibitor of CAM-endocytosis and macropinocytosis 
(amiloride) or an inhibitor of macropinocytosis only (wortmannin; wtm). Data are means ± S.E.M. 
and represent percent intracellular ICAM-1. *: p < 0.05 against control (sham) values. 
 
The results shown thus far are depicted in Fig. 5.11. To summarize, monomeric 
ligands targeted to ICAM-1 in model endothelial cells induces uptake into cells by CAM-
mediated endocytosis. The intracellular itinerary of anti-ICAM differed from that of 
multimeric entities: anti-ICAM appears to undergo recycling to the cell membrane, 







Figure 5.11. Distinct intracellular itineraries of ICAM-1 and monomeric vs. multimeric 
ICAM-1 ligands in vascular endothelial cells. Multimeric ligands to ICAM-1, such as anti-ICAM 
NCs (a) are internalized by cells via CAM-mediated endocytosis, and subsequently undergo 
lysosomal degradation. Monomeric ligands to ICAM-1, e.g. anti-ICAM (b), as well as ICAM-1 in 
the absence of ligand-binding (c) are also endocytosed by the CAM pathway, yet subsequently 
undergo Rab11-dependent recycling to the plasma membrane.  
 
In continuation of these findings, the following section aims to exploit this 
knowledge for oral delivery. As such, we evaluated whether (A) uptake induced by 
monomeric ligands also holds for GI epithelial cells, and whether (B) such uptake leads to 
transcytosis, as it did for anti-ICAM NCs [13]. Hence, these studies will determine, for the 
first time, the potential of monomeric ICAM-1 targeting strategies for oral delivery into 
and across the GI epithelium.  
 
5.2.8 Binding and Endocytosis of Monomeric Anti-ICAM by Model Gastrointestinal 
Epithelial Cells 
In light of our observation that monomeric anti-ICAM does indeed undergo endocytosis 




which may offer the opportunity for targeting and uptake to this tissue upon oral delivery. 
With this in mind, we examined the behavior of Caco-2 cells, a well-established model of 
the GI epithelial cells [130], when exposed to monomeric anti-ICAM. Confirming previous 
results [13], we first verified binding of anti-ICAM on these cells by fluorescence 
microscopy (Fig. 5.12), which was: (a) specific vs. control IgG, a non-specific antibody 
with an isotype matching that of anti-ICAM (8-fold over IgG at 1 h); (b) similar for 
inflammation-mimicking (TNFα) vs. control conditions (99% of control at 1h); and (c) 




Figure 5.12. Binding specificity of anti-ICAM in model gastrointestinal epithelial cells. (A) 
Mouse anti-human ICAM-1 (anti-ICAM) vs. non-specific mouse IgG were incubated with control 
(Ctr) vs. TNFα-activated Caco-2 cells for 1h at 37 ᵒC. Cells were washed, fixed and permeabilized, 
and total cell-associated anti-ICAM or IgG were immunostained with FITC-labeled goat anti-
mouse IgG. Scale bar = 10 µm. Dashed lines mark the cell borders, as observed by phase-contrast 
microscopy. (B) Association of anti-ICAM to control cells was quantified by measuring the sum 
fluorescence intensity per cell, expressed in arbitrary units (A.U.), after subtracting the background 
fluorescence for the equivalent surface area of samples voided of cells. The horizontal continuous 
and dashed lines are association of non-specific IgG to control cells and anti-ICAM association to 
TNFα-treated cells, respectively, both at 1 h. Data are Mean ± S.E.M. No difference was observed 
between control and TNFα-treated cells;* compares anti-ICAM vs. IgG; # compares each time 






Then, uptake was assessed in these cells using a pulse-chase incubation method, in 
which antibody was allowed to bind to cells for 30 min and then removed from the cell 
medium in order to track internalization of the pre-bound fraction without the confounding 
effects of concomitant binding. Using differential immunostaining of surface-bound anti-
ICAM (yellow color marked by arrowheads) from internalized anti-ICAM (green color 
marked by arrows), we observed that the total amount of antibody internalized per cell was 
highly specific for anti-ICAM vs. IgG (IgG displayed non-detectable uptake; Fig. 5.13A). 
In addition, uptake did not occur at 4 ºC (16% of 37 ºC at 1 h), indicating an energy-
dependent mechanism (Fig. 5.13B). Uptake was also significant, since ~30% of all cell-
associated anti-ICAM was internalized within 30 min and this increased to ~50% by 1 h, 
which was similar for both control and TNFα-treated cells (Fig. 5.13C). Interestingly, the 
percentage of uptake decreased after 1 h, e.g., to 24% by 5 h. In agreement with the 
percentage of uptake, anti-ICAM internalized in TNFα-activated and control cells similarly 







Figure 5.13. Uptake of anti-ICAM by gastrointestinal epithelial cells. (A) Anti-ICAM or non-
specific IgG were incubated with control vs. TNFα-activated Caco-2 cells (only control is shown) 
at 37 ᵒC for 30 min to allow binding (pulse period). Non-bound antibody was removed and cells 
were chase-incubated at 37 ᵒC with fresh medium for additional time periods up to 5 h (only 1 h is 
shown) to allow endocytosis. Incubation at 4 ᵒC served as a negative control for uptake. Cells were 
fixed and incubated with TxR-goat anti-mouse IgG, which is only accessible to surface-bound 
counterparts. Cells were then permeabilized in order to label total cell-surface and internalized 
antibody with FITC-goat anti-mouse IgG. This renders differential staining of cell-surface antibody 
(green + red = yellow; arrowheads) vs. internalized counterparts (green; arrows). Scale bar = 10 
µm. Dashed lines mark the cell borders, observed by phase contrast microscopy. (B) Total 
internalized fluorescence (area occupied by green pixels) per cell was quantified using image 
analysis. (C) The percentage of internalization was assessed using the ratio of internalized antibody 
vs. total (surface-bound and internalized) antibody, as measured by fluorescence image analysis. 
The total time shown includes the 30 min pulse incubation. Internalization of IgG was undetectable. 
Data are Mean ± S.E.M. * Compares each time point to the preceding one, for control cells; ‡ 
compares each time point to the preceding one, for TNFα-activated cells; # compares control vs. 
TNFα at respective time points; † compares 1 h uptake in control cells at 37 ᵒC vs. 4 ᵒC; (p < 0.05, 
Student’s t test). 
 
 
However, this was not due to degradation of the internalized pool, since the total 
amount of antibody associated with cells did not change over this period of time (Fig. 5.14), 
and additional binding was precluded after the first 30 min pulse. As shown in Fig. 5.15, 
uptake of anti-ICAM in Caco-2 cells occurred by an endocytic pathway similar to that 




affects the Na+/H+ exchanger involved in the CAM pathway, but not filipin (88% of 
control) or MDC (99% of control), which affect caveolae- and clathrin-mediated 
endocytosis, respectively [12].  
 
Figure 5.14. Total anti-ICAM associated 
to gastrointestinal epithelial cells. Control 
Caco-2 cells were incubated with anti-
ICAM for a 30 min pulse period, washed, 
and incubated in fresh media for a total of 1, 
3, and 5 h to permit uptake. Cells were fixed, 
permeabilized, and treated with FITC-goat 
anti-mouse IgG to label total cell-associated 
anti-ICAM in green. The sum fluorescence 
of anti-ICAM per cell was quantified using 
image analysis. The total incubation time is 
shown. Data are Mean ± S.E.M. No 
difference was observed between successive 





Figure 5.15. Mechanism of endocytosis of anti-ICAM by gastrointestinal epithelial cells. (A) 
Caco-2 cells were incubated for 1 h at 37 ᵒC with anti-ICAM in the presence of control (Ctr) cell 
medium or medium containing amiloride (Amil), filipin (Fil), or MDC, which are inhibitors of 
CAM-, caveolae-, and clathrin-mediated endocytosis, respectively. Surface-bound vs. internalized 
anti-ICAM was differentially immunostained to appear yellow (arrowheads) vs. green (arrows). 
Scale bar = 10 µm. Dashed lines mark the cell borders, as observed from phase-contrast 
microscopy. (B) The percentage of internalized anti-ICAM with respect to total cell-associated 
anti-ICAM was quantified by image analysis, and normalized to control cells. Data are Mean ± 






Following uptake in vascular endothelial cells, anti-ICAM had exhibited minimal 
lysosomal trafficking and degradation. To assess whether this is the case for GI epithelial 
cells, we examined the colocalization of anti-ICAM with a lysosomal marker, LAMP-1. 
As shown in Fig. 5.16, anti-ICAM exhibited modest trafficking to lysosomes, with 14 and 
27% LAMP-1 colocalization between 1 h and 5 h. As expected, IgG exhibited no binding, 
uptake, or subsequent intracellular trafficking (Fig. 5.16A). We also examined trafficking 
in the presence of chloroquine, a weak base that diminishes lysosomal degradation. 
Interestingly, lysosomal colocalization of anti-ICAM decreased by 45 and 39% at 3 h and 
5 h in the presence of chloroquine with respect to control cells (Fig. 5.16B).  
 
Figure 5.16. Lysosomal trafficking of anti-ICAM in gastrointestinal epithelial cells. (A) Caco-
2 cells cultured on coverslips were treated with FITC-labeled anti-ICAM or non-specific IgG for 
30 min at 37 ºC to allow binding to the cell surface, followed by washing non-bound antibodies 
and incubation at 37C for the indicated time to allow uptake and intracellular trafficking. As a 
control for degradation, cells were incubated in the presence of chloroquine. Cells were fixed and 
permeabilized, and LAMP-1-positive lysosomes were then immunostained with TxR mouse anti-
LAMP-1 for 1 h. This protocol renders antibodies colocalized with lysosomes double-labeled with 
TxR and FITC, rendering yellow fluorescence (arrowheads), while non-colocalized antibodies 
appear single-labeled in green (arrows). Scale bar = 10 μm. Dashed lines mark the cell borders, as 
observed by phase-contrast microscopy. (B) Colocalization of green objects with red-labeled 
lysosomes was calculated from fluorescence micrographs. (C) Degradation of FITC-labeled anti-
ICAM was estimated by comparing the total fluorescence remaining over time to the cell-associated 
fluorescence achieved after the first 30 min incubation. Data are Mean ± S.E.M. * compares cells 
in the presence vs. absence of chloroquine; # compares each time point to the preceding one (p < 
0.05, Student’s t test). 
 
 
It is possible that in the event of degradation of anti-ICAM by lysosomal proteases, 




microscopy, we quantified the degree of immunodetectable anti-ICAM associated to cells 
over time, indicative of degradation. In agreement with minimal LAMP-1 colocalization, 
only 11% of total cell-associated anti-ICAM was degraded by 5 h (Fig. 5.16C). 
Chloroquine reduced degradation to 2% by 5 h, indicating that anti-ICAM undergoes a 
minor level of lysosomal trafficking and degradation. Given that the degree of lysosomal 
trafficking and degradation was similar to that in vascular endothelial cells, anti-ICAM 
may follow a similar intracellular fate in GI epithelial cells. In addition, minimal lysosomal 
trafficking may indicate that anti-ICAM is deferred to an alternative route in a cell barrier 
model, such as trafficking across the cell body for transcytosis.  
 
5.2.9 Transport of Anti-ICAM Into and Across Gastrointestinal Epithelial Monolayers 
The following section seeks to determine whether endocytosis of anti-ICAM leads 
to transport across GI epithelial cells, analogous to anti-ICAM NCs [13], in order to reveal 
the potential of this strategy for oral delivery across the GI epithelium. Whereas the studies 
conducted thus far utilized cells cultured on coverslips to enable characterization of uptake 
and intracellular trafficking by fluorescence microscopy, this cell culture model does not 
expose the basolateral surface of cells, precluding the possibility of transepithelial 
transport. Consequently, the following work utilized Caco-2 cells cultured on transwell 
inserts (Section 3.2; Fig. 3.1), which exposes both apical and basolateral membranes to the 
extracellular space. Cells cultured in this configuration serves as a prevalent model of the 
GI epithelium for studying transepithelial drug transport, and expresses ICAM-1 in both 




in this model was previously validated by immunostaining of occludin-positive tight 
junctions, consistent with a rise and plateau of TEER, as shown in Fig. 5.17 [13].  
 
 
Figure 5.17. Validation of a gastrointestinal epithelial cell barrier model for studying 
transepithelial transport. (A) Cell barrier formation of Caco-2 monolayers cultured on transwell 
inserts was validated by transepithelial electrical resistance (TEER) and (B) the presence of 
occludin, a tight junction protein. Data are means ± S.E.M. Figure is reproduced from Ghaffarian, 
et al., 2012 [13]. 
 
Prior to evaluating transport in this transwell model, we first verified by 
fluorescence immunostaining that anti-ICAM binds specifically to ICAM-1 on the apical 
surface of fixed Caco-2 cells (Fig. 5.18A).  This was not the case for mouse IgG, a non-
specific control which lacks a variable domain targeting ICAM-1, ruling out any 
contribution of the Fc region in binding, e.g. to Fc receptors (Fig. 5.18A). Staining of bound 
anti-ICAM also revealed the presence of microvilli on these cells, giving rise to the 
appearance of small clusters on the apical surface. Specific, time-dependent binding was 
also demonstrated by radioisotope tracing of 125I-labeled antibodies incubated with live 
cells: non-specific IgG displayed 12 and 4-fold lower association to cells after 3 h and 24 
h (Fig. 5.18B). Despite negligible binding, non-specific uptake or leakage between cells 






Figure 5.18. Specific binding of anti-ICAM in gastrointestinal epithelial cell monolayers. (A) 
Caco-2 cell monolayers cultured on transwell inserts were fixed (to prevent antibody 
internalization) and treated with anti-ICAM or control, non-targeted IgG for 1 h at room 
temperature to allow binding. FITC-labeled goat anti-mouse IgG was used to stain the total cell 
surface-bound fraction. Samples were imaged by fluorescence microscopy. Scale bar = 10 μm. 
Dashed lines mark the cell borders, as observed by phase-contrast microscopy. (B) Antibody 
binding and uptake in live caco-2 cell monolayers cultured on transwell inserts was assessed by 
incubation with 125Iodine-labeled anti-ICAM or IgG for 3 h or 24 h at 37 ºC. The radioisotope 
content in the cell fraction was then quantified using a gamma counter to derive the number of 
antibody molecules associated to cells. Data are Mean ± S.E.M. * compares anti-ICAM vs. IgG (p 
< 0.05, Student’s t test). 
 
To assess the possibility that anti-ICAM traffics across cells for release at the 
basolateral side, analogous to the pathway triggered by anti-ICAM coated nanocarriers, we 
incubated 125I-labeled anti-ICAM with Caco-2 monolayers cultured on transwell inserts to 
allow transport from the apical to basal compartment. Radioisotope tracing revealed that 
anti-ICAM is indeed transported across Caco-2 monolayers in a time-dependent manner, 
with an increase from 3×108 to 3×109 molecules transported per mm2 of epithelium 
between 3 h and 24 h (Fig. 5.19A). Transport appeared to be ICAM-1-specific, considering 
that the apparent permeability coefficient (Papp), which signifies the rate of transport, was 
4-fold greater than that of non-specific IgG antibodies at 24 h (Fig. 5.19C). Fig. 5.19B 
represents the efficiency of transport as the percentage transported with respect to the 
amount of total cell-associated anti-ICAM. In terms of this parameter, 25% of cell-




transported by 5 h. Taken together, these findings verified that monomeric targeting to 
ICAM-1 may indeed provide oral delivery across the GI epithelial barrier.  
 
 
Figure 5.19. Transepithelial transport of anti-ICAM across gastrointestinal epithelial 
monolayers. 125I-anti-ICAM or non-specific 125I-IgG were added to the apical chamber above 
Caco-2 cell monolayers cultured on transwell inserts, and incubated at 37 ºC to permit transport 
into cells and/or across cells to the basolateral chamber. (A) 125I content in the basolateral chamber 
was measured at the indicated time points, to calculate the amount of antibodies transported per 
mm2. The dashed line represents the level of transported IgG after 24 h. (B) The percentage of 
transport was calculated as the ratio of radioisotope content found in the basolateral fraction to that 
in the combined basolateral and cell fractions. (C) The apparent permeability coefficients (Papp) 
were calculated as described in Methods to represent the rates of transport of 125I-anti-ICAM or 
125I-IgG. Data are Mean ± S.E.M. * compares anti-ICAM vs. IgG; # compares each time point to 
the preceding one (p < 0.05, Student’s t test). 
 
 
5.2.10 Assessment of the Mechanism of Transport of Anti-ICAM 
Given that anti-ICAM was transported across cells, and that such transport was 
substantially greater than that of non-targeted IgG, there is evidence to believe that ICAM-
1 binding triggers either transcellular transcytosis, as previously shown for anti-ICAM 
nanocarriers, or opening of junctions leading to paracellular transport. First, to evaluate the 
role of transcytosis in the transepithelial transport of anti-ICAM, Caco-2 cells were treated 
with EIPA, an inhibitor of Na+/H+ exhanger-1 involved in CAM-mediated endocytosis 
[91]. As shown in Fig. 5.20A, EIPA significantly reduced transport of anti-ICAM in terms 
of molecules transported per mm2 (3% of control, untreated cells) and Papp (50% of the 




did not result from changes in monolayer permeability, as EIPA does not alter TEER values 
during transport [13].  
Furthermore, to identify a possible contribution of paracellular transport between 
adjacent cells, TEER was monitored during transport of anti-ICAM, whereby a decrease 
in TEER would signify opening of intercellular junctions. Fig. 5.20 reveals that 
transepithelial passage of anti-ICAM over 24 h did not trigger substantial changes in TEER 
compared with control, untreated cells (TEER was 91 and 102% of the control between 30 
min and 24 h). In contrast, treatment with H2O2, known to disrupt monolayer integrity, 
drastically decreased TEER values to 9% of the control by 24 h (Fig. 5.20A). In parallel 
with TEER, we also tested permeability of albumin, a tracer compound to identify changes 
in paracellular leakage. Transport of anti-ICAM over 24 h did not increase albumin 
permeability, as the Papp was 76% of untreated cells (Fig. 5.20A). On the other hand, H2O2 
significantly increased leakage of albumin by 2-fold, in agreement with opening of 
intercellular junctions (Fig. 5.20A). 
 
Figure 5.20. Mechanism of transport of anti-ICAM across gastrointestinal epithelial 
monolayers. (A) Transcellular transport of 125I-anti-ICAM across Caco-2 cell monolayers was 
assessed at 5 h in the absence or presence of EIPA, an inhibitor of CAM-mediated endocytosis. 
Quantification of 125I content in the basolateral chamber was used to calculate the amount of 
antibody molecules transported per mm2 as well as the rate of transport (Papp). (B) TEER was 
measured during transport of 125I-anti-ICAM across Caco-2 cells, to assess paracellular transport. 
Incubation with H2O2 is a positive control for opening of intercellular junctions. TEER was 
expressed as a percentage of values measured for untreated, control cells. (C) Paracellular protein 




of H2O2 or anti-ICAM. Data are Mean ± S.E.M. * compares values to control, untreated cells (p < 




Many cell surface receptors undergo different endocytic outcomes when bound to ligands, 
e.g., monomeric vs. multimeric counterparts, compared to their unbound state. Yet, this is 
still a rather unexplored phenomenon, particularly in cases where natural ligands of a 
receptor represent multimeric engagement entities. The present study has examined these 
aspects in the case of endothelial ICAM-1, using monomeric anti-ICAM vs. multimeric 
anti-ICAM NCs and conjugates as representative ligands. Although previous investigations 
had deemed monomeric anti-ICAM unable to enter cells as multimeric anti-ICAM 
counterparts (NCs and conjugates) do [9, 12], to our surprise, a closer examination revealed 
appreciable uptake via a similar mechanism, CAM-mediated endocytosis. Lower apparent 
or steady-state levels of endocytosis of monomeric anti-ICAM resulted from a distinct 
intracellular itinerary. At initial time points, both anti-ICAM and anti-ICAM NCs localized 
to Rab11a compartments at the cell periphery. Yet, with time, multimeric anti-ICAM NCs 
and conjugates trafficked to perinuclear lysosomes with significant degradation of the 
antibody counterpart (as previously reported [122]), while monomeric anti-ICAM 
remained localized to Rab11a-compartments with little degradation and recycled back to 
the plasma membrane. Similar trafficking was found for ICAM-1 in the absence of ligand 
binding, suggesting that this molecule recycles between the plasmalemma and an 
endosomal-like subplasmalemma compartment. Hence, contrary to anti-ICAM NCs and 
conjugates that follow an endo-lysosomal pathway, anti-ICAM simply follows the route of 




These results demonstrate a clearly differential endocytic fate for monomeric vs. 
multimeric ligands against ICAM-1. The pattern observed for this cell surface marker held 
similarities and differences as compared to other receptors. For instance, greater uptake of 
multimeric anti-ICAM NCs with respect to monomeric anti-ICAM contrasted observations 
of slower internalization of an oligomer composed of ten transferrin molecules vs. 
monomeric transferrin [141]. Yet, greater intracellular retention of anti-ICAM NCs relative 
to anti-ICAM was somewhat similar to longer intracellular retention of transferrin 
oligomers vs. monomeric transferrin [141]. Nevertheless, multimeric ligands in these two 
cases resided in different sites, i.e. lysosomes for multimeric ICAM-1 ligands as opposed 
to pericentriolar recycling compartments for multimeric transferrin counterparts [141]. 
Another example is that of monomeric folate-drug conjugates vs. multivalent folate-
decorated carriers [142]. Analogous to ICAM-1, multivalent folate carriers trafficked to 
lysosomes, whereas monomeric folate conjugates followed a recycling route to the plasma 
membrane [142]. However, distinct from ICAM-1, monomeric folate carriers followed the 
route of the natural ligand (folate)-receptor pair [142], whereas monomeric anti-ICAM 
followed the recycling route of naked ICAM-1. Antibody receptors have also shown 
different patterns of endocytic routing for different ligands, e.g. binding of an artificial 
monovalent ligand of macrophage Fc receptor (a modified Fab) resulted in recycling to the 
cell membrane, whereas a polyvalent immunoglobulin G complex triggered lysosomal 
trafficking and degradation [144, 145]. However, no difference in the final intracellular 
destination was found between these divalent and polyvalent Fc receptor ligands, while 




The differences observed between monomeric and multimeric anti-ICAM ligands 
are not due to physicochemical characteristics of the polymer particle in the case of anti-
ICAM NCs, since a similar uptake, perinuclear distribution, lysosomal colocalization, and 
degradation was found for multivalent anti-ICAM conjugates formed by crosslinking 
biotinylated anti-ICAM with streptavidin. It is likely that different physicochemical 
properties of the carrier may further impact the intracellular behavior. Yet, the fact that 
multimeric ICAM-1-targeted entities with diverse composition and valency (anti-ICAM-
coated PLGA particles, DNA-built dendrimers, liposomes, etc.) behave similarly in terms 
of intracellular trafficking [132, 164, 165], supports that this is a general feature of 
multimeric vs. monomeric targeting to ICAM-1. However, it is likely that intracellular 
trafficking to other receptors and pathways may be more sensitive to variations of the 
carrier formulation [132, 164, 165]. 
Importantly, our results indicate that intracellular trafficking of anti-ICAM reflects 
a pathway by which endothelial ICAM-1 seems to recycle between the cell surface and a 
subplasmmalema compartment in the absence of ligand binding, which was previously 
overlooked. This was supported by the fact that, in the absence of de novo protein synthesis 
or ICAM-1 ligands, ICAM-1 expressed on the cell surface was internalized, as observed 
by tracking the endothelial plasmalemma after lectin-labeling. Following uptake, ICAM-1 
diverged from the perinuclear distribution of lectin-positive internalized compartments. 
This, along with lack of significant disappearance (reflective of degradation) of 
immunodetectable ICAM-1 with time and reappearance of this molecule at the cell surface 




This may explain why endocytosis of monomeric anti-ICAM had been overlooked in the 
past [9, 12].  
Given that the outcome and kinetics for all these events were similar upon ICAM-
1 engagement by monomeric anti-ICAM, it is possible that this ligand does not induce 
endocytosis and rather passively follows the route of the receptor to which it is bound. 
Multimeric anti-ICAM NCs are also internalized via CAM-mediated endocytosis and 
localized at early time points to similar Rab11a compartments. However, from here this 
ligand did not follow subsequent recycling but lysosomal transport, as previously shown 
[31, 92]. Hence, multimeric engagement of the receptor may not provide the signal for 
CAM-endocytosis as previously believed [9, 12], but rather the signal to deviate the 
subsequent intracellular trafficking from the “constitutive” recycling route. In fact, a 
previous study had shown that, although anti-ICAM NCs traffic to endo-lysosomal 
compartments within cells, a significant fraction of ICAM-1 co-internalized with such 
carriers also recycles back to the plasmalemma [92]. The fact that higher uptake is observed 
for anti-ICAM NCs and conjugates vs. anti-ICAM may be due not to a greater endocytic 
efficiency but to cumulative retention of endocytosed carriers within the cell. Hence, anti-
ICAM recycling, which leads to lower intracellular accumulation, would be misinterpreted 
as a lower degree of endocytosis.  
From a biological standpoint, ICAM-1 uptake and recycling by endothelial cells in 
the absence of ligands is a new finding whose biological significance remains to be 
elucidated. However, recycling of membrane determinants is a common process, broadly 
involved in numerous cellular processes, such as cell-cell adhesion, migration, 




presenting cells (APCs), ICAM-1 has been observed to undergo uptake and recycling at 
sites of T-cell contact, which was mediated by an amiloride-sensitive pathway [155], 
analogous to CAM endocytosis in endothelial cells. This uptake and recycling seemed to 
provide a continuous redistribution of ICAM-1 on the APC surface, which helped maintain 
the dynamic contact with T-cells and strengthen cell-cell signaling [155]. In addition, 
platelet-endothelial cell adhesion molecule 1 (PECAM-1), a surface molecule structurally 
and functionally related to ICAM-1, and also associated with CAM endocytosis, has been 
shown to undergo constant recycling through specialized submembrane compartments of 
endothelial cells, to guide transmigration of leukocytes across the endothelium [167]. It is 
possible that CAM-mediated endocytosis of ICAM-1 represents an analogous 
phenomenon. Indeed, ICAM-1 also contributes to extravasation of leukocytes, where 
ICAM-1 continuously redistributes on the endothelial surface toward the migrating fronts 
of leukocyte contacts [168]. 
From a translational perspective, the findings of this study significantly extend 
previous knowledge on the potential for targeted drug delivery via ICAM-1. As indicated 
in Chapter 1, ICAM-1 is being explored for targeted interventions against conditions 
involving inflammation, immune disorders, cardiovascular disease, genetic and metabolic 
syndromes, etc. [9, 24, 31, 112, 133, 134, 164, 169-172]. In most of these settings, 
multimeric targeting to ICAM-1 has been pursued, e.g. by coupling affinity moieties to 
liposomes, microbubbles, polymer particles, gold nanorods, iron oxide nanoparticles, and 
other NC formulations [9, 24, 31, 112, 133, 134, 164, 169-172]. By providing endocytosis 
and intraendothelial trafficking, said multimeric ICAM-1-targeting strategies are valuable 




transport of multimeric ICAM-1-targeted carriers is ideal for delivery of lysosomal enzyme 
replacement therapies necessary to treat genetic deficiencies of these enzymes (i.e., 
lysosomal storage disorders) [31, 37, 39]. However, lysosomal trafficking is expected to 
result in premature degradation and/or entrapment of most other therapeutic agents [92, 
122]. Therefore, delivery by conjugation to monomeric ICAM-1-targeting ligands may 
resolve this problem by avoiding lysosomal transport while retaining the therapeutic agent 
within cells via an uptake-recycling pathway, providing more sustained delivery. This is 
feasible since several ICAM-1 targeting monoclonal antibodies, their humanized 
counterparts, antibody fragments, and peptides, have shown efficient ICAM-1 targeting 
and significant safety in animal models and clinical trials [25, 31, 33, 37, 45, 173]. 
In light of our observations above, uptake of monomeric anti-ICAM in endothelial 
cells revealed an opportunity to use monomeric ICAM-1 ligands as vehicles for drug 
delivery via the oral route. In exploring this opportunity, we first validated that monomeric 
anti-ICAM binds specifically to ICAM-1 on cultured GI epithelial cells, in agreement with 
prior observations for both endothelial and epithelial cells [9, 13, 116]. As in our earlier 
work using Caco-2 cells [13] and contrary to endothelial cells [9, 116], anti-ICAM binding 
to Caco-2 cells did not significantly vary between control and disease-like conditions 
mimicked by TNFα activation. This may be due to the fact that this cell line is derived from 
cancer tissue and its basal state already reflects a disease condition [174]. In fact, this 
supports previous evidence indicating that ICAM-1 expression is up-regulated in many 
pathologies affecting the vasculature and GI tissues, including inflammatory disorders, 
pathogenic infections, and cancers [10, 113, 150, 174-176]. Interestingly, monomeric 




shown success in neutralizing the receptor’s involvement in pathology [45, 173, 177]. As 
such, it has been proposed that ICAM-1 targeting may not only improve biodistribution of 
therapeutics to disease sites but may simultaneously serve as an ICAM-1-blocking agent 
to reduce its own involvement in pathology [113, 178].  
 
More importantly for the focus of this study, our results demonstrate that 
internalization of monomeric anti-ICAM is not restricted to endothelial cells, but also 
occurs in model GI epithelial cells. In comparison to endothelial cells, uptake in Caco-2 
cells was more efficient, reaching a maximum of ~50% internalization of all cell-associated 
anti-ICAM vs. 25-30% for endothelial cells. Considering that enterocytes have a high 
absorptive capacity, in line with their physiological function [174], it is possible that these 
cells may be better suited for said uptake. This difference may also be due to the fact that 
cancer derived cell lines, such as Caco-2 cells, generally have enhanced uptake capacity in 
support of their high metabolic, mitotic, and migratory activity [179]. Nevertheless, 
analogous to endothelial cells, internalization of anti-ICAM in GI epithelial cells occurred 
via active endocytosis, in particular, the CAM pathway. In light of this result, it is possible 
that CAM-mediated endocytosis is utilized for uptake of anti-ICAM in all cell types 
expressing ICAM-1, as previously shown in the case of multimeric ICAM-1-targeted 
formulations [12-14, 27, 164]. Given that in endothelial cells, ICAM-1 itself undergoes 
endocytic internalization via the CAM route in the absence of ligand binding, it is expected 
that anti-ICAM would follow a similar internalization pathway. As such, having reached a 
maximum between 1 h to 3 h, the level of anti-ICAM located intracellularly decayed over 




to cells. This may be due to a continuous process encompassing uptake and surface 
recycling of internalized materials, which we demonstrated in the case of uptake of 
monomeric anti-ICAM by endothelial cells.  
 
Interestingly, likely because of the above phenomenon, anti-ICAM associated to 
cells did not decay or traffic to lysosomes over 5 h, although uptake via endocytic 
mechanisms, including the CAM pathway, typically leads to lysosomal transport and 
degradation of biological molecules [92, 172]. This is in contrast to lysosomal degradation 
of anti-ICAM coated on multimeric NCs, which occurs between 3-5 h from their uptake 
[92], and similar to our previous finding on monomeric anti-ICAM in endothelial cells. 
Such enhanced intracellular stability associated with uptake of monomeric ICAM-1 
targeted ligands may be a significant advantage for drug delivery. 
In GI epithelial monolayers cultured on transwell inserts, which exposes the 
basolateral face of cells to the extracellular milieu, we observed substantial transepithelial 
transport of anti-ICAM. Whereas this phenomena was previously observed upon 
multimeric binding [13], the present work elucidates a novel role for ICAM-1 mediated 
transport upon monomeric binding. As such, monomeric ligands to ICAM-1 may serve as 
an alternative vehicle for transport across cellular barriers. Indeed, transepithelial transport 
of anti-ICAM appeared to be more efficient than anti-ICAM NCs in terms of the percentage 
of transport (84 vs 41% at 24 h) and Papp denoting the rate of transport (4×10
-8 vs. 2×10-8 
cm/s at 24 h) [13]. It can be speculated that anti-ICAM NCs are more likely to become 
retained in cells due to differences in intracellular routing, as observed for monomeric vs. 




multimeric ICAM-1-targeted systems undergo greater endosomal accumulation as well as 
lysosomal trafficking and degradation [116]. On the other hand, lower intracellular 
retention of monomeric ligands may be more conducive to transepithelial transport. In light 
of minimal lysosomal trafficking, monomeric ligands may be deferred to the transcytosis 
route. In addition, while the coverslip model restricted recycling of endocytosed anti-
ICAM to the apical membrane, it is possible that transport across cells in a transwell model 
is attributed to recycling to the basolateral membrane, yet this remains to be elucidated.  
Despite differences in transport efficiency, both anti-ICAM and anti-ICAM NCs 
follow a CAM-mediated transcytotic pathway, in agreement with the fact that both systems 
are internalized into cells via CAM-mediated endocytosis [13]. Moreover, the paracellular 
pathway does not appear to contribute to transport, as no increase in albumin permeability 
or electrical conductivity was observed in the presence of anti-ICAM. Compared to 
paracellular mechanisms, transcytosis is preferred for drug delivery across cellular barriers 
considering that the permeability barrier regulating the passage of undesired substances is 
more likely to remain intact [6]. CAM-mediated transport may also provide for effective 
oral drug delivery in light of its flexibility compared with more restrictive vesicular 
pathways, such as clathrin- and caveolin-mediated transport; as described in Section 2.3.2, 
CAM-mediated endocytosis accommodates drugs and drug carriers with a wide range of 
size, shape, chemistry, and targeting valency [9, 12, 24-34]. Transport of a monomeric 
antibody, which varies in size and valency compared with previous multimeric systems 






5.4 Conclusion  
The first portion of this chapter has provided insight into the differential endocytic fates 
associated with bound (via monomeric vs. multimeric ligands) and unbound endothelial 
ICAM-1. This highlights the complex regulation of endocytic events, which at present still 
remains elusive, particularly for non-conventional clathrin- and caveolae-independent 
pathways such as CAM-mediated endocytosis. Our findings reveal that this pathway may 
be a constitutive process in activated endothelial cells, which provides a means to maintain 
a subplasmalemma pool of recycling ICAM-1 molecules. This pool may allow for rapid 
redistribution of ICAM-1 to the cell surface, e.g. at sites of adhesion by natural ligands 
(primarily leukocytes). ICAM-1-trafficking does not appear to be disrupted by binding of 
monomeric affinity molecules but by multimeric carriers, which traffic to lysosomes. These 
findings pair well with the biological function of ICAM-1 and provide new avenues for 
therapeutic targeting to this marker. For instance, monomeric delivery vehicles directed at 
ICAM-1 may allow more prolonged therapy without undergoing lysosomal degradation, 
contrary to multimeric formulations that are more amenable for delivery into endo-
lysosomal compartments. Hence, these newly identified features are critical to the selection 
and optimization of formulations that tailor particular therapeutic needs.  
In the second portion of this chapter, we revealed that in GI epithelial cells, 
monomeric ICAM-1-ligands (anti-ICAM) undergo CAM-mediated uptake and 
intracellular trafficking in a similar manner as endothelial cells, expanding the utility of 
this targeting strategy for oral delivery. We further demonstrated that, analogous to 
multimeric ICAM-1 ligands, monomeric ligands also elicited CAM-mediated, vesicular 




mediated transport may provide a safe and effective avenue for oral delivery, given that it 
does not compromise GI barrier integrity and relative to classical vesicular pathways, it 
provides greater versatility in accommodating different drug delivery systems [9, 12, 24-
34]. From a translational perspective, these results reveal a novel opportunity for using 
monomeric ICAM-1 ligands as drug carriers for oral delivery into and across the GI 
epithelium. From a biological standpoint, this knowledge also lends novel insight on 





Chapter 6: A Monomeric ICAM-1 Targeted Ligand Delivers 




In Chapter 5, we demonstrated that monomeric ICAM-1 ligands are transported 
into GI epithelial cells by CAM-mediated endocytosis, which led to CAM-mediated 
transcytosis across these cells. These findings revealed a novel opportunity for direct 
conjugation of these ligands to therapeutic or imaging agents for oral delivery, which may 
bypass the barriers in formulating a more complex, multimeric carrier system. In addition, 
Chapter 5 demonstrated that although transport is mediated by the same CAM-mediated 
pathway, monomeric vs. multimeric ICAM-1 binding leads differential cellular regulation 
in terms of efficiency of uptake, intracellular itinerary, and extent and rate of transepithelial 
transport. Therefore, monomeric vehicles may expand the range of future oral applications 
of ICAM-1 targeting beyond existing multimeric strategies.  
In light of these results, the aim of Chapter 6 was to exploit the transport avenue 
triggered by monomeric targeting for delivery of a drug cargo into and across the GI 
epithelial barrier, as was shown for multimeric anti-ICAM-coated nanoparticles carrying 
α-Gal enzymes as a model drug cargo [13]. In addition, we examined the retention of drug 
activity after targeting and transport into and across GI epithelial cells. This holds 
significance, as the GI epithelium represents a valuable gateway for therapies aimed at 
either treating gastrointestinal disorders or reaching the systemic circulation via the oral 
route [1, 2]. As a proof-of-concept, we have conjugated anti-ICAM antibodies to a model 




of therapeutic enzymes has been extensively explored in the case of multimeric targeting 
[9, 13, 25, 27, 30, 31, 36, 37, 128, 178] and a monomeric delivery platform may offer 
alternative opportunities. Our results shown herein indicate that monomeric targeting to 
ICAM-1 indeed represents a valid alternative to multimeric targeting for delivery of 
therapeutics into and across the GI epithelium.  
 
6.2 Results 
6.2.1 Conjugation of a Model Enzyme to Anti-ICAM 
The fact that anti-ICAM can bind to and be endocytosed by cells, such as model GI 
epithelial cells shown here, suggests that direct coupling of a cargo to anti-ICAM could be 
sufficient to achieve specific targeting and transport within cells, without the need of a 
multivalent strategy as previously thought. As a proof-of-concept to examine this, we 
conjugated anti-ICAM to a model cargo, horseradish peroxidase (HRP), an enzyme that is 
commercially available and well characterized in terms of molecular weight and activity. 
We used a commercial kit for conjugation, employing an antibody-to-enzyme molar ratio 
of 1:2 (see Section 3.6).  
We initially verified the presence of a conjugate and its constituents by 
electrophoretic (SDS-PAGE) separation of the reaction mixture using denaturing, non-
reducing conditions, followed by Coomassie blue staining and Western blot 
immunodetection (Fig. 6.1A). Coomassie blue staining showed protein bands at ~150 kDa 
for control unconjugated anti-ICAM (Lane 2) and ~40 kDa for control unconjugated HRP 
(Lane 3), in agreement with their theoretical molecular weights. In the case of the conjugate 




1), which is the theoretical size of a conjugate carrying 2 HRP molecules per anti-ICAM 
molecule, as expected. This band was clearly positive for the presence of both antibody 
and HRP components by Western blot (arrows in Lanes 4 and 7), whose specificity was 
verified by differentially labeling control unconjugated anti-ICAM or HRP, respectively 
(Lanes 5-6 and 8-9). Apart from this predominant ~230 kDa conjugate band, faint bands 
of ~150 kDa and ~40 kDa were also present in the conjugate reaction (Lane 1), which were 
positive for either anti-ICAM or HRP, but not both (Lanes 4 and 7). This indicates traces 
of unconjugated antibody and enzyme in the reaction mixture. In addition, two bands above 
230 kDa (Lane 1) were positive for both anti-ICAM and HRP (Lanes 4 and 7), suggesting 
the presence of larger conjugates. However, the Coomassie blue intensity of these lower 
and higher molecular weight bands was much lower than that of the predominant 230 kDa 
band (2.2-, 1.5-, and 1.7-fold lower for the 40 kDa, 150 kDa, and >230 kDa bands, 
respectively; Lane 1), indicating that only a minor fraction of these species is present in the 
conjugate mixture. These results indicate that the predominant conjugate species had a 
molecular weight of ~230 KDa, expected for a conjugate bearing anti-ICAM-to-HRP 







Figure 6.1. Characterization of anti-ICAM-HRP conjugates using SDS-PAGE and AF4. 
Horseradish peroxidase (HRP) was conjugated to anti-ICAM antibody (Ab) according to the 
manufacturer’s instructions to yield a theoretical antibody-to-enzyme molar ratio of 1:2. (A) The 
anti-ICAM-HRP conjugate mixture vs. unconjugated anti-ICAM or HRP were separated by SDS-
PAGE in denaturing, non-reducing conditions. Left: Coomassie blue staining was used to visualize 
protein bands. For Western blot, proteins were transferred to a PVDF membrane and 
immunostained with either goat anti-mouse IgG-HRP to visualize protein bands containing anti-
ICAM (Lanes 4-6) or with rabbit anti-HRP followed by goat anti-rabbit IgG-HRP to visualize 
protein bands containing HRP (Lanes 7-9). Arrows designate a predominant ~230 kDa conjugate 
band. (B) HRP, anti-ICAM, and anti-ICAM-HRP were fractionated using AF4 connected with 




eluted samples as a function of molar mass (kDa). A predominant peak with an average molar mass 
of 233 kDa is observed for anti-ICAM-HRP (arrow). 
 
 
We then characterized the conjugate population using AF4 coupled to MALS, RI, 
and UV absorbance detectors [180] to more accurately determine average molecular 
weight. The differential weight fraction vs. molecular weight represented in Fig. 6.1B 
shows that unconjugated HRP and anti-ICAM result in relatively monodisperse peaks with 
average molecular weights of 43 and 155 kDa, respectively, in agreement with the SDS-
PAGE determination (Fig. 6.1A). The anti-ICAM-HRP reaction mixture contained a range 
of conjugate species. The major peak representing ~40% of the conjugate population 
contained conjugates ranging between ~190 – 340 kDa, which correspond to antibody-to-
enzyme molar ratios of 1:1 – 1:4, therefore, all with the ability to bind ICAM-1 in a 
monomeric manner. Within this population, the average molecular weight was 233 kDa, 
indicating a predominant species of 1:2 antibody-to-enzyme molar ratios (just as in SDS-
PAGE). This pick was preceded by a minor peak of 196 kDa representing ~10% of the 
population, which contained monomeric conjugates with a 1:1 antibody-to-enzyme molar 
ratio and a fraction of unconjugated anti-ICAM at 155 kDa. Unconjugated HRP was not 
detected. Finally, the higher molecular weight tail following the major conjugate peak 
represented ~40% of the population and an average molecular weight of 686 kDa. This 
fraction is presumably composed of large multimeric conjugates and/or aggregates, 
therefore, with the ability to bind ICAM-1 in a multimeric manner. In light of these results, 
the cellular uptake studies discussed below employ AF4 to separate conjugates into 233 
kDa and 686 kDa fractions, in order to evaluate uptake from monomeric vs. multimeric 
binding.  




6.2.2 Specific Binding of Active Anti-ICAM-Enzyme Conjugates to Model 
Gastrointestinal Epithelial Cells 
Specific binding of monomeric anti-ICAM antibodies, as well as multimeric anti-ICAM 
conjugates and carriers, have been extensively demonstrated in previous work [9, 12, 24-
34] and in this dissertation (Fig. 5.12). However, the question remaining is the induction 
of uptake by monomeric anti-ICAM. As such, in this study we simply verified the 
specificity of binding of the anti-ICAM-HRP conjugate mixture (Fig. 6.2 and Fig. 6.3). 
Using fixed Caco-2 cells to avoid concomitant uptake that may confound binding results, 
anti-ICAM and HRP were differentially immunostained in green and red, respectively, and 
both the fluorescence of these components as well as their colocalization were quantified 
by fluorescence microscopy.  
Unconjugated anti-ICAM bound to cells (fluorescence intensity of 970 A.U.; Fig. 
6.2A-B), yet as anticipated, did not exhibit significant HRP staining (136 A.U.; Fig. 6.2A-
B) or colocalization (1.7%; Fig. 6.2C). Also as expected, unconjugated HRP did not bind 
to cells, as deduced from minimal staining for anti-ICAM (88 A.U.; Fig. 6.2A-B) and HRP 
(15 A.U.; Fig. 6.2A-B), and lack of colocalization of these components (0.5%; Fig. 6.2C). 
These results support that only trace amounts, if any, of unconjugated anti-ICAM and HRP 
are present in the conjugation reaction (as observed in Fig.6.1), and they will not interfere 
with targeting and activity studies to be subsequently conducted. In contrast, incubation of 
cells with anti-ICAM-HRP conjugates showed substantial binding to cells, with positive 
staining of both the anti-ICAM (907 A.U.; 6.2A-B) and HRP (1343 A.U.; Fig. 6.2A-B) 
counterparts. In fact, the degree of targeting by anti-ICAM-HRP conjugates was similar to 




supports the predominant presence of conjugates bearing one antibody molecule. This 
binding was 88-fold above the binding level of unconjugated HRP (Fig. 6.2B), 
demonstrating that targeting is attributed to the anti-ICAM component of conjugates. In 
agreement with this, co-incubation of anti-ICAM-HRP conjugates in the presence of naked 
anti-ICAM, to compete for ICAM-1 binding sites, significantly reduced binding of HRP 
(e.g., 59% of fluorescence compared to control), while non-specific IgG did not compete 
for binding (e.g., 95% HRP fluorescence compared to control) (Fig. 6.2B and Fig. 6.3). 
Moreover, 100% of the anti-ICAM component of conjugates colocalized with the HRP 
component, and 96% of the HRP component colocalized with anti-ICAM (Fig. 6.2C). This 
confirms that we tracked conjugates rather than unconjugated species. Anti-ICAM-HRP 
conjugates also showed high binding specificity to cells when compared to control IgG-
HRP conjugates (Fig. 6.2A), which represented only 1% of the antibody and HRP 
fluorescence displayed by anti-ICAM-HRP conjugates (Fig. 6.2B). This verifies the ability 




Figure 6.2. Specific binding of anti-ICAM-HRP conjugates to model gastrointestinal 
epithelial cells. (A) Fixed Caco-2 cells were incubated for 1 h at room temperature with non-
conjugated HRP or anti-ICAM vs. anti-ICAM-HRP conjugates or control IgG-HRP conjugates. 
Incubations were performed either in control cell medium or medium containing anti-ICAM, to 




FITC-labeled goat anti-mouse IgG (green), while HRP was immunostained with rabbit anti-HRP 
and TxR goat anti-rabbit IgG (red). Colocalization of anti-ICAM with HRP appears in yellow 
(green + red). Scale bar = 10 µm. Dashed lines mark the cell borders, as observed from phase-
contrast microscopy. (B) The green FITC fluorescence was used to quantify binding of the anti-
ICAM counterpart and the red TxR fluorescence was used to quantify binding of the HRP 
counterpart. (C) Colocalization was calculated as the percentage of anti-ICAM colocalized with 
HRP, or vice versa, relative to the total amount of anti-ICAM, or HRP, respectively. Data are Mean 
± S.E.M. * Compares any condition against anti-ICAM-HRP in the absence of competitors (p < 




Figure 6.3. Binding of anti-ICAM-HRP 
conjugates to cells in the presence of 
competitors. Fixed Caco-2 cells were incubated 
for 1 h at room temperature with anti-ICAM-HRP 
conjugates either in control cell medium or cell 
medium containing anti-ICAM or non-specific 
IgG. Anti-ICAM was immunostained with FITC-
labeled goat anti-mouse IgG (green) and HRP was 
immunostained with rabbit anti-HRP and TxR 
goat anti-rabbit IgG (red). Colocalization of anti-
ICAM with HRP appears in yellow (green + red). 
Scale bar = 10 µm. Note that anti-ICAM 
competitor is detected by the corresponding 
secondary antibody. Hence, competition is 





In addition to fluorescence microscopy, we evaluated HRP activity of anti-ICAM-
HRP conjugates bound to fixed cells (Fig. 6.4). Incubation with unconjugated anti-ICAM 
rendered no measurable HRP activity, as expected since no HRP component is attached to 
the naked antibody. In addition, incubation with unconjugated HRP did not result in 
significant activity, in agreement with the fact that the unconjugated enzyme did not bind 
to cells. This was also the case for IgG-HRP conjugates, in accord with their lack of binding 
observed above. Instead, anti-ICAM-HRP resulted in marked enzyme activity (equivalent 




(42% of control), but not IgG (95% of control). Hence, HRP conjugated to anti-ICAM is 




Figure 6.4. Enzyme activity of anti-ICAM-HRP conjugates bound to gastrointestinal 
epithelial cells. Fixed Caco-2 cells were incubated for 1 h at room temperature with non-conjugated 
HRP or anti-ICAM vs. anti-ICAM-HRP conjugates or control IgG-HRP conjugates. This was 
performed either in control cell medium or medium containing anti-ICAM, to compete for ICAM-
1 binding sites, or non-specific IgG. Cells were washed to remove the non-bound counterparts and 
HRP substrate was then added to cells to measure HRP activity (pM HRP). Data are Mean ± S.E.M. 
* Compares any condition against anti-ICAM-HRP in the absence of competitors (p < 0.05, 
Student’s t test). 
 
 
6.2.3 Active Anti-ICAM-Enzyme Conjugates Are Internalized by Gastrointestinal Epithelial 
Cells 
Having demonstrated binding specificity, we focused on the main question of this study: 
whether monomeric vs. multimeric binding to ICAM-1 by anti-ICAM-HRP conjugates 
induces uptake by cells, rendering intracellular enzyme activity. For this purpose, 
separation of the different conjugates species, as opposed to using the conjugate mixture, 
is paramount. Hence, we used AF4 to separate conjugates into two fractions: (1) the most 
prominent 233 kDa species (1:2 antibody-to-enzyme molar ratio), which binds to ICAM-1 




>326 kDa (average = 686 kDa) species that is likely composed of larger conjugates or 
aggregates and, thus, binds to ICAM-1 in a multimeric manner as it contains more than one 
antibody molecule. The isolated monomeric vs. multimeric fractions as well as the 
unseparated anti-ICAM-HRP conjugate mixture were incubated with Caco-2 cells and then 
immunostained to distinguish surface-bound vs. internalized counterparts. As observed by 
the presence of single-labeled green anti-ICAM or HRP (arrows; Fig. 6.5A), the 686 kDa 
conjugate fraction providing multimeric binding showed uptake by cells when tracking 
either the antibody or enzyme counterparts (87% and 69% compared to the unseparated 
mixture), as expected. Most importantly, tracking the antibody and enzyme counterparts 
revealed that the 233 kDa conjugate was internalized by cells to an equivalent degree 
(100% and 91%) as the unseparated mixture. This demonstrates that monomeric binding 
to ICAM-1 by anti-ICAM-HRP conjugates induces internalization similar to that produced 
by multimeric species. Since this was the case and the main species in the conjugate 
mixture consisted of the 1:2 antibody-to-enzyme conjugate, we conducted the subsequent 




Figure 6.5. Uptake of anti-ICAM-HRP conjugates after monomeric vs. multimeric binding 
to gastrointestinal epithelial cells. The anti-ICAM-HRP conjugate mixture was separated into two 
main molecular weight fractions by AF4: a form corresponding to 1:2 antibody-to-enzyme molar 
ratio (233 kDa) and a form representing larger multimolecular or aggregated conjugates (>326 kDa; 




the separated conjugate fractions for a 30 min pulse period, washed, and then incubated with fresh 
medium for up to 1 h to track uptake. In parallel assays, either surface-bound anti-ICAM or HRP 
were immunostained to fluoresce in yellow (arrowheads), whereas internalized anti-ICAM or HRP 
were immunostained to fluoresce in green alone (arrows). Scale bar = 10 µm. Dashed lines mark 
the cell borders, as observed from phase-contrast microscopy. (B) The percentage of internalization 
of each conjugate fraction was obtained from micrograph analysis, which was normalized to that 
of the unseparated conjugated mixture used as a control (Ctr). Data are Mean ± S.E.M. * Compares 
each conjugate fraction against the control mixture (p < 0.05, Student’s t test).  
 
 
Moreover, the uptake of anti-ICAM-HRP conjugates was time-dependent: from 1 
h to 3 h, the fluorescence corresponding to internalized anti-ICAM counterparts increased 
from 557 to 1254 A.U., and similarly, internalized HRP fluorescence increased from 739 
to 995 A.U. (Fig. 6.6A-B, and Fig. 6.7). Tracking the HRP component, this level of uptake 
corresponded to ~34% of all cell-associated enzymes found at 3 h (Fig. 6.7C), similar to 
the rate of uptake observed for unconjugated anti-ICAM shown in Fig. 5.13. Therefore, 
uptake is likely mediated by the targeting antibody. Supporting this, amiloride diminished 
uptake of both the antibody and enzyme cargo components of the conjugate by 59% and 
72% with respect to the control condition (Fig. 6.7D), demonstrating CAM-mediated 







Figure 6.6. Uptake of the anti-ICAM HRP conjugate mixture by gastrointestinal epithelial 
cells. (A) The anti-ICAM-HRP conjugate mixture was incubated at 37 o C in the absence or presence 
of amiloride (an inhibitor of CAM-mediated endocytosis) with Caco-2 cells for 30 min to allow 
binding (pulse). Non-bound conjugates were removed by washing and cells were incubated with 
fresh medium for a total of 1 h or 3 h (only 1 h is shown). In parallel assays, either surface-bound 
anti-ICAM or HRP were immunostained to fluoresce in yellow (arrowheads), whereas internalized 
anti-ICAM or HRP were immunostained to fluoresce in green (arrows). Scale bar = 10 µm. Dashed 
lines mark the cell borders, as observed from phase-contrast microscopy. (B) The total internalized 
fluorescence per cell and the (C) percentage of internalization, either corresponding to anti-ICAM 
or HRP conjugate counterparts, were quantified using image analysis. (D) Uptake in cells treated 
with amiloride was quantified and compared to the control condition shown for 1 h in (C). Data are 
Mean ± S.E.M. * compares 3 h to 1 h for each conjugate component; # compares control vs. 




Figure 6.7. Time-dependent uptake of anti-ICAM 
HRP conjugates in gastrointestinal epithelial 
cells. Caco-2 cells were incubated with the anti-
ICAM-HRP conjugate mixture for a 30 min pulse 
period, washed, and incubated with fresh medium for 
up to 1 or 3 h to track uptake. In parallel assays, either 
surface-bound anti-ICAM or HRP were 
immunostained to fluoresce in yellow (arrowheads), 
whereas internalized anti-ICAM or HRP were 
immunostained to fluoresce in green (arrows). Scale 
bar = 10 µm. Dashed lines mark the cell borders, as 






Finally, we tested whether uptake of anti-ICAM-HRP conjugates could sustain 
HRP activity within cells (Fig. 6.8). To evaluate this, we examined the HRP activity of 
cells incubated with anti-ICAM-HRP conjugates vs. unconjugated anti-ICAM or HRP 
controls, which was performed with or without cell permeabilization. The rationale is that 
if cells are not permeabilized, the detectable HRP activity must come from the surface-
bound fraction, while in permeabilized cells the enzyme substrate added would be 
accessible to both surface-bound and internalized HRP. Hence, the difference between 
these conditions shall render the internalized enzyme activity. As expected, in cells 
incubated with anti-ICAM-HRP conjugates, the activity detected after permeabilization 
(total activity) was 3.7-fold greater than that detected without permeabilization (surface 
activity); hence, 68% of the total HRP activity provided by anti-ICAM-HRP locates within 
the cell (Fig. 6.8A). In contrast, minimal HRP activity was detected in cells incubated with 
unconjugated HRP or anti-ICAM, whether or not cells were permeabilized (10- and 30-
fold lower for permeabilized cells and 13- and 17-fold lower for non-permeabilized cells, 
respectively; Fig. 6.8A). This demonstrates insignificant contribution of endogenous cell 
peroxidases to the HRP activity measured, validating our method. Also, this result 
demonstrates that both surface and internalized enzyme activity are specifically delivered 
by anti-ICAM conjugates. Indeed, inhibition of the internalized HRP activity by amiloride 
(28% of the control condition; Fig. 6.8B) verifies the role of the CAM pathway in this 
process. As such, looking at the internalized activity alone (the difference between the 
activity in permeabilized vs. non-permeabilized cells), this was 9- and 45-fold greater for 




respectively (Fig. 6.8C), indicating the potential of conjugates to deliver active cargoes, 
such as enzymes, within target cells.  
 
 
Figure 6.8. Enzyme activity delivered by anti-ICAM conjugates to gastrointestinal epithelial 
cells. (A) Caco-2 cells were incubated for 30 min at 37 ᵒC with non-conjugated HRP or anti-ICAM 
vs. anti-ICAM-HRP conjugates in the absence or presence of amiloride (and inhibitor of CAM-
mediated uptake). Non-bound conjugates were removed by washing and HRP substrate was added 
to measure HRP activity (pM HRP) in permeabilized cells (total internalized and cell surface-bound 
conjugate) vs. non-permeabilized cells (surface-bound fraction only) in parallel. The difference 
between these two measurements represents internalized activity (C). (B) The percentage of HRP 
activity internalized with respect to the total cell-associated activity was calculated from (A) in 
cells treated or not with amiloride. Data are Mean ± S.E.M. * Compares unconjugated counterparts 
to anti-ICAM-HRP conjugate; # compares permeabilized to non-permeabilized cells; ‡ compares 
amiloride vs. control; (p < 0.05, Student’s t test). 
 
 
6.2.4 Transport of Anti-ICAM-HRP Conjugates Into and Across Gastrointestinal 
Epithelial Monolayers 
Having demonstrated the binding specificity of anti-ICAM-HRP, we then addressed the 
primary aim of this work, to assess whether monomeric binding by conjugates induces 
transport across cells. Previous characterization of anti-ICAM-HRP conjugates by SDS-
PAGE and AF4 revealed a non-homogenous mixture consisting of (1) a predominant 
species with 2 HRP molecules conjugated per antibody (average molecular weight = 233 
kDa), which contains a single copy of anti-ICAM and hence, binds to ICAM-1 in a 
monomeric manner, and (2) an aggregated species (average molecular weight = 686 kDa), 




(unpublished results under review). Thus, imperative to the objective of this study, we 
evaluated the transepithelial transport of the non-separated conjugate mixture vs. 
conjugates separated by AF4 into its respective monomeric (233 kDa) and multimeric (686 
kDa) fractions (See Materials and Methods). By measuring the HRP activity of the 
basolateral (transported) fraction below cell monolayers over time, we demonstrated that 
monomeric ICAM-1-targeting by conjugates indeed led to delivery of HRP across these 
cells (Fig. 6.9). To our surprise, the monomeric, 233 kDa species delivered 10-fold and 
2.6-fold greater HRP than the multimeric, 686 kDa fraction and the non-separated 
conjugate mixture, respectively (Fig. 6.9A). This trend was also observed in terms the rate 
of transport, Papp, which was 11-fold and 2.4-fold greater for 233 kDa conjugates relative 
to 686 kDa and non-separated conjugates (Fig. 6.9C). However, the percentage of transport 
with respect to the total cell-bound fraction, indicating the efficiency of the pathway, was 
~50% for all molecular weight fractions (Fig. 6.9B). This suggests that the increase in 
absolute and rate of transport following monomeric binding resulted from enhanced initial 
uptake into cells. Taken together, monomeric binding to ICAM-1 led to transepithelial 
transport of conjugates, which did not increase in the presence of multimeric aggregates in 
the conjugate mixture. Considering that the non-separated conjugate mixture, produced a 
similar, although underestimated, level of transport, it was utilized for the remainder of 







Figure 6.9. Transport of anti-ICAM-HRP conjugates after monomeric vs. multimeric binding 
to gastrointestinal epithelial monolayers. The anti-ICAM-HRP conjugate mixture was separated 
into two main molecular weight fractions by AF4: a form corresponding to 1:2 antibody-to-enzyme 
molar ratio (233 kDa) and a form representing larger multimolecular or aggregated conjugates 
(average = 686 kDa). Caco-2 cells cultured on transwell inserts were incubated with the conjugate 
mixture vs. each one of the separated conjugate fractions for 24 h at 37 ºC to allow transport 
into/across cells. HRP activity in the basolateral and cell fractions was measured using a 
spectrophotometric enzyme activity assay, and used to calculate (A) transported HRP activity 
(pmol/L), (B) the ratio of HRP activity found in the basolateral fraction to that in the combined 
basolateral and cell fractions (% transport), and (C) the rate of transport in terms of Papp. Data are 
Mean ± S.E.M. * compares values to the unseparated conjugate mixture (p < 0.05, Student’s t test). 
 
 
Similar to non-conjugated anti-ICAM, conjugates transported HRP across cells in 
a time-dependent manner: 2 pM HRP was transported across the cell monolayer by 1 h, 
accounting for 7% of the combined transported and cell fractions, which increased to 14 
and 30 pM HRP, or 25 and 49% of the total cell-associated activity, by 5 h and 24 h (Fig. 
6.10A-B). HRP activity in the basolateral chamber did not appear to result from 
endogenous peroxidase activity, as treatment with non-conjugated anti-ICAM produced 
negligible transport (3% of the level of anti-ICAM-HRP conjugates at 24 h) (Fig. 6.10C). 
In addition, conjugates enhanced transepithelial delivery by 2-fold relative to non-
conjugated HRP (Fig. 6.10C). Nevertheless, a considerable amount of HRP was 
transported across cells, despite negligible association to cells (Fig. 6.9), perhaps owing to 
paracellular leakage or a non-specific transport mechanism. In contrast, minimal transport 




this size do not undergo non-specific leakage and that targeted counterparts of similar size 
undergo specific, non-paracellular transport.  
 
 
Figure 6.10. Transepithelial transport kinetics and specificity of anti-ICAM-HRP conjugates. 
Caco-2 cells cultured on transwell inserts were treated with anti-ICAM-HRP conjugates in the 
apical chamber for the indicated time intervals to allow intra- and transepithelial transport. To 
assess whether transport was specific to ICAM-1 binding, Caco-2 monolayers were also treated 
with non-conjugated HRP or anti-ICAM, or non-specific IgG-HRP conjugates. HRP activity in the 
basolateral and cell fractions was measured using a spectrophotometric enzyme activity assay, and 
used to calculate (A, C) transported HRP activity (pmol/L) or (B) the percent of transport, or the 
ratio of HRP activity found in the basolateral fraction to that in the combined basolateral and cell 
fractions. Data are Mean ± S.E.M. # compares each time point to the preceding one; * compares 
values to anti-ICAM-HRP conjugates (p < 0.05, Student’s t test). 
 
 
6.2.5 Anti-ICAM-HRP Conjugates Are Transported By a CAM-Mediated Pathway 
Next, we evaluated whether conjugates traffic across cells by a vesicular, CAM-mediated 
pathway analogous to that utilized by anti-ICAM. First, we verified that transport of anti-
ICAM-HRP was mediated by ICAM-1, given that the addition of an anti-ICAM competitor 
decreased accumulation of enzyme in the basolateral fraction by 76% relative to control, 
untreated conjugates, whereas the presence of IgG did not significantly alter transport (Fig. 
6.11A). In identifying the contribution of CAM-endocytosis to transport, we demonstrated 
that EIPA inhibited both the amount and rate (Papp) of HRP activity transported by 60 and 
92% of cells in the absence of an inhibitor (5h) (Fig. 6.11B). Moreover, similar to non-
conjugated anti-ICAM, transport of conjugates did not seem to disrupt intercellular 




for control, untreated cells over 24 h of transport. These results suggest that transport 




Figure 6.11. The mechanism of transport of anti-ICAM-HRP conjugates. (A) Caco-2 
monolayers were incubated at 37 ºC for 24 h with anti-ICAM-HRP conjugates in the presence of 
anti-ICAM, to compete for ICAM-1 binding sites, or non-specific IgG. The HRP activity in the 
basolateral (transported) fraction was derived as described in Fig. 5, and normalized to control 
conditions in the absence of anti-ICAM or IgG. (B) Transport of anti-ICAM-HRP conjugates was 
assessed in the presence or absence of EIPA, an inhibitor of CAM-mediated endocytosis. Transport 
was expressed as the quantity HRP activity in the basolateral chamber (pM) as well as the rate of 
transport (Papp). (C) TEER was measured during transport of anti-ICAM-HRP conjugates across 
Caco-2 cells, to assess paracellular transport, and expressed as a percentage of values measured for 
untreated, control cells. Data are Mean ± S.E.M. * compares values to control cells treated with 





Access of therapeutics into and across the GI epithelial lining, is imperative for the 
treatment disorders affecting the barrier itself and/or reaching the systemic circulation [6, 
7, 52, 123]. Targeting drugs to cell-surface receptors involved in endocytosis has shown 
much success in this regard [6, 7, 52, 123]. In contrast to classical endocytic pathways, 
such as phagocytosis, clathrin- and caveolin-dependent endocytosis, and fluid-phase 
macropinocytosis, non-classical routes are less explored for this purpose. One such 
pathway that shows promise for drug delivery into and across cell barriers involves 
targeting to ICAM-1 [10, 13, 14]. Delivery of a model enzyme therapeutic across GI 




strategies, i.e. anti-ICAM NCs carrying α-Gal, an enzyme used to treat Fabry disease [13]. 
In Chapter 5 of this dissertation, we demonstrated intracellular and transcellular transport 
of anti-ICAM in GI epithelial cells, revealing the potential of monomeric ICAM-1-
targeting ligands as alternative drug vehicles that may provide distinct advantages with 
respect to multimeric targeting strategies [116]. In light of this work, this chapter examined 
whether such transport facilitates delivery of a therapeutic cargo, as was shown for 
multimeric counterparts.  
For this purpose, we conjugated anti-ICAM to a drug cargo, represented here by 
the model enzyme, HRP. Our findings demonstrate that anti-ICAM-enzyme conjugates 
bind to ICAM-1 in a monomeric manner, and undergo specific transport into and across 
these cells. In parallel with anti-ICAM, anti-ICAM-enzyme conjugates are transported 
across cells by CAM-mediated transcytosis rather than a paracellular mechanism. This 
pathway was amenable to delivering HRP into and across GI epithelial cells, while 
preserving enzyme activity.  
Specific binding to ICAM-1 on the GI epithelium has implications for minimizing 
clearance of freely circulating drug delivery systems, ultimately optimizing biodistribution 
to the site of absorption. Importantly, anti-ICAM retained its targeting ability after 
conjugation to an enzyme cargo, and preserved a considerable degree of enzyme activity 
upon binding to cells. In addition, uptake of monomeric anti-ICAM by ICAM-1 expressing 
cells may provide intracellular transport of therapeutic cargoes, as previously demonstrated 
in the case of multimeric binding to ICAM-1 [9, 12, 13, 25, 27, 30, 31, 35, 37, 86, 93, 112, 
132-134, 164, 165, 169, 171]. Here, we examined cellular uptake of anti-ICAM conjugated 




40% of the mixture contained a 233 kDa species, which corresponds to one antibody 
bearing two enzymes and, therefore binds to ICAM-1 in a monomeric manner; and (b) a 
686 kDa fraction, which comprises 40% of the reaction and likely encompasses large 
conjugates or aggregates, and thus binds to ICAM-1 in a multimeric manner. The presence 
of both antibody and enzyme components of conjugates was verified by Western blot. As 
expected, binding was specifically driven by the anti-ICAM counterpart of conjugates. In 
accord with anti-ICAM uptake, endocytosis was found for anti-ICAM-HRP conjugates. 
Therefore, this strategy may be used for intracellular drug delivery via ICAM-1 in addition 
to published strategies that target ICAM-1 in a multimeric manner. Indeed, a similar degree 
of uptake (40-60% uptake) was observed between the unseparated conjugated mixture and 
conjugates species that bind to ICAM-1 in a monomeric (233 kDa) or multimeric (686 
kDa) manner. This rate of uptake is similar to that of unconjugated anti-ICAM, further 
validating uptake upon monomeric binding. The process was abolished by an inhibitor of 
the CAM pathway, indicating its mediation by the antibody rather than the enzyme 
counterpart. Anti-ICAM-triggered uptake was further verified using IgG-HRP conjugates 
and unconjugated components.  
Importantly, the enzyme counterpart of conjugates was active upon binding to the 
cell surface as well as after uptake, since significant activity was measured in both 
scenarios, and this was specific to ICAM-1-targeted counterparts. Efficient uptake of 
enzyme cargoes via ICAM-1 has been previously shown upon multimeric binding to cells 
[25, 30, 31, 181], including the case of anti-ICAM-coated nanoparticles loaded with α-Gal, 
which were observed to transcytose across Caco-2 cells [13]. Although the drug payload 




ICAM conjugates that bind in a monomeric fashion (~200 vs. 2 enzymes per targeting 
vehicle), the latter strategy provided greater targeting in terms of the number of enzyme 
molecules associated per cell (~4.5×105 vs. 2×105, respectively) and enzyme molecules 
internalized (~2×107 vs. 4×105 enzyme molecules per cell) [13]. This may be due to less 
steric hindrance between small antibody-enzyme conjugates binding to adjacent ICAM-1 
molecules on the cell surface compared to ~250 nm antibody-coated nanocarriers. Hence, 
the smaller size afforded by monomeric vs. multimeric ligands may prove more beneficial 
in delivering therapeutics. Alternatively, this may be due to higher degradation of the 
enzyme cargo upon trafficking of anti-ICAM NCs to lysosomes, as previously shown [92], 
compared to low lysosomal transport and degradation of monomeric anti-ICAM. Whether 
these advantages hold true for other drug cargoes, such as smaller or more lipophilic agents, 
and upon administration in vivo, are aspects to be explored in future studies. Nevertheless, 
accumulation of monomeric ICAM-1-targeting vehicles within cells may benefit disorders 
affecting cell linings themselves, particularly GI epithelial and vascular complications 
where ICAM-1 is up-regulated by an inflammatory state, as in the case for inflammatory 
bowel disease, pathogenic infections, and atherosclerosis [19-22].  
Importantly, transcytosis of anti-ICAM provided an avenue for delivery of an active 
drug cargo across GI epithelial cells, analogous to anti-ICAM NCs. Separation of anti-
ICAM-enzyme conjugates into its respective molecular weight fractions revealed that such 
delivery was mediated by both monomeric and multimeric species. To our surprise, 
monomeric binding by conjugates induced significantly greater transport of enzymes 
across cells than multimeric counterparts. This was surprising considering that anti-ICAM 




(4×105 vs. 4×104 molecules transported per cell at 24 h) and Papp (2×10
-8 cm/s vs. 4×10-9 
cm/s at 24 h) [13]. Therefore, multimeric formulations targeting ICAM-1 may benefit from 
the presence of a drug carrier rather than direct drug conjugation (multimeric conjugates), 
in terms of drug payload, uniform shape and orientation of targeting ligands, etc. 
Nevertheless, monomeric conjugates as well as multimeric conjugates and carriers behaved 
similarly with respect to the percentage of transport (40-50% at 24 h), indicating that the 
absolute amount of drug transport largely depends on initial cellular accumulation, which 
as noted above, was greater for ICAM-1 targeted NCs.   
In addition, whereas the parameters characterizing transport of anti-ICAM NCs 
remained similar in the presence vs. absence of a drug cargo [13], conjugation of enzymes 
to anti-ICAM significantly reduced transport with respect to the unconjugated antibody. 
This may arise from discrepancies in the method of formulation; direct conjugation may 
compromise targeting and/or enzyme activity to a greater degree than non-covalent coating 
of the targeting ligand and enzymes onto the surface of nanocarriers. Moreover, in the latter 
formulation, many copies (i.e., >100) of targeting ligands and enzymes per NC results in a 
higher probability that the functionality of each NC is retained despite a fraction of the coat 
becoming denatured/deactivated. Another possibility for differences in transport between 
anti-ICAM-HRP and anti-ICAM is that conjugation significantly increases the size of anti-
ICAM by ~50%, whereas coating of enzymes onto anti-ICAM NCs does not alter its size 
[13].  
As demonstrated for anti-ICAM, anti-ICAM conjugated to an enzyme cargo is 
transported across cells by a vesicular CAM pathway, rather than a paracellular 




such as monomeric vs. multimeric systems, presence vs. absence of a drug cargo, etc., 
targeting ICAM-1 leads to CAM-mediated transcytosis in cellular barriers [13]. This pairs 
well with previous reports indicating that CAM-mediated uptake and intracellular 
trafficking accommodates drug delivery systems with varying size, shape, targeting 
valency, and chemistry [25, 116, 132, 165]. In addition, extensive literature demonstrates 
that CAM-mediated endocytosis is amenable for the intracellular delivery of therapeutic 
and imaging agents, particularly enzyme cargoes [28, 30, 31, 36, 122, 132, 133, 165], 
providing efficient uptake while preserving their functional activity. Together with our 
observations using anti-ICAM NCs, the present work further supports that CAM-mediated 




The results in this chapter demonstrate that monomeric ligands targeted to ICAM-1 may 
serve as a vehicle for the delivery of active therapeutics into and across GI epithelial cells, 
significant for oral therapies aimed at treating the GI epithelium itself or accessing the 
systemic circulation. This provides a valuable alternative to multimeric carrier 
formulations in that it may offer distinct advantages for oral drug delivery, therefore 





Chapter 7: Overall Conclusions and Future Directions  
7.1 Overall Conclusions 
Among the various routes of drug administration, oral delivery through the GI tract is 
considered the most favorable for patients, healthcare workers, and manufacturers, owing 
to greater patient compliance, low cost, and fewer safety concerns relative to parenteral 
injections or infusions [1]. In light of these benefits, oral dosage forms represent the 
majority (90%) of all medicines and a substantial, USD $49 billion market [1]. However, 
efficient drug absorption by this route remains a major challenge due to various 
physiological barriers posed by the GI tract, including: (1) premature degradation and/or 
deactivation of drugs, e.g. by the low pH and proteolytic activity in the stomach; (2) poor 
mucus penetration and binding to the GI epithelium, resulting in low biodistribution to the 
site of drug absorption; and (3) suboptimal transport into GI epithelial cells, for treatment 
of GI pathologies, or across these cells for subsequent delivery into the systemic circulation 
[2, 3]. Numerous therapeutics entering the market are particularly susceptible to these 
barriers, including protein or peptide-containing biotherapeutics, necessitating more 
invasive routes of administration [2, 3]. Hence, the goal of this dissertation was to establish 
a strategy to improve oral delivery of therapeutics, particularly those with negligible oral 
bioavailability.  
 The work herein sought to achieve this goal by targeting therapeutics to ICAM-1, 
a cell-surface receptor located on the GI epithelial lining and various other tissues accessed 
by the systemic circulation [7, 13]. Extensive characterization by our lab has revealed 




27, 30, 31, 36-38]. In the context of oral delivery, we previously demonstrated that ICAM-
1 targeted NCs were capable of efficient binding, uptake, and a novel means of transport 
across GI epithelial cells grown in culture [13]. Uptake and transepithelial transport relied 
on CAM-mediated endocytosis and transcytosis [13], which was favorable in that CAM-
endocytosis has been previously characterized and optimized to deliver drugs and drug 
carriers with wide-ranging size, shape, chemistry, and targeting valency, while preserving 
the functionality of these cargoes [9, 12, 24-34]. In addition to the ability to fine-tune and 
regulate this pathway, CAM-transport did not induce prolonged opening of intercellular 
junctions that keep the epithelial permeability barrier intact, providing a relatively safe 
means of transport [13]. In addition, relative to NCs exploiting other transcytosis pathways, 
including NCs targeted to the B12 and Fc receptors, CAM-mediated transcytosis is more 
efficient in terms of the percentage of cell-bound NCs that are transported [13, 182, 183]. 
Importantly, this pathway enabled delivery of a model therapeutic cargo, enzymes for the 
treatment of Fabry disease, into and across these cells [13]. Apart from promising results 
in cell culture, oral gavage of ICAM-1 targeted antibodies either as single entities (anti-
ICAM) or coated onto the surface of polymer NCs (anti-ICAM NCs) in mice revealed 
targeting of these systems to GI tissue [15]. However, the efficacy of these strategies was 
limited by enzymatic degradation of targeting antibodies in the stomach, reducing 
biodistribution to the small intestine, the main site of drug absorption [15].  
These studies prompted the need to encapsulate ICAM-1 targeted systems for 
protection in the stomach and site-specific release in the small intestine, while preserving 
the function of targeting moieties. Ultimately, this would enable us to better evaluate the 




a comparison to previous reports by our lab examining systemic delivery upon intravenous 
injections in mice [25, 27, 29-31, 37]. Encapsulation would not only benefit ICAM-1 
targeted systems, but other drug delivery systems with labile targeting components that are 
susceptible to GI degradation, particularly those that are protein-based. In Chapter 4, we 
successfully addressed these requirements using alginate and chitosan-alginate hydrogel 
microspheres. Given that the binding and transport efficacy of anti-ICAM NCs was 
previously established in cultured GI epithelial cells, we characterized encapsulation of 
model antibody-coated NCs. Although there is extensive literature on utilization of alginate 
and chitosan-alginate hydrogels for effective oral delivery of therapeutics, including a wide 
range of delicate biological entities [16, 17, 47-49, 106-111], this application was not yet 
described for antibody-coated NCs, nor for other targeted drug delivery systems.  
First, we demonstrated that we were able to adjust the size of alginate beads to 
conform to different in vivo applications: we formulated ~180 µm-diameter microspheres 
for mice studies (which were selected for the remainder of this work), as well as 2.8 mm-
diameter beads for future studies in larger animals, such as rats. Both of these formulations 
exhibited uniform size, shape, and efficient loading of targeted NCs within the bead 
population, which did not differ in the presence of a chitosan shell. Moreover, the loading 
efficiency within microspheres exceeded that of previous works encapsulating large 
biological entities. We then confirmed that microspheres remained stable in storage 
conditions, and displayed pH-triggered release in GI conditions: they remained intact in 
gastric conditions and released their contents in intestinal conditions. We were able to 
further attenuate burst release by the addition of a chitosan shell, increasing chitosan shell 




control over release kinetics using these strategies. Moreover, examination of encapsulated 
NCs after treatment in GI conditions revealed substantial targeting to ICAM-1 expressing 
endothelial and GI epithelial cells, even in the presence of digestive enzymes. Importantly, 
these results held true upon oral gavage of encapsulated NCs in mice. Relative to non-
encapsulated NCs, microspheres provided significantly greater protection of NCs from 
degradation in all GI organs, site-specific release in the small intestine. Furthermore, we 
revealed that greater intestinal accumulation of NCs was attributed to ICAM-1 targeting. 
Therefore, this work provided an important foundation for studying the efficacy of ICAM-
1, and potentially other, targeted platforms, for oral delivery in vivo. For example, this 
encapsulation method is not only limited to antibody-coated NCs but can be applied to 
systems with different targeting moieties, NCs, or drug-ligand conjugates in the absence of 
NCs, such as the anti-ICAM-enzyme conjugates described here. 
Whereas our work on GI cell transport and encapsulation of ICAM-1 targeting 
strategies involved multimeric strategies employing anti-ICAM-coated carriers, Chapter 5 
was dedicated to evaluating an alternative targeting platform utilizing monomeric ICAM-
1 targeting, which would provide a novel opportunity for direct conjugation to therapeutics 
rather than loading onto NCs. In addition to providing a less complex formulation, 
monomeric targeting may endow distinct drug delivery outcomes, such as biodistribution, 
cellular binding and transport, metabolism, elimination, etc. These differences were first 
evaluated in vascular endothelial cells, to compare to extensive literature on CAM-
mediated endocytosis of anti-ICAM NCs in these cells [12, 91-93]. Here we revealed, for 
the first time, uptake of monomeric ligands (i.e., anti-ICAM) by CAM-mediated 




lysosomal degradation encountered by multimeric platforms, we demonstrated that 
endocytosed monomeric anti-ICAM instead recycled to the plasma membrane, mimicking 
trafficking of its receptor in the absence of ligands.  From a biological standpoint, these 
results alluded to novel roles for differential cellular regulation of ICAM-1 and its ligands. 
Furthermore, such regulation presented unique differences with respect to that of other cell-
surface receptors. For example, in contrast to multimeric ICAM-1 ligands, multimeric 
ligands targeted to the Fc, transferrin, and B12 receptors were observed to avoid lysosomal 
degradation, while their monomeric counterparts trafficked to lysosomes [141, 182, 183]. 
These differences may arise from the fact that natural ligands to most receptors are 
monomeric, whereas ICAM-1 typically binds in a multimeric manner, e.g. to leukocytes 
and viruses [10]. In addition, while CAM-mediated endocytosis holds for both monomeric 
and multimeric ligands, the mechanism of endocytosis has been shown to switch upon 
monomeric vs. multimeric targeting to other receptors, as in the case of the B12 receptor 
[182]. From a drug delivery perspective, these observations exposed a novel avenue for 
intracellular drug delivery using monomeric ligands targeted to ICAM-1. This strategy may 
prove especially valuable for intracellular interventions, in light of minimal lysosomal 
degradation as compared with multimeric counterparts. Therefore, we subsequently 
explored these aspects in the context of improving oral delivery into GI epithelial cells.   
 In continuation of our findings in vascular endothelial cells, we then demonstrated 
that anti-ICAM undergoes similar uptake in GI epithelial cells by CAM-mediated 
endocytosis. Moreover, reduced uptake and minimal lysosomal trafficking and degradation 
relative to multimeric anti-ICAM NCs suggested that differential regulation of monomeric 




Moreover, we revealed that such uptake led to transcytosis across a GI epithelial cell barrier 
model, as it did for multimeric formulations. Similar to anti-ICAM NCs [13], anti-ICAM 
were transported across cells by a CAM-mediated, rather than a paracellular, pathway, 
hence preserving cell barrier integrity. Hence, by characterizing an alternative carrier 
platform, we have expanded the range of oral drug delivery outcomes afforded by ICAM-
1 targeting. This will also enables us to select an appropriate therapeutic intervention that 
caters to these distinct outcomes.  
Furthermore, similar to anti-ICAM NCs, anti-ICAM provided substantial binding 
and intracellular delivery of a model enzyme cargo in GI epithelial cells, while preserving 
its enzyme activity. This finding is valuable for oral delivery of drugs, particularly 
biotherapeutics, with low innate affinity to and transport into/across the GI epithelial 
barrier. In addition, these results allow us to expand our knowledge and translation of 
enzyme delivery by ICAM-1 targeting, which has been a major focus of our lab. Uptake of 
biotherapeutics, or other drugs, into cells would be valuable for treating pathologies that 
affect the GI epithelial lining, such as infections, inflammatory bowel disease (Crohn’s 
disease and ulcerative colitis), cancers, etc. where ICAM-1 is preferentially expressed [19-
22]. 
 Importantly, CAM-mediated transcytosis mediated delivery of active enzymes 
across the GI epithelial cell barrier, advocating the potential for oral delivery across these 
cells for access into the systemic circulation. Enzyme delivery by anti-ICAM was lower 
than that of anti-ICAM NCs, yet these comparisons do not take into account that delivery 
by the latter strategy was reported in terms of the total amount of enzymes transported 




demonstrate that CAM-mediated transcytosis is also flexible in that it caters to drug carriers 
and cargoes of different size, shape, and valency. Hence, monomeric vehicles targeted to 
ICAM-1 serves as a viable alternative to multimeric carriers for oral delivery across the GI 
epithelium.  
 Taken together, this dissertation has provided the groundwork for implementation 
of ICAM-1 targeting strategies for oral delivery: (1) in continuation of previous results 
demonstrating the efficacy of ICAM-1 targeted NCs for oral delivery, we encapsulated 
these NCs for protection in gastric conditions, site-specific release in intestinal conditions, 
and retention of targeting ability in vitro, cell culture, and animal models; (2) we explored 
monomeric ligands to ICAM-1 as an alternative carrier that provides distinct uptake and 
intracellular trafficking relative to former multimeric strategies, enabling a novel 
opportunity to deliver drugs into GI epithelial cells; and (3) we exploited this monomeric 
targeting strategy for delivery of active drugs into and across a model GI epithelial barrier. 
Therefore, this work establishes two complementary ICAM-1 targeting systems that endow 
different advantages for oral delivery, and the framework for evaluating the efficacy of 
these systems in vivo.  
 
7.2 Future Directions 
As noted above, the work performed in this dissertation has advocated the potential of 
ICAM-1 targeting strategies for improving oral absorption of therapeutics, as well as 




characterization and optimization has yet to be performed for future translation of these 
strategies.  
First, the components used to formulate monomeric and multimeric ICAM-1 
targeting systems thus far, including whole antibodies, polystyrene NCs, and enzyme drug 
cargoes, served as prototypes for facilitating their characterization and reducing the time, 
labor, and cost required to produce clinical-grade formulations. However, more clinically 
relevant alternatives may be used for future studies examining oral delivery by targeting 
ICAM-1. For example, while the work described herein employed whole antibodies from 
another species as the targeting ligand, this would lead to adverse immune reactions in 
patients, as well as potential detachment from drugs or drug carriers due to high shear stress 
in a physiological environment. Truncating the antibody to only include the variable 
region, the domain responsible for molecular recognition and binding, may result in less 
shear stress and minimize potential toxicity and immune recognition of antibody Fc 
regions. To address this, our lab has recently established a 17-mer linear peptide (γ3) as a 
viable substitute for targeting ICAM-1 from the systemic circulation [112]. Indeed, recent 
work demonstrated that γ3-coated NCs closely mimic the drug delivery parameters 
afforded by anti-ICAM NCs, in terms of targeting, CAM-endocytosis, lysosomal 
trafficking, and biodistribution upon intravenous administration in mice [112]. In addition, 
γ3 is likely to target ICAM-1 in different species (e.g., mouse, chimpanzee, and humans), 
which is suitable for the translation of ICAM-1-targeting platforms in future preclinical 
and clinical studies [112]. Hence, future studies may similarly utilize these peptides for 




In addition, we could employ PLGA particles as an alternative to model polystyrene 
particles. PLGA is a biodegradable material that is already in several FDA-approved 
devices [58]. As noted in Chapter 3, ICAM-1 targeted PLGA particles demonstrated 
similar binding, internalization, intracellular trafficking characteristics as polystyrene 
counterparts. Future work may include confirming oral delivery achieved by anti-ICAM 
NCs presented in this thesis with PLGA particles, which has already been formulated and 
optimized in-house. Another benefit of using PLGA particles is the ability to chemically 
conjugate targeting moieties and polyethylene glycol (PEG) chains to the polymer end 
groups, which would endow greater stability of targeting entities on the particle surface in 
the GI lumen and post-GI trafficking [2]. We could also enhance the efficacy of monomeric 
ICAM-1 ligand-drug conjugates by PEG conjugation, which has been shown to increase 
mucus permeation and reduce enzymatic degradation, opsonization, and clearance by 
immune cells [8].    
 The work described previously and within this dissertation utilized enzymes as a 
model drug cargo, expanding upon the extensive studies performed by our lab 
demonstrated effective delivery of enzymes, particularly those used for the treatment of 
LSDs, in other cell types grown in culture and upon intravenous administration in mice 
[27, 30, 31, 36, 37, 94]. To further extend our knowledge on this application for oral 
delivery, future work may involve direct conjugation of a monomeric ICAM-1 ligand to 
more clinically relevant enzymes, such as α-Gal for the treatment of Fabry disease, and 
evaluation of drug activity as well as disease attenuation in cell culture and animal models. 
Furthermore, while α-Gal was used as a drug cargo for anti-ICAM NCs [13], the level of 




Moreover, oral delivery applications involving direct conjugation or NC coupling to other 
types of therapeutics could be the subject of future studies employing ICAM-1 targeting 
strategies. Lipophilic drugs, for instance, would benefit from these strategies in terms of 
solubility in aqueous buffers but also cellular binding and regulation of transport.   
In addition, the work conducted thus far on monomeric ICAM-1 ligand-drug 
conjugates demonstrated targeting and cellular transport in GI epithelial cell culture 
models. To further progress our knowledge on the potential of this strategy for oral 
delivery, future experiments will involve encapsulation of monomeric ICAM-1 ligands, as 
performed in this dissertation using multimeric platforms. Furthermore, in vivo 
characterization of drug delivery parameters (e.g., biodistribution, accumulation in tissues, 
etc.) could be permitted by future encapsulation of ICAM-1 targeted platforms with a drug 
cargo. Encapsulation of different formulations, such as monomeric vehicles and ICAM-1 
targeted platforms coupled to a drug cargo, and enhanced control over release patterns, 
may warrant further optimization of chitosan-alginate microspheres. For example, we can 
optimize loading and release of these formulations by modulating alginate crosslinking 
density, e.g. using alginate with a higher guluronic acid content or adjusting the amount or 
type of divalent cations in the crosslinking media, or altering the pH, concentration, and 
crosslinking density of the chitosan coating, as explored herein and in previous literature 
[48, 49, 105]. We could also substitute alginate with alginate derivatives or other anionic 
hydrogels that are described for controlled release at neutral pH, including natural polymers 
(e.g., gellan gum, carrageenan, pectin, etc.) or synthetic polymers (e.g., polyacrylic and 
polymethacrylic acids) [4, 5, 16, 96]. In addition, it is likely that chitosan and genipin-




conditions due to total or partial solvation of the chitosan shell at low pH [4]. This could 
be resolved in future studies by providing an additional layer of crosslinked alginate or by 
substituting chitosan with other cationic polymers that swell but do not dissolve in acidic 
medium, such as derivatized chitosan or poly-L-lysine [4, 16, 96, 107].  
Importantly, the encapsulation method provided by this dissertation represents a 
valuable tool for future studies evaluating translation of ICAM-1 targeting strategies for 
oral delivery in vivo. Retention of ICAM-1 targeting of anti-ICAM NCs following release 
from microspheres will presumably allow for subsequent uptake into GI epithelial cells, 
although this has yet to be confirmed. Moreover, our previous work using anti-ICAM NCs 
and the present studies using anti-ICAM demonstrates that targeting ICAM-1 elicits 
delivery of therapeutics into GI epithelial cells. Distinct intracellular delivery outcomes 
have also been achieved as a result of: (1) differential endocytic routing taken by either 
targeting strategy; and (2) adjusting intracellular trafficking using chemical agents and 
carriers of different size, shape, and targeting valency [24, 25, 91, 122]. In light of these 
benefits, future work may involve ICAM-1 mediated delivery into the GI tissue for 
alleviation of GI disorders. For appropriate selection of a GI intervention, future 
experiments may involve quantification of the levels and distribution ICAM-1 expression 
throughout the various regions of the GI tract, and differential expression in healthy vs. 
diseased conditions. As previously noted, ICAM-1 is overexpressed in pathological 
conditions, as observed in the case of colon cancer, inflammatory bowel disease, and GI 
infections [19-22]. Hence, site-specific delivery to diseased tissues in the gut is 
conceivable. Indeed, our lab has recently established a model of intestinal inflammation in 




employ acid sphingomyelinase- or α-Gal-knockout mice, mimicking Niemman Pick and 
Fabry disease (two types of LSDs), which have been established in-house. Future 
experiments may evaluate whether biodistribution of ICAM-1 targeted systems favors 
inflamed tissues, as they did upon intravenous injection into disease-model mice.  
Future studies may also probe the biological basis of CAM-mediated transcytosis, 
which has yet to be elucidated. In the case of transport across the vascular endothelial cells, 
the CAM pathway induced by anti-ICAM NCs presents similarities with ICAM-1 assisted 
transcellular transmigration of leukocytes across the vascular endothelial barrier, relevant 
to its biological role in mediating inflammation [113]. With regard to the intestinal 
epithelial barrier, a recent publication also revealed an analogous role for ICAM-1 in 
docking leukocytes to the apical surface of the intestinal epithelium, leading to 
transmigration across these cells [184]. Hence, future experiments may assess the overlap 
of cellular events regulating the transport of ICAM-1 targeted drug delivery systems with 
those observed during ICAM-1 mediated intestinal leukocyte transport, such as activation 
of the myosin light-chain kinase pathway.  
Moreover, future work must assess the potential of ICAM-1 targeting for drug 
delivery into the systemic circulation via the oral route. For this purpose, the degradation 
status and targeting viability of ICAM-1 ligands can be assessed following transport across 
cultured GI epithelial monolayers, e.g. by Western blot, ELISA, and examining binding to 
a sub-epithelial cell lining cultured on the underside of transwells. Biodistribution of 
ICAM-1 targeted systems to the circulation and organs beyond the GI tract may also be 
evaluated upon oral gavage of microspheres in mice. These studies would allow us to 




following absorption by the GI tract, as well as select appropriate therapeutic interventions 
that reflect biodistribution patterns.  
Taken together, this dissertation has established significant milestones for the 
advancement of ICAM-1 targeted systems for oral drug delivery: (1) we characterized an 
encapsulation strategy for evaluating oral delivery of ICAM-1 targeted systems in vivo; 
and (2) identified monomeric ICAM-1 targeting vehicles as a viable alternative to 
multimeric systems that enables intracellular delivery and (3) transcellular delivery of 
active therapeutics. These strategies show much promise for improving delivery of 
therapeutics into and across the GI tract, for interventions aimed at treating GI disorders 
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